Sentence,class,file
"A detailed de-scription of SBtab, together with many examples, is given in theSBtab specification document (http://arxiv.org/abs/1502.01463,Liebermeister et al., 2015 ).To simplify the work with SBtab documents, we provide free on- line tools and software for using SBtab in MS Excel, Python,MATLAB and R. The online tools on www.sbtab.net comprise anautomatic syntax validator for SBtab files and a tool for convertingmodels from SBtab to SBML and vice versa .",OADS,/arxiv_data1/oa_pdf/b1/05/btw179.PMC4978929.pdf
Availability and Implementation : ProtPOS is freely available for academic and non-proﬁt uses at http://cbbio.cis.umac.mo/software/protposSupplementary information: Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/d1/d0/btw182.PMC4978930.pdf
"2537 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d1/d0/btw182.PMC4978930.pdf
"The automated generationand efﬁcient annotation of non-redundant reference catalogs by propagating pre-computed assign- ments from 18 databases covering various functional categories allows for fast and comprehensive functional characterization of metagenomes.Availability and Implementation: MOCAT2 is implemented in Perl 5 and Python 2.7, designed for 64-bit UNIX systems and offers support for high-performance computer usage via LSF, PBS or SGE queuing systems; source code is freely available under the GPL3 license at http://mocat.embl.de.",OADS,/arxiv_data1/oa_pdf/32/76/btw183.PMC4978931.pdf
"2520 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/32/76/btw183.PMC4978931.pdf
Availability and Implementation: MINTbase is freely accessible at http://cm.jefferson.edu/MINTbase/.,OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
Dataset submissions to MINTbase can be initiated at http://cm.jefferson.edu/MINTsubmit/.,OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
"2481 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
MINTbase is freely accessible at http://cm.jefferson.edu/ MINTbase/.,OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
Codes for generating tRF-license plates and for con-verting them back to nucleotide sequences are available at https://cm.jefferson.edu/MINTcodes/.,Non-OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
"To conclude, under this new mapping scheme,the tRF CTGTCACGCGGGAGACCGGGGTT will be encoded bythe license plate ‘tRF-23-NMEH623K0E.’ The scripts needed togenerate a tRF-license plate for a tRF and to decode a tRF-licenseplate are available at http://cm.jefferson.edu/MINTcodes/.",Non-OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
Auser interaction with MINTsubmit begins at https://cm.jefferson.edu/MINTsubmit/.,OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
"The secondary structures for the nuclearly-encoded tRNAs that are highlighted in the ‘tRNA alignment’ vista were obtained fromhttp://gtrnadb2009.ucsc.edu/Hsapi19/Hsapi19-structs.html ( Chan and Lowe, 2009 ).",OADS,/arxiv_data1/oa_pdf/bf/c3/btw194.PMC4978933.pdf
"Results: hotspot consists of four programs: asp looks up SNPs and designs allele-speciﬁc primers; aso constructs allele-speciﬁc oligos for mapping recombinants; xov implements a maximum- likelihood method for estimating the crossover rate; six, ﬁnally, simulates typing data.Availability and Implementation : hotspot is written in C. Sources are freely available under the GNU General Public License from http://github.com/evolbioinf/hotspot/ Contact: haubold@evolbio.mpg.de Supplementary information: Supplementary data are available at Bioinformatics online.",OADS,/arxiv_data1/oa_pdf/73/4e/btw195.PMC4978934.pdf
"2554 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/4e/btw195.PMC4978934.pdf
"1837 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/3.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/8b/ntw117.PMC4978985.pdf
2012.  http://ec.europa.eu/health/tobacco/docs/eurobaro_attitudes_towards_ tobacco_2012_en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/e1/8b/ntw117.PMC4978985.pdf
"J Am Med Assoc 2002; 288(16), http://dx.doi.org/10.1001/jama.288.16.1974  4.",Non-OADS,/arxiv_data1/oa_pdf/ba/a7/10.1177_1460458215572925.PMC4979250.pdf
"The CEN/ISO EN13606 standard, http://www.en13606.org/the-ceniso-en13606-standard (2014,  accessed 31 August 2014).",Non-OADS,/arxiv_data1/oa_pdf/ba/a7/10.1177_1460458215572925.PMC4979250.pdf
"IHE IT infrastructure technical framework, cross-enterprise clinical document sharing (XDS)  by the IHE ITI technical committee, http://www.ihe.net/Technical_Framework/index.cfm#IT (2007,  accessed 17 June 2014).",OADS,/arxiv_data1/oa_pdf/ba/a7/10.1177_1460458215572925.PMC4979250.pdf
"Integrating the healthcare enterprise (IHE), http://www.ihe.net (2014, accessed 17 June 2014).",Non-OADS,/arxiv_data1/oa_pdf/ba/a7/10.1177_1460458215572925.PMC4979250.pdf
"LinkEHR normalization platform, http://pangea.upv.es/linkehr/ (2014, accessed 17 June 2014).",OADS,/arxiv_data1/oa_pdf/ba/a7/10.1177_1460458215572925.PMC4979250.pdf
"Value  Health 2012; 15(8): 1172–1181, http://dx.doi.org/10.1016/j.jval.2012.06.015",OADS,/arxiv_data1/oa_pdf/ba/a7/10.1177_1460458215572925.PMC4979250.pdf
Available from: http://www.amar.org.ir/ Default.aspx?tabid=1228.,Non-OADS,/arxiv_data1/oa_pdf/8a/87/IJNMR-21-345.PMC4979255.pdf
Available from: https://www.un.org/ en/ga/ncdmeeting2011/pdf/ncd_profiles_report.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8a/87/IJNMR-21-345.PMC4979255.pdf
Available from: http://books.google.com/books?hl=en&lr=& id=Ycbr2e2WPdcC&oi=fnd&pg=PR5&dq=Global+health+r isks+mortality+and+burden+of+disease+attributable+to +selected+major+risks&ots=aeG_0CTc9t&sig=pNJqODXaMXiW7XL4JQ4MI_d0CRU#v=onepage&q=Global%20health%20 risks%20mortality%20and%20burden%20of%20disease%20 attributable%20to%20selected%20major%20risks & f=false.,Non-OADS,/arxiv_data1/oa_pdf/8a/87/IJNMR-21-345.PMC4979255.pdf
Available from: http://www.who.int/reproductivehealth/ publications/violence/24159358X/en/.,Non-OADS,/arxiv_data1/oa_pdf/b4/da/IJNMR-21-368.PMC4979259.pdf
Available from: http://www.jahannews.com.,Non-OADS,/arxiv_data1/oa_pdf/61/54/IJNMR-21-372.PMC4979260.pdf
Available from: http://www.thebump.com/a/best‑sex‑position s‑for‑getting‑pregnant.,Non-OADS,/arxiv_data1/oa_pdf/99/de/IJNMR-21-379.PMC4979261.pdf
Available  from: http://www.webmd.com/infertility‑and‑reproduction/ features/truth‑about‑sexual‑positions‑getting‑pregnant.,Non-OADS,/arxiv_data1/oa_pdf/99/de/IJNMR-21-379.PMC4979261.pdf
Available from: http://umm.edu/health/medical/altmed/ treatment/massage.,Non-OADS,/arxiv_data1/oa_pdf/88/ce/IJNMR-21-402.PMC4979265.pdf
Available from: https://www.yahoo.com/beauty/ massage‑as‑medicine‑111316482388.html.,Non-OADS,/arxiv_data1/oa_pdf/88/ce/IJNMR-21-402.PMC4979265.pdf
2010 July  7 Available from: http://www.oarsi.org/sites/default/files/ docs/2013/oarsi‑omearact_initiative‑new_oa_pain_measure.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/a4/8c/IJNMR-21-417.PMC4979267.pdf
https://oarsi org/2014 [cited 2014 Aug 11]; Available  from: URL: https://oarsi.org.,OADS,/arxiv_data1/oa_pdf/a4/8c/IJNMR-21-417.PMC4979267.pdf
Available  from: http://kb.osu.edu/dspace/handle/1811/60284.,OADS,/arxiv_data1/oa_pdf/7c/d4/IJNMR-21-436.PMC4979270.pdf
Available from: http://www.chop.edu/services/ hospital‑school‑program.,Non-OADS,/arxiv_data1/oa_pdf/7c/d4/IJNMR-21-436.PMC4979270.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ed/30/omw058.PMC4979272.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3c/f6/omw027.PMC4979291.pdf
": Concept map for conversational learning summarizationInternational Journal of Applied and Basic Medical Research, Jul-Sep 2016, Vol 6, Issue 3 153moderators for emerging keywords and agreeable statements   The emerging arguments and consensus statements at the  end of thread were further refined and restructured for  sense‑making  This “extracted” sense‑making and the process  adapted to attain the same was pictorially depicted by  interactive infographics on concept map scaffolding as process  summary for each learning thread  Open aid software such  as Compendium (http://compendiuminstitute.net) FreeMind  map software, EDraw (https://www.edrawsoft.com/freemind.",OADS,/arxiv_data1/oa_pdf/38/3c/IJABMR-6-151.PMC4979293.pdf
Available  from: http://www.mciindia.org/Rules‑and‑Regulation/Ethics%20 Regulations‑2002.pdf.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.mciindia.org/tools/ announcement/MCI_booklet.pdf.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from:  http://www.mciindia.org/Rules‑and‑Regulation/GME_REGULATIONS.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from:  http://www.mciindia.org/fdp/MCI_decisions_on_MET .pdf.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.icmr.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.icmr.nic.in/bioethics/ final_cpcsea.pdf.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.envfor.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.ich.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.nus.edu.sg/irb/Articles/ WHO%20GCP%201995.pdf.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.cdsco.nic.in/forms/contentpage1.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.ncdrc.nic.in/1_1.html.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available from: http://www.medhum.,Non-OADS,/arxiv_data1/oa_pdf/77/1c/IJABMR-6-157.PMC4979294.pdf
Available  from: https://www.amee.org/getattachment/Conferences/AMEE ‑ Past‑ Conferences/AMEE‑ Conference‑2008/Introduction‑to ‑Medical‑ Education‑Bradley ‑Mattick.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a2/00/IJABMR-6-182.PMC4979300.pdf
Available from: http://www.apps.searo.who.int/pds_docs/B3426.,OADS,/arxiv_data1/oa_pdf/85/8e/IJABMR-6-191.PMC4979302.pdf
Available  from: http://www.who.int/whr/2008/whr08_en.pdf.,OADS,/arxiv_data1/oa_pdf/85/8e/IJABMR-6-191.PMC4979302.pdf
Available from: http://www.mciindia.org/RulesandRegulations/ GraduateMedicalEducationRegulations1997.aspx.,Non-OADS,/arxiv_data1/oa_pdf/47/d1/IJABMR-6-215.PMC4979307.pdf
Available from: https://www.cdn.auckland.ac.nz/assets/education/ hattie/docs/teachers‑make‑a‑difference‑ACER‑(2003).pdf.,Non-OADS,/arxiv_data1/oa_pdf/99/2b/IJABMR-6-220.PMC4979308.pdf
Available from: http://www.cybersight.org/bins/volume_page.,Non-OADS,/arxiv_data1/oa_pdf/4a/10/AMS-6-50.PMC4979343.pdf
"This is an open-access article distributed under the terms of the Creative Com - mons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material  just in noncommercial usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/7a/87/aapm-06-02-26172.PMC4979454.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b1/c3/rjw130.PMC4979529.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/3b/rjw114.PMC4979530.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e2/8a/rjw110.PMC4979531.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c2/61/main.PMC4979532.pdf
Contents lists available at ScienceDirect Clinical Oncology journal homepage: www.clinicaloncologyonline.net http://dx.doi.org/10.1016/j.clon.2016.02.009 0936-6555/ /C2112016 The Royal College of Radiologists.,Non-OADS,/arxiv_data1/oa_pdf/c2/61/main.PMC4979532.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0b/23/main.PMC4979596.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.07.056 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/0b/23/main.PMC4979596.pdf
"(2016),  http://dx.doi.org/10.1007/s12565-016-0349-7 .",Non-OADS,/arxiv_data1/oa_pdf/0b/23/main.PMC4979596.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/bd/23/ppa-10-1471.PMC4979597.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1471–1479Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1471OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S11259 8 comparison of adherence and persistence among  adults with type 2 diabetes mellitus initiating  saxagliptin or linagliptin Amanda M Farr1 John J sheehan2 Brian M Davis1 David M smith1 1life sciences, Truven health Analytics,   an iBM company, cambridge, MA,   2health economics and Outcomes  research – Diabetes, AstraZeneca,   Fort Washington, PA, UsABackground:  Adherence and persistence to antidiabetes medications are important to control  blood glucose levels among individuals with type 2 diabetes mellitus (T2D).",Non-OADS,/arxiv_data1/oa_pdf/bd/23/ppa-10-1471.PMC4979597.pdf
"Keywords:  type 2 diabetes, dipeptidyl peptidase-4 inhibitors, saxagliptin, linagliptin, adherence,  discontinuation Introduction In the US, the incidence and prevalence of diabetes mellitus have risen dramatically.1  Using 2012 data, the Centers for Disease Control and Prevention estimates that  29 million individuals in the US have diabetes mellitus.2 Among individuals with  diabetes mellitus, the majority have type 2 diabetes mellitus (T2D).3 T2D is man - aged with lifestyle modifications, such as diet and exercise, and with medications.4–6  Controlling diabetes mellitus by maintaining low blood glucose levels, measured correspondence: Amanda M Farr life sciences, Truven health Analytics,  an iBM company, 150 cambridgepark  Drive, cambridge, MA 02140, UsA Tel +1 603 801 5193 email amanda.farr@truvenhealth.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Farr et al Running head recto: Adherence and persistence with saxagliptin vs linagliptin DOI: http://dx.doi.org/10.2147/PPA.S11259 8",Non-OADS,/arxiv_data1/oa_pdf/bd/23/ppa-10-1471.PMC4979597.pdf
"The poster’s abstract was  published in the Journal of Managed Care & Specialty Phar - macy , supplement volume 21, number 10-a and may be found  here: http://www.amcp.org/WorkArea/ DownloadAsset .",Non-OADS,/arxiv_data1/oa_pdf/bd/23/ppa-10-1471.PMC4979597.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/bd/23/ppa-10-1471.PMC4979597.pdf
T HIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE ( http://creativecommons.o rg/licenses/by-nc-nd/4.0/ ).ISSN 2452-302X http://dx.doi.org/10.1016/j.jacbts.2016.03.003,Non-OADS,/arxiv_data1/oa_pdf/6d/cd/main.PMC4979747.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/ by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6d/cd/main.PMC4979747.pdf
Medicine (2016) 95:31(e3485)Received: 28 September 2015 / Received in ﬁnal form: 16 March 2016 / Accepted: 31 March 2016 http://dx.doi.org/10.1097/MD.0000000000003485Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/fe/2c/medi-95-e3485.PMC4979769.pdf
Medicine (2016) 95:31(e4076)Received: 9 January 2016 / Received in ﬁnal form: 1 June 2016 / Accepted: 5 June 2016 http://dx.doi.org/10.1097/MD.0000000000004076Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/3f/79/medi-95-e4076.PMC4979771.pdf
Medicine (2016) 95:31(e4108)Received: 28 January 2016 / Received in ﬁnal form: 3 June 2016 / Accepted: 9 June 2016 http://dx.doi.org/10.1097/MD.0000000000004108Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/63/bc/medi-95-e4108.PMC4979772.pdf
International Diabetes Federation; 2014. http://www.diabetesatlas.org/content/epidemiology-and-morbidity.,Non-OADS,/arxiv_data1/oa_pdf/63/bc/medi-95-e4108.PMC4979772.pdf
Diabetes Hong Kong; 2008. http://www.fhb.gov.hk/beStrong/ ﬁles/organizations/O017.pdf.,Non-OADS,/arxiv_data1/oa_pdf/63/bc/medi-95-e4108.PMC4979772.pdf
Department of Health (HK); 2012. http://www.pco.gov.hk/english/ initiatives/frameworks.html.,Non-OADS,/arxiv_data1/oa_pdf/63/bc/medi-95-e4108.PMC4979772.pdf
Primary Care Of ﬁce (HK); 2013 http://www.pco.gov.hk/english/resource/ ﬁles/RF_DM_full.pdf.,Non-OADS,/arxiv_data1/oa_pdf/63/bc/medi-95-e4108.PMC4979772.pdf
Medicine (2016) 95:31(e4111)Received: 28 January 2016 / Received in ﬁnal form: 5 May 2016 / Accepted: 9 June 2016 http://dx.doi.org/10.1097/MD.0000000000004111Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/3c/15/medi-95-e4111.PMC4979773.pdf
"Appendix 1 During consultations to general practice, general practitioners use the Read system to code all morbidity to eighteen diagnoses codes (http://www.gp-training.net/it/synergy_archive/synergy/readcode.htm).",Non-OADS,/arxiv_data1/oa_pdf/3c/15/medi-95-e4111.PMC4979773.pdf
Available from: http://www.nice.org.uk/guidance/cg177.,Non-OADS,/arxiv_data1/oa_pdf/3c/15/medi-95-e4111.PMC4979773.pdf
Medicine (2016) 95:31(e4176)Received: 1 December 2015 / Received in ﬁnal form: 9 May 2016 / Accepted: 6 June 2016 http://dx.doi.org/10.1097/MD.0000000000004176Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
"All statistical analyses were performed using Empower (R)(www.empowerstats.com, X&Y solutions, Inc., Boston, MA)and R (http://www.R-project.org) and Statistical Package for Social Sciences (SPSS) 21.0 software (IBM, Armonk, NY), with a 2-sided signi ﬁcant level setting at P<0.05.",OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
"Threshold evaluation by ROC analysis For tumor shrinkage threshold assessment, ROC curve analysis yielded –8.32% in SLD as the optimal threshold for responsive- ness/nonresponsiveness with respect to OS (Supplementary Figure S1, http://links.lww.com/MD/B164) and the AUC areaunder the ROC curve was 0.714 (95% con ﬁdence interval [95% CI]: 0.574 –0.849, P=0.002).",OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
"The linear regression analysis of PFS and tumor shrinkage rate indicated that longer PFS was positively correlatedwith higher tumor shrinkage rate ( P<0.001) (Supplementary Figure S2, http://links.lww.com/MD/B164).",OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
"The curve of linear regression analysis of OS and tumor shrinkage rateindirectly showed that OS was positively correlated with tumor shrinkage ( P=0.071) (Supplementary Figure S3, http://links.lww.",OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
"Responder patients who received Ge ﬁtinib or Erlotinib had a better outcome in comparison to nonresponder patients for PFS and OS (Supplementary Tables 1 and 2, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
"Although the responder patients who received ZD6474 had no statistically signi ﬁcant, the results of the univariate analyses indicated that the nonresponder patients hadhigher hazard of progression or death from the target therapy (Supplementary Tables 1 and 2, http://links.lww.com/MD/B164).",Non-OADS,/arxiv_data1/oa_pdf/06/d2/medi-95-e4176.PMC4979775.pdf
Medicine (2016) 95:31(e4200)Received: 25 November 2015 / Received in ﬁnal form: 3 June 2016 / Accepted: 12 June 2016 http://dx.doi.org/10.1097/MD.0000000000004200Quality Improvement Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/7f/f8/medi-95-e4200.PMC4979779.pdf
Medicine (2016) 95:31(e4235)Received: 2 May 2016 / Received in ﬁnal form: 10 June 2016 / Accepted: 20 June 2016 http://dx.doi.org/10.1097/MD.0000000000004235Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/cf/aa/medi-95-e4235.PMC4979782.pdf
Medicine (2016) 95:31(e4250)Received: 23 January 2016 / Received in ﬁnal form: 14 June 2016 / Accepted: 19 June 2016 http://dx.doi.org/10.1097/MD.0000000000004250Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/80/ac/medi-95-e4250.PMC4979783.pdf
Medicine (2016) 95:31(e4268)Received: 1 April 2016 / Received in ﬁnal form: 16 June 2016 / Accepted: 22 June 2016 http://dx.doi.org/10.1097/MD.0000000000004268Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/55/be/medi-95-e4268.PMC4979784.pdf
Medicine (2016) 95:31(e4290)Received: 27 April 2016 / Received in ﬁnal form: 7 June 2016 / Accepted: 26 June 2016 http://dx.doi.org/10.1097/MD.0000000000004290Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/a2/75/medi-95-e4290.PMC4979785.pdf
Medicine (2016) 95:31(e4296)Received: 1 May 2016 / Received in ﬁnal form: 20 June 2016 / Accepted: 26 June 2016 http://dx.doi.org/10.1097/MD.0000000000004296Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/11/0c/medi-95-e4296.PMC4979787.pdf
Medicine (2016) 95:31(e4329)Received: 29 February 2016 / Received in ﬁnal form: 28 June 2016 / Accepted: 29 June 2016 http://dx.doi.org/10.1097/MD.0000000000004329Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/3a/98/medi-95-e4329.PMC4979789.pdf
"More than 1500 craniotomies are performedin our healthcare system every year (Appendix 1, http://links.lww.com/MD/B148).",Non-OADS,/arxiv_data1/oa_pdf/3a/98/medi-95-e4329.PMC4979789.pdf
"The clinical information for ABM is listed in Appendix 2, http://links.lww.com/MD/B148.",Non-OADS,/arxiv_data1/oa_pdf/3a/98/medi-95-e4329.PMC4979789.pdf
"Thirdly, >1500 craniotomies are performed in our healthcare system annually (Appendix 1, http://links.lww.com/MD/B148), Figure 2.",Non-OADS,/arxiv_data1/oa_pdf/3a/98/medi-95-e4329.PMC4979789.pdf
Medicine (2016) 95:31(e4334)Received: 19 January 2016 / Received in ﬁnal form: 24 June 2016 / Accepted: 29 June 2016 http://dx.doi.org/10.1097/MD.0000000000004334Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6f/4d/medi-95-e4334.PMC4979791.pdf
Medicine (2016) 95:31(e4338)Received: 27 February 2016 / Received in ﬁnal form: 28 June 2016 / Accepted: 30 June 2016 http://dx.doi.org/10.1097/MD.0000000000004338Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/bf/4d/medi-95-e4338.PMC4979793.pdf
Available at: http://www.ohri.ca/programs/clinical_epidemiol ogy/oxford.asp.,Non-OADS,/arxiv_data1/oa_pdf/bf/4d/medi-95-e4338.PMC4979793.pdf
Medicine (2016) 95:31(e4360)Received: 5 November 2015 / Received in ﬁnal form: 15 June 2016 / Accepted: 30 June 2016 http://dx.doi.org/10.1097/MD.0000000000004360Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/98/b6/medi-95-e4360.PMC4979795.pdf
Medicine (2016) 95:31(e4368)Received: 2 March 2016 / Received in ﬁnal form: 2 July 2016 / Accepted: 4 July 2016 http://dx.doi.org/10.1097/MD.0000000000004368Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/45/5f/medi-95-e4368.PMC4979796.pdf
Medicine (2016) 95:31(e4372)Received: 21 April 2016 / Received in ﬁnal form: 16 June 2016 / Accepted: 30 June 2016 http://dx.doi.org/10.1097/MD.0000000000004372Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/5f/eb/medi-95-e4372.PMC4979798.pdf
Medicine (2016) 95:31(e4376)Received: 11 March 2016 / Received in ﬁnal form: 10 June 2016 / Accepted: 15 June 2016 http://dx.doi.org/10.1097/MD.0000000000004376Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6d/b3/medi-95-e4376.PMC4979801.pdf
Medicine (2016) 95:31(e4384)Received: 5 March 2016 / Received in ﬁnal form: 9 June 2016 / Accepted: 20 June 2016 http://dx.doi.org/10.1097/MD.0000000000004384Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/21/2f/medi-95-e4384.PMC4979804.pdf
Medicine (2016) 95:31(e4388)Received: 11 March 2016 / Received in ﬁnal form: 7 June 2016 / Accepted: 20 June 2016 http://dx.doi.org/10.1097/MD.0000000000004388Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c5/b7/medi-95-e4388.PMC4979805.pdf
Medicine (2016) 95:31(e4395)Received: 24 February 2016 / Received in ﬁnal form: 1 July 2016 / Accepted: 2 July 2016 http://dx.doi.org/10.1097/MD.0000000000004395Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/58/d4/medi-95-e4395.PMC4979808.pdf
Medicine (2016) 95:31(e4411)Received: 11 January 2016 / Received in ﬁnal form: 30 June 2016 / Accepted: 6 July 2016 http://dx.doi.org/10.1097/MD.0000000000004411Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/44/0f/medi-95-e4411.PMC4979812.pdf
Medicine (2016) 95:31(e4417)Received: 16 February 2016 / Received in ﬁnal form: 2 June 2016 / Accepted: 30 June 2016 http://dx.doi.org/10.1097/MD.0000000000004417Meta-Analysis of Observational Studies in Epidemiology Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"We used chi squared distribution to calculate HWE andthe corresponding Pvalues were given in Supplemental Table 1, http://links.lww.com/MD/B159.",OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"Wecalculated pooled OR of other inheritance models based ongenotype distribution data from 8 studies, whose details were shown in Supplemental Table 1, http://links.lww.com/MD/B159.",OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"As for different study design (Supplemental Figure 1, http://links.lww.com/MD/ B159), rs1495741 was signi ﬁcantly negative associated with bladder cancer risk in cohort study (OR =0.91, 95% CI = 0.83 –0.98), hospital-based case-control study (OR =0.83, 95% CI=0.78 –0.88), population-based case-control study (OR = 0.87, 95% CI =0.80 –0.93), and case-control study without further description (OR =0.83, 95% CI =0.75 –0.92).",Non-OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"Sensitivity analysis showed that the association between rs1495741 and bladder cancer was solid when any single study was omitted (Supplemental Figure 2, http://links.lww.com/MD/B159).",Non-OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"The corresponding forest plots and heterogeneity test results were represented in Supplemental Figure 3 to Supplemental Figure 6, http://links.lww.com/MD/ B159.Table 1 Characteristics of the included studies.",OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"Subgroup analysis by region showed OR=2.71, 95% CI =2.30 to 3.20 in Europe, OR =2.098, 95% CI=1.62 to 2.72 in America and OR =0.59, 95% CI =0.26 to 1.36 in Asia (Supplemental Figure 7, http://links.lww.com/MD/ B159).",OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
"As regard to study design, we observed different association strengths between smoking and bladder cancer incohort study (OR =1.48, 95% CI =1.02 –2.14), hospital-based case-control study (OR =2.35, 95% CI =1.51 –3.65), popula- tion-based case-control study (OR =2.79, 95% CI =2.33 –3.34), and case-control study without further description (OR =2.38, 95% CI =1.69 –3.34), as can been seen in Supplemental Figure 8, http://links.lww.com/MD/B159.",Non-OADS,/arxiv_data1/oa_pdf/2d/b3/medi-95-e4417.PMC4979814.pdf
Medicine (2016) 95:31(e4419)Received: 19 April 2016 / Received in ﬁnal form: 21 June 2016 / Accepted: 25 June 2016 http://dx.doi.org/10.1097/MD.0000000000004419Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/d2/46/medi-95-e4419.PMC4979815.pdf
"In addition, we also examined the association between AMI and various de ﬁnitions of depression, but no association was found, although this was mainly due to the small sample size of AMI(Supplementary Table 1, http://links.lww.com/MD/B154).",OADS,/arxiv_data1/oa_pdf/d2/46/medi-95-e4419.PMC4979815.pdf
"Similarly, therewas no association between AMI and the use of psychotropic medications except for antipsychotic use (Supplementary Table 2, http://links.lww.com/MD/B154).",Non-OADS,/arxiv_data1/oa_pdf/d2/46/medi-95-e4419.PMC4979815.pdf
"As noted earlier, we found no association between AMI and mental illness, although this was likely due to the small sample size ofAMI (Supplementary Table 3, http://links.lww.com/MD/B154).",Non-OADS,/arxiv_data1/oa_pdf/d2/46/medi-95-e4419.PMC4979815.pdf
"In addition, after taking into account the use of cardiac medications, we repeatedthe analyses and found comparable results to those presented in Table 2 (Supplementary Table 4, http://links.lww.com/MD/ B154).",Non-OADS,/arxiv_data1/oa_pdf/d2/46/medi-95-e4419.PMC4979815.pdf
Medicine (2016) 95:31(e4420)Received: 17 April 2016 / Received in ﬁnal form: 23 June 2016 / Accepted: 24 June 2016 http://dx.doi.org/10.1097/MD.0000000000004420Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/74/7b/medi-95-e4420.PMC4979816.pdf
Medicine (2016) 95:31(e4432)Received: 6 March 2016 / Received in ﬁnal form: 8 July 2016 / Accepted: 8 July 2016 http://dx.doi.org/10.1097/MD.0000000000004432Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/24/c2/medi-95-e4432.PMC4979820.pdf
Medicine (2016) 95:31(e4438)Received: 1 December 2015 / Received in ﬁnal form: 15 March 2016 / Accepted: 24 June 2016 http://dx.doi.org/10.1097/MD.0000000000004438Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/d9/7f/medi-95-e4438.PMC4979823.pdf
Medicine (2016) 95:31(e4444)Received: 2 May 2016 / Received in ﬁnal form: 5 July 2016 / Accepted: 10 July 2016 http://dx.doi.org/10.1097/MD.0000000000004444Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: http://www.who.int/mediacentre/fact sheets/fs369/en/.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: http://www.diabetes.org/living-with-diabetes/complica tions/mentalhealth/depression.html.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
"Available from: https://www.diabetesaustralia.com.au/depression-and-mental-health.Accessed April 25, 2016.",Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: http://www.nimh.nih.gov/health/ publications/chronic-illness-mental-health-2015/nih-15-mh-8015_151898.pdf.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
].Available from: http://www.healthline.com/health/type-2-diabetes/depression.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: http://www.ctihalifax.com/images/CounselingInABook.pdf.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: http://www.cognitivebehaviouralcoachingworks.com/.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: https://www.mentalhealth.org.uk/a-to-z/d/depression.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Available from: http://www.scireproject.com/outcome-measures- new/beck-depression-inventory-bdi.,Non-OADS,/arxiv_data1/oa_pdf/14/fb/medi-95-e4444.PMC4979825.pdf
Medicine (2016) 95:31(e4445)Received: 8 June 2016 / Received in ﬁnal form: 29 June 2016 / Accepted: 1 July 2016 http://dx.doi.org/10.1097/MD.0000000000004445Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/d8/a0/medi-95-e4445.PMC4979826.pdf
Medicine (2016) 95:31(e4447)Received: 1 April 2016 / Received in ﬁnal form: 7 June 2016 / Accepted: 30 June 2016 http://dx.doi.org/10.1097/MD.0000000000004447Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/5c/d0/medi-95-e4447.PMC4979827.pdf
"However, GGT did notsigniﬁcantly increase the odds ratios for incident DM in a fully adjusted model (Supplemental Table 1, http://links.lww.com/ MD/B172).",Non-OADS,/arxiv_data1/oa_pdf/5c/d0/medi-95-e4447.PMC4979827.pdf
"However, the addition of BMI and/or WC to conventional DM prediction model did not signi ﬁcantly improve the AUC values (Supplemental Table 2, http://links.lww.com/ MD/B172).",Non-OADS,/arxiv_data1/oa_pdf/5c/d0/medi-95-e4447.PMC4979827.pdf
Medicine (2016) 95:31(e4448)Received: 1 December 2015 / Received in ﬁnal form: 8 July 2016 / Accepted: 9 July 2016 http://dx.doi.org/10.1097/MD.0000000000004448Diagnostic Accuracy Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/04/87/medi-95-e4448.PMC4979828.pdf
"eMedicine, Updated: Jan 2014 http://emedicine.medscape.com/article/1819862-overview.Accessed November 4, 2015.",OADS,/arxiv_data1/oa_pdf/04/87/medi-95-e4448.PMC4979828.pdf
Medicine (2016) 95:31(e4452)Received: 12 May 2016 / Received in ﬁnal form: 30 June 2016 / Accepted: 3 July 2016 http://dx.doi.org/10.1097/MD.0000000000004452Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
"Table 1, http://links.lww.com/MD/B163).",Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
"The multiple-adjusted HR values (95% CI) (model 2) were 1.60 (1.30 –1.97) for BMI <21, 1.33 (1.08 –1.64) for BMI 21 to <23, and 1.55 (1.14 –2.10) for BMI ≥29 (Supplementary Table 2, http://links.lww.com/MD/B163).",Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
2014; http://www.mhlw.go.jp/ ﬁle/06-Seisakujouhou-10900000- Kenkoukyoku/overview.pdf.,Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
2014; https://www.health.qld.,Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
2008; http://www.mhlw.go.jp/english/topics/elderly/care/index.html.,Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
2013; http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa13/index.html.,OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
2016; http://www.euro.who.int/en/ health-topics/environment-and-health/urban-health/activities/healthy-cit ies.,Non-OADS,/arxiv_data1/oa_pdf/45/5e/medi-95-e4452.PMC4979829.pdf
Medicine (2016) 95:31(e4453)Received: 7 April 2016 / Received in ﬁnal form: 27 June 2016 / Accepted: 4 July 2016 http://dx.doi.org/10.1097/MD.0000000000004453Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/71/2b/medi-95-e4453.PMC4979830.pdf
Medicine (2016) 95:31(e4455)Received: 19 April 2016 / Received in ﬁnal form: 27 June 2016 / Accepted: 5 July 2016 http://dx.doi.org/10.1097/MD.0000000000004455Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6c/07/medi-95-e4455.PMC4979831.pdf
Available at: http://www.mohw.gov.tw/EN/Ministry/Index.aspx.,Non-OADS,/arxiv_data1/oa_pdf/6c/07/medi-95-e4455.PMC4979831.pdf
Available at: http://nhird.nhri.org.tw/en/ index.html.,Non-OADS,/arxiv_data1/oa_pdf/6c/07/medi-95-e4455.PMC4979831.pdf
Medicine (2016) 95:31(e4458)Received: 6 April 2016 / Received in ﬁnal form: 22 June 2016 / Accepted: 3 July 2016 http://dx.doi.org/10.1097/MD.0000000000004458Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/96/24/medi-95-e4458.PMC4979834.pdf
Medicine (2016) 95:31(e4460)Received: 16 April 2016 / Received in ﬁnal form: 22 June 2016 / Accepted: 10 July 2016 http://dx.doi.org/10.1097/MD.0000000000004460Diagnostic Accuracy Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/23/bc/medi-95-e4460.PMC4979835.pdf
Medicine (2016) 95:31(e4471)Received: 22 March 2016 / Received in ﬁnal form: 7 July 2016 / Accepted: 8 July 2016 http://dx.doi.org/10.1097/MD.0000000000004471Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8d/27/medi-95-e4471.PMC4979839.pdf
Medicine (2016) 95:31(e4476)Received: 15 April 2016 / Received in ﬁnal form: 29 June 2016 / Accepted: 11 July 2016 http://dx.doi.org/10.1097/MD.0000000000004476Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/3c/4a/medi-95-e4476.PMC4979843.pdf
Medicine (2016) 95:31(e4478)Received: 19 April 2016 / Received in ﬁnal form: 6 July 2016 / Accepted: 11 July 2016 http://dx.doi.org/10.1097/MD.0000000000004478Diagnostic Accuracy Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/7c/4f/medi-95-e4478.PMC4979845.pdf
Medicine (2016) 95:31(e4485)Received: 21 June 2016 / Received in ﬁnal form: 7 July 2016 / Accepted: 11 July 2016 http://dx.doi.org/10.1097/MD.0000000000004485Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c5/df/medi-95-e4485.PMC4979846.pdf
Available at: http://www.ginasthma.org/.,Non-OADS,/arxiv_data1/oa_pdf/c5/df/medi-95-e4485.PMC4979846.pdf
Medicine (2016) 95:31(e4489)Received: 27 April 2016 / Received in ﬁnal form: 29 June 2016 / Accepted: 12 July 2016 http://dx.doi.org/10.1097/MD.0000000000004489Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/39/30/medi-95-e4489.PMC4979848.pdf
Medicine (2016) 95:31(e4490)Received: 19 May 2016 / Received in ﬁnal form: 20 June 2016 / Accepted: 12 July 2016 http://dx.doi.org/10.1097/MD.0000000000004490Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"”More details are provided in the Supplemental Digital Content 1 –3, http://links.lww.com/MD/ B173.",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"However, length of hospital stay was reduced by 2.31 days in the cell salvage group compared with the controlgroup (WMD =/C02.31; 95% CI /C02.50 to /C02.11; P<0.001) (Supplemental Digital Content 4A-F, http://links.lww.com/MD/ B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"The use of cell salvage resulted in an overall saving of allogeneic RBC by a relative 99%(RR=1.00; 95% CI 0.92 to 1.09; P=1.00; Supplemental Digital Content 5A, http://links.lww.com/MD/B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"In average 4.70 units (RR =/C04.70; 95% CI /C08.01 to /C01.39; P=0.005) of RBCs per patient could be saved in the cell salvage group (SupplementalDigital Content 5B, http://links.lww.com/MD/B173).",OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"Infection and mortality rate did not vary between the two groups (infection: RR =0.78; 95% CI 0.29 to 2.09; P=0.62; mortality: RR=1.02; 95% CI 0.67 to 1.56; P=0.92; Supplemental Digital Content 5C, D, http://links.lww.com/MD/B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"One trial[21]addressed the number of patients exposed to allogeneic blood transfusion (n =12 cell saver group vs. n =12 control group), and revealed a reduced exposure by a relative of 25% (RR=0.75; 95% CI 0.38 to 1.50; P=0.42; Supplemental Digital Content 6A, http://links.lww.com/MD/B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"In average 1.21 units of RBCs (RR =/C01.21; 95% CI /C02.27 to /C00.16; P=0.02) could be saved (Supplemental Digital Content 6B, http://links.lww.com/MD/B173).",OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"Two studies [11,34]used cell salvage of which one study[34]assessed the number of patients (11 patients per group) exposed to allogeneic RBC transfusion that wasreduced by a relative 78% (RR =0.22; 95% CI 0.07 to 0.66; P= 0.007; Supplemental Digital Content 7A, http://links.lww.com/ MD/B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"Theuse of cell salvage did not reduce infection (RR =1.13; 95% CI 0.47–2.69; P=0.79) or mortality rate (RR =3.00; 95% CI 0.32–27.93; P=0.33; Supplemental Digital Content 7C, D, http://links.lww.com/MD/B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
"All included studies did not provide suf ﬁcient comparable data to either estimate the quality of salved blood or to perform cost analysis (see Supplemental Digital Content 8 –9, http://links.lww.com/ MD/B173).",Non-OADS,/arxiv_data1/oa_pdf/47/e7/medi-95-e4490.PMC4979849.pdf
Medicine (2016) 95:31(e4491)Received: 9 June 2015 / Received in ﬁnal form: 24 June 2016 / Accepted: 12 July 2016 http://dx.doi.org/10.1097/MD.0000000000004491Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/35/d9/medi-95-e4491.PMC4979850.pdf
"[25] The Cochrane Collaboration; 2011;Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://www.cochrane-handbook.orghttp://www.cochrane-handbook.orgUpdated March, 2011.",OADS,/arxiv_data1/oa_pdf/35/d9/medi-95-e4491.PMC4979850.pdf
Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 2011;http://www.cochrane-handbook.orghttp://www.cochrane-handbook.org Updated March 2011.Yuan et al.,OADS,/arxiv_data1/oa_pdf/35/d9/medi-95-e4491.PMC4979850.pdf
Medicine (2016) 95:31(e4497)Received: 20 April 2016 / Received in ﬁnal form: 7 July 2016 / Accepted: 8 July 2016 http://dx.doi.org/10.1097/MD.0000000000004497Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6b/0e/medi-95-e4497.PMC4979851.pdf
Medicine (2016) 95:31(e4498)Received: 18 January 2016 / Received in ﬁnal form: 24 June 2016 / Accepted: 8 July 2016 http://dx.doi.org/10.1097/MD.0000000000004498Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/medi-95-e4498.PMC4979852.pdf
"Search terms included: Ringer, albumin, dextran, hydroxyethyl starch, HES, surgery, operative, bleeding, hemor- rhage, coagulation, and random allocation (See SupplementaryTable 1, http://links.lww.com/MD/B175).",Non-OADS,/arxiv_data1/oa_pdf/cf/3f/medi-95-e4498.PMC4979852.pdf
Medicine (2016) 95:31(e4503)Received: 15 December 2015 / Received in ﬁnal form: 17 May 2016 / Accepted: 13 July 2016 http://dx.doi.org/10.1097/MD.0000000000004503Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/fe/75/medi-95-e4503.PMC4979855.pdf
Medicine (2016) 95:31(e4536)Received: 13 April 2016 / Received in ﬁnal form: 5 July 2016 / Accepted: 14 July 2016 http://dx.doi.org/10.1097/MD.0000000000004536Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/2d/82/medi-95-e4536.PMC4979864.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)Regulation of NCOA3 by XBP1 A Gupta et al 5871 © 2016 Macmillan Publishers Limited, part of Springer Nature.",Non-OADS,/arxiv_data1/oa_pdf/52/a8/onc2016121a.PMC4979996.pdf
We assessed enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and diseasegene association tests using WebGestal t (http://bioinfo.vanderbilt.edu/RESEARCH ARTICLE Mason et al.,OADS,/arxiv_data1/oa_pdf/c8/d0/1600633.PMC4980104.pdf
"sequences to the G_variegatus-3.0.2 genome assembly with BWA v0.7.5a-r405, bwa-mem (http://bio-bwa.sourceforge.net/bwa.shtml).",OADS,/arxiv_data1/oa_pdf/c8/d0/1600633.PMC4980104.pdf
"Raw Illumina sequences were filtered with SeqPrep to remove Illumina adaptersequences, trim low-quality bases, and merge overlapping sequencepairs (parameters: -A AGATCGGAAGAGCACACGTC -B AGATCG- GAAGAGCGTCGTGT -q 13 -o 15 -L 30 -g) (https://github.com/jstjohn/ SeqPrep).",Non-OADS,/arxiv_data1/oa_pdf/c8/d0/1600633.PMC4980104.pdf
"Mitochondrial genomes were assembled using both de novo (SOAP and CAP3, http://seq.cs.iastate.edu/cap3.html) ( 37,56) and reference-based (BWA aln v0.7.5a-r405) ( 57) assembly strategies.",OADS,/arxiv_data1/oa_pdf/c8/d0/1600633.PMC4980104.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/8/e1600633/DC1 fig.,Non-OADS,/arxiv_data1/oa_pdf/c8/d0/1600633.PMC4980104.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/8/e1600978/DC1A.,Non-OADS,/arxiv_data1/oa_pdf/c5/6c/1600978.PMC4980106.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/8/e1600162/DC1 Relaxation of local causality Theoretical analysis of experimental imperfectionsTesting the new inequalityError analysisfig.,Non-OADS,/arxiv_data1/oa_pdf/d1/99/1600162.PMC4980107.pdf
"T. Christof, A. Löbel, PORTA —POlyhedron Representation Transformation Algorithm (2009); http://comopt.ifi.uni-heidelberg.de/software/PORTA/.",OADS,/arxiv_data1/oa_pdf/d1/99/1600162.PMC4980107.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/8/e1600947/DC1table S1.,Non-OADS,/arxiv_data1/oa_pdf/22/5c/1600947.PMC4980108.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/ © The Author(s) (2016) Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/33/20/mtm201654.PMC4980109.pdf
"33 However, this effect was  achieved using a small molecule drug that allows read-through of specific nonsense mutations, which represent only ~12% of  reported human PAX6  mutations (http://lsdb.hgu.mrc.ac.uk/home.",Non-OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"16 PAX6  CAGE data was collected for all available human tissues using  the ZENBU data explorer (http://fantom.gsc.riken.jp/zenbu/, accessed January 2014).",OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"The low, medium, and high score thresholds were determined by taking the distribution of the mean phastCons scores for each of the 2,325 scoring windows and applying a Gaussian mixture model using the R-statistics package (www.r-project.org, version 3.1.2) with the mixtools library (http://cran.r-project.org/web/packages/mixtools/index.html, version 1.0.1).",OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"71 Precisely, TFBS were defined by scanning the peaks from a set of  477 TF ChIP-seq experiments from ENCODE (http://www.encodeproject.org, accessed March 2014) 72 and PAZAR (www.pazar.info, accessed March 2014)73  with the corresponding transcription factor binding profiles were retrieved from the JASPAR database of transcription factor binding site profiles (http://jaspar.genereg.net/, version 5.0).",OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"The combined Segway and ChromHMM segmentation data 17 was  obtained from the ENCODE project at UCSC (http://genome.ucsc.edu/ENCODE/downloads.html, accessed March 2014).",OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"Raw image files were converted to com- posite tagged image file format (TIFF) files using imageJ software (http://imagej.nih.gov/ij/, version 1.48)) with the Bio-Formats plugin (http://www.openmicroscopy.org/site/support/bio-formats5.1/users/imagej/).",OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/  © J W Hickmott et al.",Non-OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
(2016) Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm),Non-OADS,/arxiv_data1/oa_pdf/32/a2/mtm201651.PMC4980111.pdf
"To view a copy of this license, visit http://cre - ativecommons.org/licenses/by-nc-nd/4.0/ © The Author(s) (2016) Supplementary Information accompanies this paper on the Molecular Therapy— Oncolytics  website (http://www.nature.com/mto)",Non-OADS,/arxiv_data1/oa_pdf/8f/6e/mto201619.PMC4980112.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.Quadrivalent versus trivalent inﬂuenza vaccination in Finland 949",Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
http://www.eurosurvei llance.org/ViewArticl e.aspx?ArticleId= 19700 7.,Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.stat.ﬁ/til/vaerak/ tau_en.html .,OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.stat.ﬁ/til/kuol/index_en.,OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.who.int/inﬂuenza/ vaccines/virus/en/ .,Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.who.int/inﬂuenza/gisrs_laboratory/ ﬂunet/en/ .,Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.stat.ﬁ/til/ksyyt/index_en.,OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.stm.,Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: https://easiointi.kela.ﬁ/laakekys_ app/LaakekysApplication?kieli=en .,Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.stat.ﬁ/til/khi/ index_en.html .,OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available: at: http://www.stat.ﬁ/til/ktps/ index_en.html .,OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at: http://www.thl.ﬁ/ﬁ/web/ rokottaminen/rokotteet/kausi-inﬂuenssarokote/vakavalle-inﬂuenssalle-alttiiden-lahipiiri .,Non-OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
Available at http://www.cdc.gov/ﬂu/ﬂuvaxview/coverage-1213estimates.htm#data .,OADS,/arxiv_data1/oa_pdf/1a/28/40273_2016_Article_430.PMC4980401.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/55/3f/10620_2016_Article_4264.PMC4980407.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/3c/10/40273_2016_Article_410.PMC4980411.pdf
2011. https://www.adjuvantonline.com .,Non-OADS,/arxiv_data1/oa_pdf/3c/10/40273_2016_Article_410.PMC4980411.pdf
2009. https://www.zorginstituutnederland.nl/ binaries/content/documents/zinl-www/documenten/publicaties/ geneesmiddelbeoordelingen/2009/0903-hpv-vaccin-type-6-11-16-en-18-gardasil/0903-hpv-vaccin-type-6-11-16-en-18-gardasil/HPV-vaccin ?,Non-OADS,/arxiv_data1/oa_pdf/3c/10/40273_2016_Article_410.PMC4980411.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/71/a8/10620_2016_Article_4159.PMC4980417.pdf
E-mail: alessandro.cirla@sanmarcovet.it Original Article DOI: http://dx.doi.org/10.4314/ovj.v6i2.7  Submitted: 07/02/2016 Accepted: 25/06/2016 Published: 21/07/201 6 Automated tru-cut imaging-guided core needle biopsy of canine o rbital  neoplasia.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
115http://www.openveterinaryjournal.com A. Cirla et al.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
116http://www.openveterinaryjournal.com A. Cirla et al.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
117http://www.openveterinaryjournal.com A. Cirla et al.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
118http://www.openveterinaryjournal.com A. Cirla et al.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
119http://www.openveterinaryjournal.com A. Cirla et al.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
120http://www.openveterinaryjournal.com A. Cirla et al.,Non-OADS,/arxiv_data1/oa_pdf/38/16/OpenVetJ-6-114.PMC4980476.pdf
"E-mail: andreazatelli1@gmail.comOriginal Article DOI: http://dx.doi.org/10.4314/ovj.v6i2.8 Submitted: 10/03/2016 Accepted: 20/07/2016 Published: 30/07/201 6 The effect of renal diet in association with enalapril or benaz epril on  proteinuria in dogs with proteinuric chronic kidney disease  A. Zatelli1,*, X. Roura2, P. D’Ippolito1, M. Berlanda3 and E. Zini3,4,5 1Medical Consultancy Services, G. Calì Street 60, TBX1424 TàXbiex, Malta 2Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Spain 3Department of Animal Medicine, Production and Health, viale dell’Università 16, 35020 Legnaro (PD), University  of Padova, Italy 4Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057  Zurich, Switzerland 5Istituto Veterinario di Novara, Strada Provinciale 9, 28060 Granozzo con Monticello (NO), Italy Abstract Treating proteinuria in dogs reduces the progression of chronic  kidney disease (CKD); renal diets and angiotensin - converting enzyme (ACE)-inhibitors are cornerstones of treatmen t. Whether different ACE-inhibitors have distinct  kidney protective effects is unknown; it is therefore hypothesi zed that renal diets and enalapril or benazepril have  different beneficial effects in proteinuric CKD dogs.",Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
122http://www.openveterinaryjournal.com A. Zatelli et al.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
"Randomization was achieved with a software (MedCalc®, Version 11.3.0.0 (http://www.medcalc.com/)).",OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
123http://www.openveterinaryjournal.com A. Zatelli et al.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
124http://www.openveterinaryjournal.com A. Zatelli et al.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
125http://www.openveterinaryjournal.com A. Zatelli et al.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
126http://www.openveterinaryjournal.com A. Zatelli et al.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
127http://www.openveterinaryjournal.com A. Zatelli et al.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
Available at: http://www.iris-kidney.com/guidelines.,Non-OADS,/arxiv_data1/oa_pdf/ad/aa/OpenVetJ-6-121.PMC4980477.pdf
"E-mail: naginaajk@gmail.comOriginal Article DOI: http://dx.doi.org/10.4314/ovj.v6i2.9  Submitted: 21/01/2016 Accepted: 23/07/2016 Published: 04/08/201 6 Effect of melatonin on maturation capacity and fertilization of  Nili-Ravi  buffalo ( Bubalus bubalis ) oocytes G. Nagina1,*, A. Asima1, U. Nemat2 and A. Shamim1 1PMAS Arid Agriculture University, Rawalpindi, Pakistan 2University of Animal and Veterinary Sciences Lahore, Pakistan Abstract This study evaluated the effect of melatonin supplementation of  in vitro  maturation media on in vitro  maturation  (IVM) and in vitro  fertilization (IVF) rate of buffalo oocytes.",Non-OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
129http://www.openveterinaryjournal.com G. Nagina et al.,OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
130http://www.openveterinaryjournal.com G. Nagina et al.,OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
131http://www.openveterinaryjournal.com G. Nagina et al.,OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
132http://www.openveterinaryjournal.com G. Nagina et al.,OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
133http://www.openveterinaryjournal.com G. Nagina et al.,OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
134http://www.openveterinaryjournal.com G. Nagina et al.,OADS,/arxiv_data1/oa_pdf/af/af/OpenVetJ-6-128.PMC4980478.pdf
"E -mail: marcodigiuseppe@yahoo.comCase Report DOI: http://dx.doi.org/10.4314/ovj.v6i2.10  Submitted: 26/03/2016 Accepted: 29/07/2016 Published: 05/08/206 Cystolithiasis in a Syrian hamster: a different outcome D. Petrini1, M. Di Giuseppe2,*, G. Deli3 and C. De Caro Carella4 1Freelance Veterinarian, Pisa, Italy 2Centro Veterinario per Animali Esotici, Viale Regione Siciliana Sud – Est 422-426, 90129 Palermo, Italy 3Freelance Veterinarian, Roma, Italy 4School of Veterinary Medicine, Louisiana State University, USA Abstract A 14-month-old intact male Syrian hamster was admitted for leth argy and hematuria.",Non-OADS,/arxiv_data1/oa_pdf/64/07/OpenVetJ-6-135.PMC4980479.pdf
http://www.openveterinaryjournal.com D. Petrini et al.,Non-OADS,/arxiv_data1/oa_pdf/64/07/OpenVetJ-6-135.PMC4980479.pdf
http://www.openveterinaryjournal.com D. Petrini et al.,Non-OADS,/arxiv_data1/oa_pdf/64/07/OpenVetJ-6-135.PMC4980479.pdf
http://www.openveterinaryjournal.com D. Petrini et al.,Non-OADS,/arxiv_data1/oa_pdf/64/07/OpenVetJ-6-135.PMC4980479.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2012 (9)/C1 650g20 min /C28208C /C1/C1 Not specified For FCM: no ultracentrifugation; forEM, NTA and MS:filtration (800 nm filter);3/C2920,500 g60 min/C1 80/C1400 nm EM, NTA, FCM, MSIsolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"The EV pellets of each of 4 corresponding tubes were resuspended in PBS, pooledIsolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"Because light scattering of EVs is dependent on a range of factors, such assize, cargo, and membrane composition, these findings could be indicative for recovery of different EV subsets inIsolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"Bars represent mean (n /C302); error bars represent minimum and maximum observed values.Isolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"Nevertheless, if steric hindrance of antibody binding by HA did take place onEVs, it could also hamper other antibody-based detectionassays, making HYase treatment indispensable.Isolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"12 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"Bars represent mean (n /C302); error bars represent minimum and maximum observed values.Isolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 13 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"14 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2011;15:756 /C162.Isolation of CD44 /C27extracellular vesicles from synovial fluid Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751 15 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
2016. doi: http://dx.doi.org/10.1002/jor.23212 20.,OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2013;2:20360, doi: http://dx.doi.org/10.3402/jev.v2i0.",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2014;3:24215, doi: http://dx.doi.org/10.3402/jev.v3.24215.",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
2013. doi:http://dx.doi.org/10.1111/jth.12207 26.,Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2014;3:26913, doi: http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2015;4:28680, doi: http://dx.doi.org/10.3402/jev.v4.28680 38.",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2015;4:29509, doi: http://dx.doi.org/10.3402/ jev.v4.29509 40.",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"2015; 4:29260, doi: http://dx.doi.org/10.3402/jev.v4.29260 41. van Antwerpen R, La Belle M, Navratilova E, Krauss RM.",Non-OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"16 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31751 - http://dx.doi.org/10.3402/jev.v5.31751",OADS,/arxiv_data1/oa_pdf/45/c3/JEV-5-31751.PMC4980521.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) OPEN Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab Leukemia (2016) 30,1763 –1766; doi:10.1038/leu.2016.41 Infusion-related reactions (IRRs) elicited by therapeutic antibodies are commonly observed in the treatment of hematologicmalignancies.",Non-OADS,/arxiv_data1/oa_pdf/55/e2/leu201641a.PMC4980557.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu).",Non-OADS,/arxiv_data1/oa_pdf/55/e2/leu201641a.PMC4980557.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) OPEN Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab Leukemia (2016) 30,1763 –1766; doi:10.1038/leu.2016.41 Infusion-related reactions (IRRs) elicited by therapeutic antibodies are commonly observed in the treatment of hematologicmalignancies.",Non-OADS,/arxiv_data1/oa_pdf/af/ae/leu201632a.PMC4980558.pdf
Available at: https://clinicaltrials.gov/show/ NCT01804985 NLM Identi ﬁer: NCT01804985 2015.,Non-OADS,/arxiv_data1/oa_pdf/91/26/leu2016115a.PMC4980559.pdf
Available at https://clinicaltrials.gov/ct2/show/NCT01657604 NLM Identi ﬁer: NCT01657604; 2014.,Non-OADS,/arxiv_data1/oa_pdf/91/26/leu2016115a.PMC4980559.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/Stopping treatment in CML S Saußele et al 1647 © 2016 Macmillan Publishers Limited Leukemia (2016) 1638 –1647",Non-OADS,/arxiv_data1/oa_pdf/91/26/leu2016115a.PMC4980559.pdf
"To view a copy of this license, visit http://creativeco mmons.org/licenses/by-nc-nd/4.0/ The Supplementary Information that accompanies this paper is available o n the Immunology and Cell Biology webs ite (http://www.nature.com/icb)Modeling T-cell activation HD Moreau et al 688 Immunology and Cell Biology",Non-OADS,/arxiv_data1/oa_pdf/fe/f4/icb201636a.PMC4980574.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/10/e0/main.PMC4980699.pdf
http://dx.doi.org/10.1016/j.btre.2015.04.0062215-017X/ ã 2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/10/e0/main.PMC4980699.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  7  (2015)  51–54 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.else  vie  r.com/locat  e/btre,Non-OADS,/arxiv_data1/oa_pdf/10/e0/main.PMC4980699.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6e/a5/main.PMC4980701.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.004 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/6e/a5/main.PMC4980701.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  10–15 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/6e/a5/main.PMC4980701.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be  found,  in the  online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.08.004 .",OADS,/arxiv_data1/oa_pdf/6e/a5/main.PMC4980701.pdf
DOI  of  original  article:  http://dx.doi.org/10.1016/j.btre.2015.03.005 DOI  of  original  article:  http://dx.doi.org/10.1016/j.btre.2015.03.005 *  Corresponding  author.,OADS,/arxiv_data1/oa_pdf/16/62/main.PMC4980702.pdf
http://dx.doi.org/10.1016/j.btre.2015.06.003 2215-017X/ ã  2015  Published  by  Elsevier  B.V.,Non-OADS,/arxiv_data1/oa_pdf/16/62/main.PMC4980702.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  160 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/16/62/main.PMC4980702.pdf
http://dx.doi.org/10.1016/j.btre.2015.10.004 2215-017X/ ã  2015  Published  by  Elsevier  B.V.,Non-OADS,/arxiv_data1/oa_pdf/90/22/main.PMC4980703.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  110–115 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/90/22/main.PMC4980703.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/37/1f/main.PMC4980704.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.006 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/37/1f/main.PMC4980704.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  16–23 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/37/1f/main.PMC4980704.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be  found,  in the  online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.08.006 .",OADS,/arxiv_data1/oa_pdf/37/1f/main.PMC4980704.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/04/07/main.PMC4980705.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.005 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/04/07/main.PMC4980705.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  24–35 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/04/07/main.PMC4980705.pdf
"Plasmids  pMJH46,  pMJH65  and  pCMT- ﬂp were  deposited  with  Addgene  (https://www.addgene.org/ )  with the  plasmid  numbers  67,272,  67,273  and  67,274,  respectively.",OADS,/arxiv_data1/oa_pdf/04/07/main.PMC4980705.pdf
"16  (1)  (1988) 355,  doi:http://dx.doi.org/10.1093/nar/16.1.355 .M.J.",Non-OADS,/arxiv_data1/oa_pdf/04/07/main.PMC4980705.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/ae/33/main.PMC4980706.pdf
http://dx.doi.org/10.1016/j.btre.2015.10.008 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/ae/33/main.PMC4980706.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  116–123 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/ae/33/main.PMC4980706.pdf
The  sequences  obtained  were  compared  with  those  present  in GenBank  database  from  the  National  Center  for  Biotechnology Information  (NCBI)  by  using  BLAST  tools  (http://blast.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/ae/33/main.PMC4980706.pdf
http://dx.doi.org/10.1016/j.btre.2015.10.009 2215-017X/ ã  2015  Published  by  Elsevier  B.V.,Non-OADS,/arxiv_data1/oa_pdf/7b/be/main.PMC4980707.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  124–132 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/7b/be/main.PMC4980707.pdf
"(2015)  ,  doi:http://dx.doi.org/10.1007/s40011-015-0603-0 .",Non-OADS,/arxiv_data1/oa_pdf/7b/be/main.PMC4980707.pdf
"(2012)  ,  doi:http://dx.doi.org/ 10.1007/s00449-012-0820-3 .",Non-OADS,/arxiv_data1/oa_pdf/7b/be/main.PMC4980707.pdf
"(2014)  ,  doi:http://dx.doi.org/ 10.1007/s13213-014-0987-8 .T.",Non-OADS,/arxiv_data1/oa_pdf/7b/be/main.PMC4980707.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/11/40/main.PMC4980709.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.0028 Matthew J. Tyska Cellular and Molecular Gastroenterology and Hepatology Vol.,OADS,/arxiv_data1/oa_pdf/11/40/main.PMC4980709.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9d/7e/main.PMC4980711.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.005 Cellular and Molecular Gastroenterology and Hepatology 2016;2:1,OADS,/arxiv_data1/oa_pdf/9d/7e/main.PMC4980711.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d0/54/main.PMC4980712.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.0036 Shanthi Srinivasan Cellular and Molecular Gastroenterology and Hepatology Vol.,Non-OADS,/arxiv_data1/oa_pdf/d0/54/main.PMC4980712.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/58/main.PMC4980713.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2016.01.005 Cellular and Molecular Gastroenterology and Hepatology 2016;2:111,OADS,/arxiv_data1/oa_pdf/af/58/main.PMC4980713.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/de/main.PMC4980714.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2016.01.001March 2016 Editorial 119,Non-OADS,/arxiv_data1/oa_pdf/7a/de/main.PMC4980714.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/26/main.PMC4980715.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2016.01.002March 2016 Editorial 115,Non-OADS,/arxiv_data1/oa_pdf/c9/26/main.PMC4980715.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/76/a9/main.PMC4980716.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.00710 Tor C. Savidge Cellular and Molecular Gastroenterology and Hepatology Vol.,OADS,/arxiv_data1/oa_pdf/76/a9/main.PMC4980716.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/15/81/main.PMC4980718.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.006 Figure 1.,OADS,/arxiv_data1/oa_pdf/15/81/main.PMC4980718.pdf
(Cell Mol Gastroenterol Hepatol 2016;2:222 –237; http://dx.doi.org/10.1016/j.jcmgh.2015.12.001 )Keywords: Colon Cancer; Early Detection; Molecular Imaging.,Non-OADS,/arxiv_data1/oa_pdf/ed/c4/main.PMC4980721.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/c4/main.PMC4980721.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.12.001,OADS,/arxiv_data1/oa_pdf/ed/c4/main.PMC4980721.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/3c/1e/main.PMC4980734.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.007 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/3c/1e/main.PMC4980734.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  138 –143 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/3c/1e/main.PMC4980734.pdf
http://dx.doi.org/10.1016/j.btre.2015.10.005 2215-017X/ ã  2015  Published  by  Elsevier  B.V.,Non-OADS,/arxiv_data1/oa_pdf/5d/1d/main.PMC4980735.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  105 –109 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.else  vie  r.com/locat  e/btre,Non-OADS,/arxiv_data1/oa_pdf/5d/1d/main.PMC4980735.pdf
"Rep.  (2015)  ,  doi:http://dx.doi.org/10.1016/j.btre.2015.10.006 .",OADS,/arxiv_data1/oa_pdf/5d/1d/main.PMC4980735.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/7a/88/main.PMC4980736.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.002 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/7a/88/main.PMC4980736.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  56–63 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/7a/88/main.PMC4980736.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
http://dx.doi.org/10.1016/j.btre.2015.09.004 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  81–87 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.else  vie  r.com/locat  e/btre,Non-OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
The  peak  list  generated  by Analyst  or  4000  Series  Explorer  software  was  analyzed  using  the MASCOT  search  engine  (http://www.matrixscience.com)  and  the GPS  Explorer  or  Protein  Pilot  software  to  identify  the  peptides.,OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
Bioinformatics  analysis Multiple  sequence  alignment  was  done  using  the  program clustalW  (http://www.ebi.ac.uk/Tools/msa/clustalw2/ ).,OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
I-TASSER server  (http://zhang.bioinformatics.ku.edu/I-TASSER/ )  was  used for  generating  3-D  model  of  the  proteins  and  quality  of  the  ﬁnal models  were  assessed  by  PROCHECK  (http://www.biochem.ucl.ac.,OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
Structural  similarity search  was  performed  using  DALI  server  (http://ekhidna.bio- center.helsinki.,OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
Active  sites  analysis  was  done  using CASTp  program  (http://sts.bioengr.uic.edu/castp )  and  structural superposition  was  done  using  SUPERPOSE  program  (http:// wishart.biology.ualberta.ca/SuperPose/ ).,OADS,/arxiv_data1/oa_pdf/a2/d4/main.PMC4980737.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b4/2e/main.PMC4980738.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2016.01.004March 2016 Editorial 117,Non-OADS,/arxiv_data1/oa_pdf/b4/2e/main.PMC4980738.pdf
http://dx.doi.org/10.1016/j.btre.2015.09.002 2215-017X/ ã  2015  Published  by  Elsevier  B.V.,Non-OADS,/arxiv_data1/oa_pdf/68/80/main.PMC4980739.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  64–71 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/68/80/main.PMC4980739.pdf
"(2014)  ,  doi:http://dx.doi.org/10.1007/s13213-014-0987-8 .",Non-OADS,/arxiv_data1/oa_pdf/68/80/main.PMC4980739.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/7f/main.PMC4980740.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.0044 Timothy L. Denning Cellular and Molecular Gastroenterology and Hepatology Vol.,Non-OADS,/arxiv_data1/oa_pdf/c1/7f/main.PMC4980740.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/26/main.PMC4980741.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.11.001,OADS,/arxiv_data1/oa_pdf/f9/26/main.PMC4980741.pdf
(Cell Mol Gastroenterol Hepatol 2016;2:92 –109; http://dx.doi.org/ 10.1016/j.jcmgh.2015.09.007 ) Keywords: Hirschsprung Disease; Aganglionosis; Cell Therapy; Megacolon; Enteric Nervous System.,Non-OADS,/arxiv_data1/oa_pdf/e1/55/main.PMC4980742.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e1/55/main.PMC4980742.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.09.007,OADS,/arxiv_data1/oa_pdf/e1/55/main.PMC4980742.pdf
Primer sequences were designed using Primer3(http://frodo.wi.mit.edu/primer3/ ) and are listed in Table 2 .,OADS,/arxiv_data1/oa_pdf/e1/55/main.PMC4980742.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/69/main.PMC4980744.pdf
http://dx.doi.org/10.1016/j.btre.2015.09.003 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/80/69/main.PMC4980744.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  72–80 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/80/69/main.PMC4980744.pdf
"Supplementary  material  related  to  this  article  found,  in  the online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.09.003 .",OADS,/arxiv_data1/oa_pdf/80/69/main.PMC4980744.pdf
"Supplementary  material  related  to  this  article  found,  in  the online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.09.003 .",OADS,/arxiv_data1/oa_pdf/80/69/main.PMC4980744.pdf
"Supplementary  material  related  to  this  article  found,  in  the online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.09.003 .",OADS,/arxiv_data1/oa_pdf/80/69/main.PMC4980744.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/78/84/main.PMC4980747.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.12.012March 2016 Editorial 113,Non-OADS,/arxiv_data1/oa_pdf/78/84/main.PMC4980747.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/88/aa/main.PMC4980749.pdf
http://dx.doi.org/10.1016/j.btre.2015.10.003 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/88/aa/main.PMC4980749.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  88–93 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/88/aa/main.PMC4980749.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be  found,  in the  online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.10.003 .",OADS,/arxiv_data1/oa_pdf/88/aa/main.PMC4980749.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/28/e6/main.PMC4980751.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.001 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/28/e6/main.PMC4980751.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  1–9 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.else  vie  r.com/locat  e/btre,Non-OADS,/arxiv_data1/oa_pdf/28/e6/main.PMC4980751.pdf
http://dx.doi.org/10.1002/ep.10606 .,Non-OADS,/arxiv_data1/oa_pdf/28/e6/main.PMC4980751.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/df/a2/main.PMC4980752.pdf
http://dx.doi.org/10.1016/j.btre.2015.10.006 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/df/a2/main.PMC4980752.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  133–137 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.else  vie  r.com/locat  e/btre,Non-OADS,/arxiv_data1/oa_pdf/df/a2/main.PMC4980752.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be  found,  in the  online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.10.006 .",OADS,/arxiv_data1/oa_pdf/df/a2/main.PMC4980752.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/2a/0f/main.PMC4980753.pdf
http://dx.doi.org/10.1016/j.btre.2015.09.001 2215-017X/ ã  2015  The  Authors.,OADS,/arxiv_data1/oa_pdf/2a/0f/main.PMC4980753.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  152–159 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/2a/0f/main.PMC4980753.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be  found,  in the  online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.09.001 .",OADS,/arxiv_data1/oa_pdf/2a/0f/main.PMC4980753.pdf
http://dx.doi.org/10.1016/j.btre.2015.08.008 2215-017X/ ã  2015  Published  by  Elsevier  B.V.,Non-OADS,/arxiv_data1/oa_pdf/41/3b/main.PMC4980756.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biotechnology  Reports  8  (2015)  36–44 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.elsevier.com/locate/btre,Non-OADS,/arxiv_data1/oa_pdf/41/3b/main.PMC4980756.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be  found,  in the  online  version,  at  http://dx.doi.org/10.1016/j.btre.2015.08.008 .",OADS,/arxiv_data1/oa_pdf/41/3b/main.PMC4980756.pdf
"[15]  N.  Kumar,  V.  Pruthi,  Structural  elucidation  and  molecular  docking  of  ferulic acid  from  Parthenium  hysterophorus  possessing  COX-2  inhibition  activity, 3  Biotech  (2014)  ,  doi:http://dx.doi.org/10.1007/s13205-014-0253-6 .",OADS,/arxiv_data1/oa_pdf/41/3b/main.PMC4980756.pdf
Available  from: http://www.archive.org/details/Yoga.As.Philosophy.,Non-OADS,/arxiv_data1/oa_pdf/a8/4d/IJPsyM-38-275.PMC4980891.pdf
Available from: http://www.isha.,Non-OADS,/arxiv_data1/oa_pdf/a8/4d/IJPsyM-38-275.PMC4980891.pdf
Available from: http://www.livestrong.com/ article/149739‑kundalini‑yoga‑dangers/.,Non-OADS,/arxiv_data1/oa_pdf/a8/4d/IJPsyM-38-275.PMC4980891.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/d2/73/IJPsyM-38-285.PMC4980893.pdf
Available from: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/24/9c/IJPsyM-38-315.PMC4980898.pdf
Available from: http://www.apps.who.int/ iris/bitstream/10665/37958/8/9241544228_eng.pdf.,OADS,/arxiv_data1/oa_pdf/e1/9c/IJPsyM-38-336.PMC4980902.pdf
Available  from: http://www.who.int/iris/handle/10665/63529.,OADS,/arxiv_data1/oa_pdf/e1/9c/IJPsyM-38-336.PMC4980902.pdf
Available from: http://www.who.int/ classifications/icf/whodasii/en/.,OADS,/arxiv_data1/oa_pdf/e1/9c/IJPsyM-38-336.PMC4980902.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/dd/c1/IJPsyM-38-344.PMC4980904.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/dd/c1/IJPsyM-38-344.PMC4980904.pdf
Available  from: http://www.accessdata.fda.gov/drugsatfda_ docs/nda/2009/022173s000MedR.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6e/f2/IJPsyM-38-366.PMC4980910.pdf
Available from: http://www.fda.gov/ohrms/dockets/ ac/08/briefing/2008‑4338b1‑03‑Lilly.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6e/f2/IJPsyM-38-366.PMC4980910.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/8f/a2/AIAN-19-295.PMC4980948.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/8f/a2/AIAN-19-295.PMC4980948.pdf
Available from: http://www.ibe‑epilepsy.org/whatsnewdet.,Non-OADS,/arxiv_data1/oa_pdf/42/2c/AIAN-19-344.PMC4980957.pdf
Available from: http://www.nobelprize.org/nobel_prizes/medicine/ laureates/2012/.,Non-OADS,/arxiv_data1/oa_pdf/5b/af/AIAN-19-367.PMC4980961.pdf
Available from: http://www.eurostemcell.org/commentanalysis/ regulation‑ unproven‑ stem ‑cell‑therapies ‑medicinal‑ product ‑or‑ medical‑procedure.,Non-OADS,/arxiv_data1/oa_pdf/5b/af/AIAN-19-367.PMC4980961.pdf
ICMR‑DBT Guidelines for stem cell Research; Available from:  http://icmr.nic.in/stem_cell/stem_cell_guidelines.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5b/af/AIAN-19-367.PMC4980961.pdf
Available  from: http://www.closerlookatstemcells.org/docs/default‑source/ patient‑resources/patient‑handbook‑‑‑english.pdf?sfvrsn=4.,Non-OADS,/arxiv_data1/oa_pdf/5b/af/AIAN-19-367.PMC4980961.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/04/d3/AIAN-19-381.PMC4980964.pdf
Available from: http://www.uic.edu/classes/epid/epid401/lectures/ lecture9.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ca/e4/AIAN-19-418.PMC4980977.pdf
"[a]Dr.J.D.Stenger-Smith, Dr.L.Baldwin, A.Chafin, Dr.P.A.Goodm an Chemistr yDivisio n,Code 4F000 0D,Research Depar tment Naval AirWarfare Cent erWeapons Division 1Administratio nCircle China Lake, CA93555(USA) E-mail :paul.go odman @navy.mil Supp orting Infor mati onand theORCID identificati onnumber (s)forthe autho r(s)ofthis article canbefoundunde rhttp://dx.doi.org/ 10.1002 / open.20160001 3.",Non-OADS,/arxiv_data1/oa_pdf/36/c9/OPEN-5-297.PMC4981047.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e2/d0/hp-4-015.PMC4981084.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Hypoxia Hypoxia 2016:4 15–27Dove press Dove press  submit your manuscript | www.dovepress.co mOriginal researcHopen access to scientific and medical research Open access Full T ext article 15 http: //dx.doi.org/10.2147/HP .S9636 6The 2-oxoglutarate analog 3-oxoglutarate  decreases normoxic hypoxia-inducible factor-1 α in  cancer cells, induces cell death, and reduces tumor  xenograft growth Peppi Koivunen1 stuart M Fell2,3 Wenyun lu4 Joshua D rabinowitz4 andrew l Kung5,6 susanne schlisio2,7 1Biocenter Oulu, Faculty of  Biochemistry and Molecular Medicine,   Oulu center for cell-Matrix  research, University of Oulu, Oulu,   Finland; 2ludwig institute for cancer  research ltd, stockholm, sweden;   3Department of cell and Molecular  Biology, Karolinska institutet,   stockholm, sweden; 4Department of  chemistry and integrative genomics,   Princeton University, Princeton, nJ,   5Department of Medical Oncology,   Dana Farber cancer institute,   Harvard Medical school, Boston,   Ma, 6Department of Pediatrics,   columbia University Medical center,   new Y ork, nY, Usa; 7Department  of Microbiology and Tumor and  cell Biology, Karolinska institutet,   stockholm, sweden correspondence: susanne schlisio   ludwig institute for cancer research  ltd, Karolinska institutet, nobels väg 3,  se-17177 stockholm, sweden   T el +46 8 5248 7117   email susanne.schlisio@licr.ki.s eAbstract:  The cellular response to hypoxia is primarily regulated by the hypoxia-inducible  factors (HIFs).",Non-OADS,/arxiv_data1/oa_pdf/e2/d0/hp-4-015.PMC4981084.pdf
"Hypoxia Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hypoxia-journa lHypoxia is an international, peer-reviewed, open access journal that aims  to improve understanding of the biological response to hypoxia.",Non-OADS,/arxiv_data1/oa_pdf/e2/d0/hp-4-015.PMC4981084.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e2/d0/hp-4-015.PMC4981084.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.ENVIRONMENTAL JUSTICE Volume 8, Number 6, 2015ªMary Ann Liebert, Inc. DOI: 10.1089/env.2015.0025 203",Non-OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"Available at: <http://www.epa.gov/ environmentaljustice/resources/publications/nejac/nejac- cum-risk-rpt-122104.pdf >(accessed July 28, 2014).",OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"Available at: <http://www.epa.gov/environmentaljustice/ resources/publications/nej ac/nejac-research-recommen dations-2014.pdf >(accessed July 25, 2014).",OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"Available at: <http://www.epa.gov/compliance/ ej/plan-ej/index.html >(accessed Oct 27, 2014).",OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"Available at: <http://www.epa.gov/ ncer/rfa/2009/2009_star_cumulative_risk.html >(accessed June 6, 2014).",OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"Available at: <http://www.epa.gov/ncer/events/calendar/ 2012/may14b/proceedings.pdf >(accessed August 5, 2014).",OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"Available at: <https://depts.washington.edu/ccph/pdf_ﬁles/CBPR_ﬁ- nal.pdf >(accessed May 31, 2015).",Non-OADS,/arxiv_data1/oa_pdf/2e/55/env.2015.0025.PMC4981147.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d8/1f/dddt-10-2507.PMC4981156.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2507–2513Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2507Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11482 6 Quantification of simvastatin in mice plasma  by near-infrared and chemometric analysis of  spectral data Usama a Fahmy Department of Pharmaceutics &  Industrial Pharmacy, Faculty of  Pharmacy, King Abdulaziz University,   Jeddah, saudi arabiaAbstract:  Time and cost saving is an essential requirement in pharmacokinetics and  bioequivalence studies.",Non-OADS,/arxiv_data1/oa_pdf/d8/1f/dddt-10-2507.PMC4981156.pdf
"NIR has advantages  over other techniques, as a fast, low cost, and sample destruction, and most importantly,  it uses no specific reagents or extraction procedure prior to sample analysis.7 Utilization of recent and advanced NIR spectrometers with the associated software  packages has led to the emergence of new applications to the NIR technique.8 The  aim of this study is to utilize NIR technique for the quantification of SMV plasma correspondence: Usama a Fahmy Department of Pharmaceutics & Industrial  Pharmacy, Faculty of Pharmacy, King  Abdulaziz University, PO Box 80200,  Jeddah 21589, Saudi Arabia email usamafahmy@hotmail.co mJournal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Fahmy Running head recto: Quantification of simvastatin in mice plasma DOI: http://dx.doi.org/10.2147/DDDT.S114826",Non-OADS,/arxiv_data1/oa_pdf/d8/1f/dddt-10-2507.PMC4981156.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/d8/1f/dddt-10-2507.PMC4981156.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/1f/dddt-10-2507.PMC4981156.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/cia-11-1061.PMC4981157.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1061–1066Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1061CAse serIesopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11063 6 Three cases of systemic amyloidosis successfully  diagnosed by subcutaneous fat tissue biopsy  of the hip Masahisa Arahata1 shigeru shimadoi1 satosi Yamatani1 shin-ichi Hayashi2 shigeharu Miwa2 Hidesaku Asakura3 shinji Nakao4 1Department of Internal Medicine,   Nanto Municipal Hospital, Nanto,   2Department of Diagnostic Pathology,   Graduate school of Medicine and  Pharmaceutical sciences, University  of T oyama, T oyama, 3Department of  Internal Medicine (III), 4Department  of Cellular Transplantation Biology,   Division of Cancer Medicine,   Graduate school of Medical science,   Kanazawa University, Kanazawa, JapanAbstract:  Fine-needle aspiration biopsy of the abdominal fat pad is considered to be a  minimally invasive procedure for diagnosing systemic amyloidosis.",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/cia-11-1061.PMC4981157.pdf
"Written informed consent was obtained Correspondence: Masahisa Arahata Department of Internal Medicine, Nanto  Municipal Hospital, 938 Inami, Nanto,  Toyama 932-0211, Japan Tel +81 763 82 1475 Fax +81 763 82 1853 email rqxhf297@yahoo.co.j p Journal name: Clinical Interventions in Aging Article Designation: Case Series Y ear: 2016 Volume: 11 Running head verso: Arahata et al Running head recto: SA diagnosed by subcutaneous fat tissue biopsy of the hip DOI: http://dx.doi.org/10.2147/CIA.S110636",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/cia-11-1061.PMC4981157.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/cia-11-1061.PMC4981157.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/6d/1b/cia-11-1061.PMC4981157.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/77/64/ott-9-4843.PMC4981158.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4843–4858OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4843Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S11018 9 Salvage therapies in relapsed and/or refractory  myeloma: what is current and what is the future?",Non-OADS,/arxiv_data1/oa_pdf/77/64/ott-9-4843.PMC4981158.pdf
"This review highlights some of the landmark Correspondence: Nishitha Thumallapally Department of internal Medicine,  Staten island University Hospital,  475 Sea view Avenue, Staten island,  New York, NY 10305, USA Tel +1 404 906 8530 email nishithareddy99@gmail.co m Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Thumallapally et al Running head recto: Salvage therapies in relapsed and/or refractory myeloma DOI: http://dx.doi.org/10.2147/OTT.S110189",Non-OADS,/arxiv_data1/oa_pdf/77/64/ott-9-4843.PMC4981158.pdf
"Available from: http://www.cancer.gov/about-cancer/treatment/drugs/ fda-thalidomid e. Accessed May 1, 2016.",Non-OADS,/arxiv_data1/oa_pdf/77/64/ott-9-4843.PMC4981158.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/77/64/ott-9-4843.PMC4981158.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/77/64/ott-9-4843.PMC4981158.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1501–1508Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1501OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10868 8 sexual attitudes, norms, condom use, and  adherence of hispanic and non-hispanic  undergraduate students: a cross-sectional study  of three community colleges in southwestern Us Yelena Bird1 luis h solis2 chinaedu Anulika Mbonu1 1school of Public health, University  of saskatchewan, saskatoon, canada;   2Department of Metallurgical,   Materials and Biomedical engineering,   University of T exas at el Paso, el Paso,   TX, UsAObjective:  To measure the sexual attitudes, norms, condom use, and adherence of Hispanic and  non-Hispanic undergraduate students in three community colleges in the southwestern US.",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Approximately half of these cases  occur among young people aged 18–24 years, accounting for almost $16 billion in correspondence: Yelena Bird school of Public health, University of  saskatchewan, 104 clinic Place, e-Wing  health sciences, room 3322, saskatoon,  sK s7n 5e5, canada Tel +1 306 966 8432 Fax +1 306 966 2264 email yelena.bird@usask.c a Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Bird et al Running head recto: Sexual attitudes of Hispanic and non-Hispanic undergraduate students DOI: http://dx.doi.org/10.2147/PPA.S108688",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available from: http://www.cdc.gov/mmwr/pdf/ ss/ss6304.pd f. Accessed October 25, 2015.",OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available from: http://www.cdc.gov/nchhstp/newsroom/ docs/factsheets/std-trends-508.pd f. Accessed October 27, 2015.",OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available from: http://www.kff.org/ content/archive/1445/std_rep3.htm l. Accessed September 24, 2015.",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available from: http://www.cdc.gov/hiv/pdf/risk_latino.pd f.  Accessed October 24, 2015.",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available  from: http://www.who.int/gho/publications/world_health_statistics/ EN_WHS2012_Full.pd f. Accessed October 14, 2015.",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available from: https://thenationalcampaign.org/why-it-matters/ public-cos t. Accessed November 15, 2015.",Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"Available from: http://www.census.gov/newsroom/facts-for- features/2014/cb14-ff22.htm l. Accessed November 28, 2015.",OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
Available from: http://www.borderhealth.,Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
Available from:  http://factfinder.census.gov/faces/tableservices/jsf/ pages/productview.,OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
Available from: http://www.cdc.,Non-OADS,/arxiv_data1/oa_pdf/96/27/ppa-10-1501.PMC4981160.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f2/95/ppa-10-1489.PMC4981161.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1489–1500Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1489OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S9290 2Patient satisfaction with treatment for alcohol use  disorders: comparing patients with and without  severe mental health symptoms stacey l Mccallum1 Jane M Andrews2,3 Matthew D gaughwin3,4 Deborah A T urnbull1 Antonina A Mikocka-Walus5 1school of Psychology, Faculty  of health sciences, University  of Adelaide, 2Department of  gastroenterology and hepatology,   royal Adelaide hospital, 3school of  Public health, University of Adelaide,   4Drug and Alcohol consultation  liaison service, royal Adelaide  hospital, Adelaide, sA, Australia;   5Department of health sciences,   University of Y ork, heslington, UKBackground:  Previous studies suggest patients with co-occurring alcohol use disorders (AUDs)  and severe mental health symptoms (SMHS) are less satisfied with standard AUD treatment  when compared to patients with an AUD alone.",Non-OADS,/arxiv_data1/oa_pdf/f2/95/ppa-10-1489.PMC4981161.pdf
"Researchers propose that correspondence: stacey l Mccallum room 715, hughes Building, school of  Psychology, Faculty of health sciences,  University of Adelaide, north Terrace,  Adelaide, sA 5005, Australia Tel +61 8 8313 5693 Fax +61 8 8313 3770 email s.mccallum@adelaide.edu.a u Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: McCallum et al Running head recto: Satisfaction with AUD treatment DOI: http://dx.doi.org/10.2147/PPA.S92902",Non-OADS,/arxiv_data1/oa_pdf/f2/95/ppa-10-1489.PMC4981161.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/f2/95/ppa-10-1489.PMC4981161.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c6/d4/ijn-11-3765.PMC4981163.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 3765–3775International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3765OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9462 2 a dual brain-targeting curcumin-loaded  polymersomes ameliorated cognitive dysfunction  in intrahippocampal amyloid- β1–42-injected mice Tingting Jia1,* Zhiguo sun1,* Ying lu1 Jie gao1 hao Zou1 Fangyuan Xie2 guoqing Zhang2 hao Xu3 Duxin sun3 Yuan Yu1 Yanqiang Zhong1 1Department of Pharmaceutical  sciences, school of Pharmacy, The  second Military Medical University,   2Department of Pharmacy, eastern  hepatobiliary surgery hospital,   shanghai, People’s republic of china;   3Department of Pharmaceutical  sciences, school of Pharmacy,   University of Michigan, ann arbor,   MI, Usa *These authors contributed equally  to this workAbstract:  Due to the impermeability of the blood–brain barrier and the nonselective distribution  of drugs in the brain, the therapeutic access to intractable neurological disorders is challenging.",Non-OADS,/arxiv_data1/oa_pdf/c6/d4/ijn-11-3765.PMC4981163.pdf
"A β  protein deposition is a key pathological feature of AD; therefore, the key strategy for correspondence: Yuan Yu;   Yanqiang Zhong Department of Pharmaceutical sciences,  school of Pharmacy, The second Military  Medical University, 325 guohe road,  shanghai 200433, People’s republic  of china Tel/fax +86 21 8187 1285 email pharmyuu@163.co m;   yqzhong68@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Jia et al Running head recto: Curcumin-loaded polymersomes ameliorated cognitive dysfunction DOI: http://dx.doi.org/10.2147/IJN.S94622",Non-OADS,/arxiv_data1/oa_pdf/c6/d4/ijn-11-3765.PMC4981163.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/c6/d4/ijn-11-3765.PMC4981163.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c6/d4/ijn-11-3765.PMC4981163.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/.,Non-OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of Nephrology and Renovascular Disease 2016:9 187–192International Journal of Nephrology and Renovascular Disease Dovepress submit your manuscript | www.dovepress.com Dovepress 187 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJNRD.S111538 Vitamin D receptor gene TaqI and Apal  polymorphisms and steroid responsiveness in  childhood idiopathic nephrotic syndrome Amal A Al-Eisa Mohammad Z Haider Department of Pediatrics, Faculty  of Medicine, Kuwait University,   Safat,  KuwaitBackground: Vitamin D activity is controlled by vitamin D receptors (VDRs), which are affected  by different genetic polymorphisms, including Taq I and Apal restriction fragment length poly- morphisms (RFLPs), which have been reported to be associated with several diseases.",Non-OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
"2,3 The gene sequence encoding  VDR can vary, resulting in polymorphic forms such as the variants produced on Correspondence: Amal A Al-Eisa Department of Pediatrics, Faculty of Medicine, Kuwait University, PO Box 24923, Safat 13110, KuwaitTel +965 2531 9486Fax: +965 2533 8940Email amal@hsc.edu.kwJournal name: International Journal of Nephrology and Renovascular Disease Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Al-Eisa and HaiderRunning head recto: VDR gene Taq I and Apal RFLPs and steroid response in INS DOI: http://dx.doi.org/10.2147/IJNRD.S111538",Non-OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
"International Journal of Nephrology and Renovascular Disease 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journalThe International Journal of Nephrology and Renovascular Disease is   an international, peer-reviewed open access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published   authors.Dovepress 192 Al-Eisa and Haider,Non-OADS,/arxiv_data1/oa_pdf/c2/44/ijnrd-9-187.PMC4981166.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/.,Non-OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of Nephrology and Renovascular Disease 2016:9 183–186International Journal of Nephrology and Renovascular Disease Dovepress submit your manuscript | www.dovepress.com Dovepress 183 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJNRD.S108529 The number of patients with severe encapsulating  peritoneal sclerosis is decreasing in a large  referral center in Germany Daniel Kitterer1 Niko Braun2 M Dominik Alscher1 Stephan Segerer3,* Joerg Latus1,* 1Division of General Medicine and  Nephrology, Department of Internal  Medicine, Robert-Bosch-Hospital,  Stuttgart, Germany;  2Nephrology  Center Stuttgart, Stuttgart, Germany;   3Division of Nephrology, University  Hospital, Zurich, Switzerland *These authors contributed equally to  this workBackground: Encapsulating peritoneal sclerosis (EPS) is the most severe complication   associated with long-term peritoneal dialysis (PD).",Non-OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
"4 Recently, the NEXT -PD Study from Japan Correspondence: Daniel Kitterer Division of General Medicine and Nephrology, Department of Internal Medical, Robert-Bosch-Hospital, Auerbachstraße 110, 70376 Stuttgart, GermanyTel +49 711 8101 3496Fax +49 711 8101 3792Email Daniel.kitterer@rbk.deJournal name: International Journal of Nephrology and Renovascular Disease Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Kitterer et alRunning head recto: Decrease of EPS incidenceDOI: http://dx.doi.org/10.2147/IJNRD.S108529",Non-OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
"International Journal of Nephrology and Renovascular Disease 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journalThe International Journal of Nephrology and Renovascular Disease is   an international, peer-reviewed open access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published   authors.Dovepress 186 Kitterer et al References  1.,Non-OADS,/arxiv_data1/oa_pdf/ea/51/ijnrd-9-183.PMC4981167.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/30/5c/ijn-11-3753.PMC4981168.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 3753–3764International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3753OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11079 6 Polymer nanoparticles for cross-presentation  of exogenous antigens and enhanced cytotoxic  T -lymphocyte immune response chanyoung song* Y oung-Woock Noh* Y ong Taik lim sKKU advanced Institute of  Nanotechnology (saINT), school of  chemical engineering, sungkyunkwan  University, suwon, south Korea *These authors contributed equally  to this workAbstract:  Effective induction of an antigen-specific cytotoxic T lymphocyte (CTL) immune  response is one of the key goals of cancer immunotherapy.",Non-OADS,/arxiv_data1/oa_pdf/30/5c/ijn-11-3753.PMC4981168.pdf
"There - fore, delivery of exogenous tumor-associated antigens to DCs and activation of the  MHC class I-presenting pathway, a process known as cross-presentation, constitute a  crucial part of DC immunotherapy.12 In this regard, the intracellular delivery of anti - gens and induction of CTL responses through cross-presentation pathways have been  realized in several NP systems, such as liposomes, polyelectrolytes, silicon particles,  and poly( d,l-lactide- co-glycolide) (PLGA) particles.13–16correspondence: Yong Taik lim sKKU advanced Institute of  Nanotechnology (saINT), school of  chemical engineering, sungkyunkwan  University, 2066 seobu-ro, Jangan-gu,  suwon 16419, south Korea Tel +82 31 299 4172 Fax +82 31 299 4119 email yongtaik@skku.ed u Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Song et al Running head recto: PEI-coated NPs for cross-presentation and enhanced CTL response DOI: http://dx.doi.org/10.2147/IJN.S110796",Non-OADS,/arxiv_data1/oa_pdf/30/5c/ijn-11-3753.PMC4981168.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/30/5c/ijn-11-3753.PMC4981168.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/30/5c/ijn-11-3753.PMC4981168.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/.,Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2016:7 467–473Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 467 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S110177 Does Spanish instruction for emergency medicine  resident physicians improve patient satisfaction  in the emergency department and adherence to  medical recommendations?",Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"Keywords: medical Spanish, medical education, patient satisfaction, adherence, emergency  department, limited English proficiency (LEP) Introduction According to a 2013 census report, the number of people speaking a language other  than English climbed 158% in the past 2 decades.1 The United States Department  of Commerce Economics and Statistics Administration filed a report on “Language Correspondence: Lisa R Stoneking Department of Emergency Medicine, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724, USATel +1 520 626 5582Email lstoneking@aemrc.arizona.eduJournal name: Advances in Medical Education and Practice Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 7Running head verso: Stoneking et alRunning head recto: Impact of Spanish instruction on patient satisfaction and adherenceDOI: http://dx.doi.org/10.2147/AMEP .S110177",Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"According to the National Council on Interpreting in  Health Care, the definition of a qualified interpreter is “an individual who has been assessed for professional skills, dem-onstrates a high level of proficiency in at least two languages and has the appropriate training and experience to interpret with skill and accuracy while adhering to the National Code of Ethics and Standards of Practice published by the National Council on Interpreting in Health Care.” 7 There are now  two national organizations (The Certification Commission for Healthcare Interpreters, http://www.cchicertification.",Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"org and The National Board of Certification for Medical  Interpreters, http://www.certifiedmedicalinterpreters.org)  offering certification to health care interpreters whose mis-sion it is to develop and direct comprehensive credentialing programs for health care interpreters.",Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 473 Impact of Spanish instruction on patient satisfaction and adherence Disclosure The authors report no conflicts of interest in this work.,Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
Available from http://www.census.gov/newsroom/press-releases/2013/cb13-143.html.,OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
Available from http://www.ncihc.org/faqs-for-healthcare-professionals.,Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
Available from: https://www.cms.gov/About-CMS/Agency-Information/OEOCRInfo/Downloads/CMS-LAP-Updated-2014-508.pdf.,Non-OADS,/arxiv_data1/oa_pdf/81/4f/amep-7-467.PMC4981169.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7b/0a/copd-11-1845.PMC4981170.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1845–1855International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1845OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11387 0 assessment of satisfaction with different dry  powder inhalation devices in greek patients  with COPD and asthma: the anasa study eleftherios Zervas Konstantinos samitas Mina gaga 7th respiratory Department and  asthma Center, athens Chest  hospital “ sotiria”, athens, greeceBackground:  Poor adherence to inhaled therapy is common in patients with asthma and COPD.",Non-OADS,/arxiv_data1/oa_pdf/7b/0a/copd-11-1845.PMC4981170.pdf
"Keywords:  asthma, COPD, dry powder inhaler, patient satisfaction, FSI-10 questionnaire Introduction Asthma and COPD are chronic obstructive lung diseases that affect millions of  patients and add a huge burden to health care systems worldwide.1–3 Based on current  treatment guidelines, both diseases are treated with maintenance medications deliv - ered daily by inhaler devices (usually a combination of bronchodilators and inhaled  corticosteroids).4,5 However, it is common for patients under prolonged treatment to  have poor adherence to medication.6,7 Patients’ adherence to treatment can be influenced  by their overall state of being, as well as by the frequency of dosing, their expecta - tions regarding treatment of their disease and its outcomes, and to a great extent by  the quality and ease of use of the device.Correspondence: eleftherios Zervas 7th respiratory Department and  asthma Center, athens Chest hospital  “sotiria”, 152 Mesogion avenue,  athens 11527, greece Tel +30 210 778 1720 Fax +30 210 778 1911 email lefzervas@yahoo.g r Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zervas et al Running head recto: Satisfaction with DPIs in COPD and asthma patients DOI: http://dx.doi.org/10.2147/COPD.S113870",Non-OADS,/arxiv_data1/oa_pdf/7b/0a/copd-11-1845.PMC4981170.pdf
Available from: http://www.ginasthma.org /.,Non-OADS,/arxiv_data1/oa_pdf/7b/0a/copd-11-1845.PMC4981170.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/7b/0a/copd-11-1845.PMC4981170.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7b/0a/copd-11-1845.PMC4981170.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fa/b3/ijn-11-3777.PMC4981171.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 3777–3788International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3777OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10541 9 Improved oral bioavailability of poorly water- soluble glimepiride by utilizing microemulsion  technique haiying li1 Tingting Pan1 Ying cui1 Xiaxia li1 Jiefang gao1 Wenzhi Yang1 shigang shen2 1Key laboratory of Pharmaceutical  Quality control of hebei Province,   college of Pharmacy, 2Key laboratory  of analytical science and Technology  of hebei Province, college of  chemistry and environmental science,   hebei University, Baoding, People’s  republic of chinaAbstract:  The objective of this work was to prepare an oil/water glimepiride (GM)  microemulsion (ME) for oral administration to improve its solubility and enhance its bioavail - ability.",Non-OADS,/arxiv_data1/oa_pdf/fa/b3/ijn-11-3777.PMC4981171.pdf
"These techniques have acquired limited success.16–18correspondence: Wenzhi Yang Key laboratory of Pharmaceutical Quality  control of hebei Province, college of  Pharmacy, hebei University, Baoding  071002, People’s republic of china email wenzhi_yang@sina.co m  shigang shen Key laboratory of analytical science and  Technology of hebei Province, college  of chemistry and environmental science,  hebei University, Baoding 071002,  People’s republic of china email pharm_shen@163.co mJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Li et al Running head recto: Improved oral bioavailability of glimepiride by microemulsion technique DOI: http://dx.doi.org/10.2147/IJN.S105419",Non-OADS,/arxiv_data1/oa_pdf/fa/b3/ijn-11-3777.PMC4981171.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/fa/b3/ijn-11-3777.PMC4981171.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fa/b3/ijn-11-3777.PMC4981171.pdf
Available from: http://www.in-pharmatechnologist.,Non-OADS,/arxiv_data1/oa_pdf/fa/b3/ijn-11-3777.PMC4981171.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/dd/5c/ppa-10-1509.PMC4981174.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1509–1519Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1509OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S11014 7 Persistence with biologic agents for the treatment  of rheumatoid arthritis in Japan Jörg Mahlich1,2 rosarin sruamsiri1,3 1health economics, Janssen  Pharmaceutical KK, T okyo, Japan;   2Düsseldorf institute for competition  economics (D ice), University of  Düsseldorf, Düsseldorf, germany;   3center of Pharmaceutical Outcomes  research, Department of Pharmacy  Practice, Faculty of Pharmaceutical  sciences, n aresuan University,   Phitsanulok, ThailandBackground:  To assess persistence rates of biologic agents for the treatment of rheumatoid  arthritis in Japan.",Non-OADS,/arxiv_data1/oa_pdf/dd/5c/ppa-10-1509.PMC4981174.pdf
"Persistence in this context refers to “the duration of time from  initiation to discontinuation of therapy” while the related concept of adherence is  “the extent to which a patient acts in accordance with the prescribed interval, and  dose of a dosing regimen.”5correspondence: Jörg Mahlich health economics, Janssen Pharmaceutical  KK, 5-2, nishi-kanda 3-chome  chiyoda-ku, Tokyo, 101-0065, Japan Tel +81 3 4411 5666 Fax +81 3 4411 5050 email jmahlich@its.jnj.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Mahlich and Sruamsiri Running head recto: Biologic agents for the treatment of rheumatoid arthritis DOI: http://dx.doi.org/10.2147/PPA.S110147",Non-OADS,/arxiv_data1/oa_pdf/dd/5c/ppa-10-1509.PMC4981174.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/dd/5c/ppa-10-1509.PMC4981174.pdf
"Mol Microbiol 2014; 91(6):1070-87; PMID:24417419; http://dx.doi.org/10.1111/mmi.12518 Torreira E, Moreno-del /C19Alamo M, Fuentes-Perez ME, Fern /C19andez C, Mart /C19ın-Benito J, Moreno-Herrero F, Giraldo R, Llorca O. Amyloidogenesis of bacterial prionoid RepA-WH1 recapitulates dimer to monomer transitions of RepA in DNA replication initiation.",Non-OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Sci Rep 2015; 5:14669; PMID:26423724; http://dx.doi.org/10.1038/srep14669 Gasset-Rosa F, Giraldo R. Engineered bacterial hydrophobic oligopeptide repeats in a synthetic yeast prion, [REP-PSI C].",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
Front Microbiol 2015; 6:311; PMID:25954252; http://dx.doi.org/10.3389/fmicb.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Prion 2010; 4:256-64; PMID:20935497;http://dx.doi.org/10.4161/pri.4.4.13676 [2] Romero D, Kolter R. Functional amyloids in bacte- ria.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Res Microbiol 2012; 163:592- 606; PMID:23108148; http://dx.doi.org/10.1016/j.resmic.2012.10.009 [4] Bieler S, Estrada L, Lagos R, Baeza M, Castilla J, Soto C. Amyloid formation modulates the biological activity of a bacterial protein, J Biol Chem 2005;280:26880-5; PMID:15917245; http://dx.doi.org/ 10.1074/jbc.M502031200 [5] Liebman SW, Chernoff YO.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"J Cell Biol2003; 161:521-33; PMID:12732614; http://dx.doi.org/10.1083/jcb.200302072 [7] Stephan JS, Fioriti L, Lamba N, Colnaghi L, Karl K, Derkatch IL, Kandel ER.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Cell Rep 2015; 11:1772-85; PMID:26074072; http://dx.doi.org/10.1016/j.celrep.2015.04.060 [8] Van Gerven N, Klein RD, Hultgren SJ, Remaut H. Bacterial amyloid formation: Structural insights into curli biogenesis.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Trends Microbiol 2015; 23:693-706; PMID:26439293; http://dx.doi.org/10.1016/j.tim.2015.07.010 [9] Sivanathan V, Hochschild A.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"FEBS J 2011; 278:2419-27; http://dx.doi.org/10.1111/j.1742-4658.2011.08165.x [11] Giraldo R, Fern /C19andez-Tresguerres ME.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"2004; 52:69-83; PMID:15336485; http://dx.doi.org/ 10.1016/j.plasmid.2004.06.002 [12] Giraldo R, Andreu JM, D /C19ıaz-Orejas R. Protein domains and conformational changes in the activa-tion of RepA, a DNA replication initiator.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
EMBO J 1998; 17:4511-26; PMID:9687517; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"J Mol Biol 2006; 364:909-20; http://dx.doi.org/10.1016/j.jmb.2006.09.013 [15] Gasset-Rosa F, D /C19ıaz-L /C19opez T, Lurz R, Prieto A, Fern/C19andez-Tresguerres ME, Giraldo R. Negative regulation of pPS10 plasmid replication: Originpairing by zipping-up DNA-bound RepA mono- mers.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Mol Microbiol 2008; 68:560-72; PMID:18284592; http://dx.doi.org/10.1111/j.1365-2958.2008.06166.x [16] D /C19ıaz-L /C19opez T, Lages-Gonzalo M, Serrano-L /C19opez A, Alfonso C, Rivas G, Giraldo R. Structural changesin RepA, a plasmid replication initiator, upon bind- ing to origin DNA.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
J Biol Chem 2003; 278:18606- 16; http://dx.doi.org/10.1074/jbc.M212024200 [17] Giraldo R. Deﬁned DNA sequences promote the assembly of a bacterial protein into distinct amyloid nanostructures.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Nucl Acids Res 2008; 36:2249-56; PMID:18285361; http://dx.doi.org/10.1093/nar/gkn067 [19] Fern /C19andez-Tresguerres ME, Moreno-D /C19ıaz de la Espina S, Gasset-Rosa F, Giraldo R. A DNA-pro- moted amyloid proteinopathy in Escherichia coli.Mol Microbiol 2010; 77:1456-69; http://dx.doi.org/ 10.1111/j.1365-2958.2010.07299.x [20] Molina-Garc /C19ıa L, Giraldo R. Aggregation interplay between variants of the RepA-WH1 prionoid in Escherichia coli.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"J Bacteriol 2014; 196:2536-42; http://dx.doi.org/10.1128/JB.01527-14 [21] Giraldo R, Moreno-D /C19ıaz de la Espina S, Fern /C19andez- Tresguerres ME, Gasset-Rosa F. RepA-WH1 prio- noid: A synthetic amyloid proteinopathy in a mini-malist host.",Non-OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
Prion 2011; 5:60-4; PMID:21293179;http://dx.doi.org/10.4161/pri.5.2.14913[22] Tycko R. Physical and structural basis for polymor- phism in amyloid ﬁbrils.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Prot Sci 2014; 23:1528-39; http://dx.doi.org/10.1002/pro.2544 [23] Diaz-Avalos R, King CY, Wall J, Simon M, Caspar DLD.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Nat Struct Mol Biol 2009; 16:973-8; PMID:19684598; http://dx.doi.org/ 10.1038/nsmb.1643 [25] Lu JX, Qiang W, Yau WM, Schwieters CD, Mere- dith SC, Tycko R. Molecular structure of b-amyloid ﬁbrils in Alzheimer disease brain tissue.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"Cell 2013;154:1257-68; PMID:24034249; http://dx.doi.org/10.1016/j.cell.2013.08.035 [26] Frederick KK, Debelouchina GT, Kayatekin C, Dorminy T, Jacavone AC, Grifﬁn RG, LindquistS.",OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
Chem Biol 2014; 21:295-305; PMID:24485763; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
Structure 2015; 23:183-9; PMID:25543255; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
J Mol Biol 2012; 424:132-49;PMID:23041425; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
Biochemis-try 2012; 51:8478-90; PMID:23016872; http://dx.doi.org/10.1021/bi300574r48 Giraldo et al.,OADS,/arxiv_data1/oa_pdf/96/7e/kprn-10-01-1129479.PMC4981189.pdf
"J Biol Chem 2015; 290(33): 20417–26; PMID:26126829; http://dx.doi.org/10.1074/jbc.M115.661710 /C211Joan Torrent, Reinhard Lange, Angelique Igel-Egalon, Vincent B /C19eringue, and Human Rezaei.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Nat Rev Mol Cell Biol 2014;15:384-96; PMID:24854788; http://dx.doi.org/ 10.1038/nrm3810 [2] Prusiner SB.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Acta Neu- ropathol 2010; 119:177-87; PMID:20052481; http://dx.doi.org/10.1007/s00401-009-0633-x [4] Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, Prusiner SB.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Science 2004; 305:673-6; PMID:15286374; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Proc Natl Acad Sci U S A 2009;106:20417-22; PMID:19915150; http://dx.doi.org/ 10.1073/pnas.0910350106 [6] Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, Nguyen HO, Lemus A, Cohen FE, DeArmond SJ, Prusiner SB.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
PLoS Pathog 2010; 6:e1000736;PMID:20107515; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Science 2010; 327:1132-5; PMID:20110469; http://dx.doi.org/10.1126/science.1183748 [9] Bessen RA, Marsh RF.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Nature 1995; 375:698-700; PMID:7791905; http://dx.doi.org/10.1038/375698a0 [11] Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E,Gambetti P, Prusiner SB.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Sci- ence 1996; 274:2079-82; PMID:8953038; http://dx.doi.org/10.1126/science.274.5295.2079 [12] Caughey B, Raymond GJ, Bessen RA.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
J Biol Chem 1998; 273:32230-5; PMID:9822701; http://dx.doi.org/10.1074/jbc.273.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Nat Med 1998; 4:1157-65; PMID:9771749; http://dx.doi.org/10.1038/2654 [14] Parchi P, Giese A, Capellari S, Brown P, Schulz- Schaeffer W, Windl O, Zerr I, Budka H, Kopp N,Piccardo P, et al.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Ann Neurol 1999;46:224-33; PMID:10443888; http://dx.doi.org/ 10.1002/1531-8249(199908)46:2%3c224::AID- ANA12%3e3.0.CO;2-W [15] Parchi P, Zou W, Wang W, Brown P, Capellari S, Ghetti B, Kopp N, Schulz-Schaeffer WJ, Kretzschmar HA, Head MW, et al.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Proc NatlAcad Sci U S A 2000; 97:10168-72; PMID:10963679; http://dx.doi.org/10.1 073/pnas.97.18.10168 [16] Collinge J, Clarke AR.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Science 2007; 318:930-6; PMID:17991853; http://dx.doi.org/ 10.1126/science.1138718 [17] Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. Darwinian evolution of prions in cell culture.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Science 2010; 327:869-72; PMID:20044542; http://dx.doi.org/10.1126/science.1183218 [18] Eigen M. Selforganization of matter and the evolu- tion of biological macromolecules.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Biophys Chem 1979; 10:153-60; PMID:486701; http://dx.doi.org/10.1016/0301-4622(79)85035-8 [20] Deleault NR, Walsh DJ, Piro JR, Wang F, Wang X, Ma J, Rees JR, Supattapone S. Cofactor moleculesmaintain infectious conformation and restrict strain properties in puriﬁed prions.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"PLoS Pathog 2012; 8:e1002589; PMID:22511864; http://dx.doi.org/10.1371/journal.ppat.1002589 [22] Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neuro toxicity.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Nat Rev Mol Cell Biol 2007; 8:552-61; PMID :17585315; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"J Virol 2015; 89:6287-93; PMID:25855735; http://dx.doi.org/10.1128/JVI.03429-14 [24] Torrent J, Vilchez-Acosta A, Munoz-Torrero D, Trovaslet M, Nachon F, Chatonnet A, Grznarova K, Acquatella-Tran Van Ba I, Le Gofﬁc R, Herzog L,et al.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Acta Neuropathol Commun 2015;3:18; PMID:25853328; http://dx.doi.org/10.1186/ s40478-015-0188-0 [25] Li J, Mahal SP, Demczyk CA, Weissmann C. Muta- bility of prions.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
EMBO Rep 2011; 12:1243-50; PMID:21997293; http://dx.doi.org/10.1038/embor.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Nat Methods 2007; 4:1023-30; PMID:18026110; http://dx.doi.org/10.1038/nmeth1131 [29] Bett C, Kurt TD, Lucero M, Trejo M, Rozemuller AJ, Kong Q, Nilsson KP, Masliah E, Oldstone MB, Sigurdson CJ.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"PLoS Pathog 2013; 9:e1003280; PMID:23637596; http://dx.doi.org/10.1371/journal.ppat.1003280 [30] Ayers JI, Schutt CR, Shikiya RA, Aguzzi A, Kincaid AE, Bartz JC.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Neuron 2002; 34:921-32; PMID:12086640; http://dx.doi.org/10.1016/S0896-6273(02)00726-2 [32] Bett C, Joshi-Barr S, Lucero M, Trejo M, Liberski P, Kelly JW, Masliah E, Sigurdson CJ.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"PLoS Pathog 2012; 8:e1002522; PMID:22319450;http://dx.doi.org/10.1371/journal.ppat.1002522 [33] Tixador P, Herzog L, Reine F, Jaumain E, Chapuis J, Le Dur A, Laude H, B /C19eringue V. The physical relationship between infectivity and prion proteinaggregates is strain-dependent.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"PLoS Pathog 2010; 6:e1000859; PMID:20419156; http://dx.doi.org/ 10.1371/journal.ppat.1000859 [34] Laferriere F, Tixador P, Moudjou M, Chapuis J, Sibille P, Herzog L, Reine F, Jaumain E, Laude H, Rezaei H, et al.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"PLoS Pathog 2013; 9:e1003702; PMID:24130496; http://dx.doi.org/10.1371/journal.ppat.1003702 [35] Cobb NJ, Apostol MI, Chen S, Smirnovas V, Sure- wicz WK.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
J Biol Chem 2014; 289:2643-50; PMID:24338015; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Proc Natl Acad Sci U S A 2012; 109:6945-50; PMID:22496593; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Trends Biochem Sci 2001; 26:612-8; PMID:11590014; http://dx.doi.org/10.1016/S0968-0004(01)01949-1 [38] Marchal S, Font J, Ribo M, Vilanova M, Phillips RS, Lange R, Torrent J. Asymmetric kinetics of pro-tein structural changes.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Acc Chem Res 2009; 42:778-87; PMID:19378977; http://dx.doi.org/ 10.1021/ar800266r [39] Kuwata K, Li H, Yamada H, Legname G, Prusiner SB, Akasaka K, James TL.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Biochemistry 2002; 41:12277-83;PMID:12369815; http://dx.doi.org/10.1021/bi026129y[40] Cordeiro Y, Kraineva J, Ravindra R, Lima LM, Gomes MP, Foguel D, Winter R, Silva JL.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Biochemistry 2004; 43:4439-46; PMID:15078089; http://dx.doi.org/10.1021/bi036123o [42] Torrent J, Alvarez-Martinez MT, Harricane MC, Heitz F, Liautard JP, Balny C, Lange R. High pres- sure induces scrapie-like prion protein misfoldingand amyloid ﬁbril formation.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Biochemistry 2004; 43:7162-70; PMID:15170353; http://dx.doi.org/ 10.1021/bi049939d [43] Torrent J, Alvarez-Martinez MT, Heitz F, Liautard JP, Balny C, Lange R. Alternative prion structural changes revealed by high pressure.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Biochemistry 2003; 42:1318-25; PMID:12564935; http://dx.doi.org/10.1021/bi0269916 [44] Torrent J, Alvarez-Martinez MT, Liautard JP, Balny C, Lange R. The role of the 132-160 region in prionprotein conformational transitions.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Protein Sci 2005; 14:956-67; PMID:15772306; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Proc Natl Acad Sci U S A 2003;100:6093-7; PMID:12732724; http://dx.doi.org/ 10.1073/pnas.1031826100 [46] Fernandez Garcia A, Heindl P, Voigt H, Buttner M, Wienhold D, Butz P, St €arke J, Tauscher B, Pfaff E. Reduced proteinase K resistance and infectivity of prions after pressure treatment at 60 /C14C.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"J Gen Virol 2004; 85:261-4; PMID:14718641; http://dx.doi.org/ 10.1099/vir.0.19410-0 [47] Garcia AF, Heindl P, Voigt H, Buttner M, Butz P, Tauber N, Tauscher B, Pfaff E. Dual nature of theinfectious prion protein revealed by high pressure.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"J Biol Chem 2005; 280:9842-7; PMID:15598650; http://dx.doi.org/10.1074/jbc.M410679200 [48] El Moustaine D, Perrier V, Acquatella-Tran Van Ba I, Meersman F, Ostapchenko VG, Baskakov IV, Lange R, Torrent J. Amyloid features andneuronal toxicity of mature prion ﬁbrils are highly sensitive to high pressure.",Non-OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"J Biol Chem 2011; 286:13448-59; PMID:21357423; http://dx.doi.org/10.1074/jbc.M110.192872 [49] Torrent J, Lange R, Rezaei H. The volumetric diver- sity of misfolded prion protein oligomers revealedby pressure dissociation.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Science 2006; 313:92-4; PMID:16825570; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Nat Methods 2007; 4:645-50; PMID:17643109; http://dx.doi.org/10.1038/ nmeth1066 [52] Colby DW, Zhang Q, Wang S, Groth D, Legname G, Riesner D, Prusiner SB.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Proc Natl Acad Sci U S A2007; 104:20914-9; PMID:18096717; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"Nat Methods 2008; 5:211-2; PMID:18309304;http://dx.doi.org/10.1038/nmeth0308-211 [54] Orru CD, Wilham JM, Hughson AG, Raymond LD, McNally KL, Bossers A, Ligios C, Caughey B.",OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
Protein Eng Des Sel 2009; 22:515-21; http://dx.doi.or g/10.1093/protein/gzp0318 Torrent et al.,OADS,/arxiv_data1/oa_pdf/3d/a9/kprn-10-01-1122161.PMC4981190.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"FUNDING Funding was provided by the EC through FP7 222887 “Priority.” ORCID Jes/C19us R. Requena http://orcid.org/0000-0003-1954- 4975 Neil Mabbott http://orcid.org/0000-0001-7395-1796 REFERENCES [1] Maheshwari A, Fischer M, Gambetti P, Parker A, Ram A, Soto C, Concha-Marambio L, Cohen Y, Belay ED, Maddox RA, et al.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Emerg Infect Dis 2015; 21:750-9; PMID:25897712 [2] http://www.oie.int/en/animal-health-in-the-world/ ofﬁcial-disease-status/bse/en-bse-carte/ (Accessed January 23, 2016).",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Physiol Rev 2009; 89:1105- 52; PMID:19789378; http://dx.doi.org/10.1152/physrev.00006.2009 [18] W ille H, Bian W, McDonald M, Kendall A, Colby DW, Bloch L, Ollesch J, Borov inskiy AL, Cohen FE,Prusiner SB, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
Proc Natl Acad Sci USA 2009; 106:16990-5; PMID:1 9805070; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"PLoS One 2012; 7(11):e50111; http://dx.doi.org/10.1371/journal.pone.0050111 [21] Richardson, JS; D. C. Richardson, Natural b-sheet proteins use negative design to avoid edge-to-edgeaggregation.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Proc Natl Acad Sci USA 2002;99:2754-9; PMID:11880627; http://dx.doi.org/ 10.1073/pnas.052706099 [22] Bryan AW Jr, Starner-Kreinbrink JL, Hosur R, Clark PL, Berger B. Structure-based prediction reveals capping motifs that inhibit b-helix aggrega- tion.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Proc Natl Acad Sci USA 2011; 108:11099-104; PMID:21685332; http://dx.doi.org/10.1073/ pnas.1017504108 [23] Giachin G, Biljan I, Ilc G, Plavec J, Legname G. Probing early misfolding events in prion protein mutants by NMR spectroscopy.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Molecules 2013; 18 (8):9451-76; PMID:23966072; http://dx.doi.org/10.3390/molecules18089451 [24] Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Prion 2013; 7:55-9; PMID:23208281; http://dx.doi.org/10.4161/pri.23061 [25] Jucker M, Walker LC.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nature 2013; 501:45-51; PMID:24005412;http://dx.doi.org/10.1038/nature12481 [26] Vidal E, Fern /C19andez-Borges N, Pintado B, Ord /C19 o~nez M, M /C19arquez M, Fondevila D, Era ~na H, Torres JM, Pumarola M, Castilla J.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Prion 2013; 7:443-6; PMID:24184875; http://dx.doi.org/ 10.4161/pri.27014 [27] Allard EK, Grujic M, Fisone G, Kristensson K. Prion formation with activation o f translation-regulating p r i o n4 E - B Pa n dn e u r o n a lt ranscription factor Elk1.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Neurobiol Dis 2013; 58:116-22; PMID:23742760; http://dx.doi.org/10.101 6/j.nbd.2013.05.014 [28] Rouvinski A, Karniely S, Kounin M, Moussa S, Goldberg MD, Warburg G, Lyakhovetsky R, Papy- Garcia D, Kutzsche J, Korth C, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
J Cell Biol2014; 204:423-41; PMID:24493590; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
2013; 34:1621-1631; PMID:23481568; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"PLoS Pathog 2009; 5(5):e1000426; PMID:19424437; http://dx.doi.org/10.1371/journal.ppat.1000426 [31] Gousset K, Schiff E, Langevin C, Marijanovic Z, Caputo A, Browman DT, Chenouard N, de Chau-mont F, Martino A, Enninga J, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nat Cell Biol 2009; 11:328-36; PMID:19198598; http://dx.doi.org/10.1038/ncb1841 [32] Marzo L, Gousset K, Zurzolo C. Multifaceted roles of tunneling nanotubes in intercellular communica- tion.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"EmergInfect Dis 2011; 17:2253-61; PMID:22172149; http://dx.doi.org/10.3201/eid1712.110333 [49] McCulloch L, Brown KL, Mabbott NA.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Immunology 2013; 138:246-57; PMID:23121447; http://dx.doi.org/10.1111/imm.12031 [50] Prinz M, Huber G, Macpherson AJ, Heppner FL, Glatzel M, Eugster HP, Wagner N, Aguzzi A.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
Am J Pathol2003; 162:1103-11; PMID:12651603; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nat Med 2001; 7:488-92;PMID:11283678; http://dx.doi.org/10.1038/86567 [53] Mabbott NA, Bruce ME, Botto M, Walport MJ, Pepys MB.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"J Immunol2012; 189:4520-7; PMID:23002439; http://dx.doi.org/ 10.4049/jimmunol.1201579 [55] O’Connor T, Frei N, Sponarova J, Schwarz P, Hei- kenwalder M, Aguzzi A. Lymphotxin, but not TNF, is required for prion invasion of lymph nodes.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"PLoS Pathog 2012; 8:e1002867; PMID:22912582; http://dx.doi.org/10.1371/journal.ppat.1002867 [56] Kujala P, Raymond CR, Romeijn M, Godsave SF, van Kasteren SI, Wille H, Prusiner SB, MabbottNA, Peters PJ.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
PLoS Pathog 2011; 7:e1002449; PMID:22216002; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nature 2003; 425:957-62; PMID:14562059; http://dx.doi.org/ 10.1038/nature02072 [58] Langevin C, Gousset K, Costanzo M, Richard-Le Goff O, Zurzolo C. Characterization of the role of dendritic cells in prion transfer to primary neurons.Biochem J 2010; 431:189-98; PMID:20670217;http://dx.doi.org/10.1042/BJ20100698 [59] Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, Bluethmann H, Bootz F, Suter M, Zinkernagel RM,Aguzzi A.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Science 2005;307:1107-10; PMID:15661974; http://dx.doi.org/10.1126/science.1106460 [61] Seeger H, Heikenwalder M, Zeller N, Kranich J, Schwarz P, Gaspert A, Seifert B, Miele G, AguzziA.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Science 2005; 310:324-6; PMID:16224026; http://dx.doi.org/10.1126/science.1118829 [62] Ligios C, Cancedda MG, Carta A, Santucciu C, Maestrale C, Demontis F, Saba M, Patta C,DeMartini JC, Aguzzi A, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"J Virol 2011; 85:1136-9; PMID:21084475; http://dx.doi.org/10.1128/JVI.02022-10 [63] Konold T, Moore SJ, Bellworthy SJ, Terry LA, Thorne L, Ramsay A, Salguero FJ, Simmons MM,Simmons HA.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"BMC Vet Res 2013; 9:99; PMID:23651710; http://dx.doi.org/ 10.1186/1746-6148-9-99 [64] Konold T, Simmons HA, Webb PR, Bellerby PJ, Hawkins SA, Gonz /C19alez L. Transmission of classical scrapie via goat milk.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Vet Rec 2013; 172:455;PMID:23625249; http://dx.doi.org/10.1136/vr.f2613 [65] Konold T, Moore SJ, Bellworthy SJ, Simmons HA.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"BMC Vet Res 2008; 4:14; PMID:18397513; http://dx.doi.org/10.1186/1746-6148-4-14 [66] Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A,Hope J, Birkett C, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nature 1997; 389:498-501; PMID:9333239;http://dx.doi.org/10.1038/39057 [67] Donnelly CA, Ferguson NM, Ghani AC, Woolhouse ME, Watt CJ, Anderson RM.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Philos Trans R Soc Lond B Biol Sci 1997; 352:781-801; PMID:9279897; http://dx.doi.org/10.1098/rstb.1997.0062 [68] Boelle PY, Cesbron JY, Valleron AJ.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"J Immunol 2009; 183:5199- 207; PMID:19786551; http://dx.doi.org/10.4049/jimmunol.0802695 [70] Brown KL, Gossner A, Mok S, Mabbott NA.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Muco- sal Immunol 2013; 6:1027-37; PMID:23360902;http://dx.doi.org/10.1038/mi.2012.141 [72] Brown KL, Mabbott NA.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
J Gen Virol 2014; 95:231-43; PMID:24123519; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Prion 2012; 6:124-33; PMID:22421209; http://dx.doi.org/10.4161/pri.18853 [74] Heppner FL, Christ AD, Klein MA, Prinz M, Fried M, Kraehenbuhl JP, Aguzzi A. Transepithelial prionTHE PRIORITY POSITION PAPER 179",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nat Med 2001; 7:976-7; PMID:11533681; http://dx.doi.org/10.1038/ nm0901-976 [75] Donaldson DS, Kobayashi A, Ohno H, Yagita H, Williams IR, Mabbott NA.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Mucosal Immunol 2012; 5:216-25; PMID:22294048; http://dx.doi.org/10.1038/mi.2011.68 [76] Raymond CR, Aucouturier P, Mabbott NA.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"J Immunol 2007;179:7758-66; PMID:18025222; http://dx.doi.org/ 10.4049/jimmunol.179.11.7758 [77] Beekes M, McBride PA.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"FEBS J 2007; 274:588-605; PMID:17288548; http://dx.doi.org/10.1111/j.1742-4658.2007.05631.x [78] McBride PA, Schulz-Shaeffer WJ, Donaldson M, Bruce M, Diringer H, Kretzschmar HA, Beekes M. Early spread of scrapie from the gastrointestinaltract to the central nervous system involves auto- nomic ﬁbers of the splanchnic and vagus nerves.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"J Virol 2001; 75:9320-7; PMID:11533195; http://dx.doi.org/10.1128/JVI.75.19.9320-9327.2001 [79] Glatzel M, Heppner FL, Albers KM, Aguzzi A.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
Neuron 2001; 31:25-34; PMID:11498048; http://dx.doi.org/ 10.1016/S0896-6273(01)00331-2 [80] EFSA Panel on Biological Hazards (BIOHAZ Panel).,OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Science 2001; 294:178-82; PMID:11546838; http://dx.doi.org/10.1126/science.1063093 [82] White AR, Enever P, Tayebi M, Mushens R, Line- han J, Brandner S, Anstee D, Collinge J, Hawke S. Monoclonal antibodies inhibit prion replication anddelay the development of prion disease.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nature 2003; 422:80-3; PMID:12621436; http://dx.doi.org/ 10.1038/nature01457 [83] Go ~ni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, Meeker HC, Rubenstein R, Brown DR, Sy MS, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Neuroscience 2005; 133:413-21; http://dx.doi.org/ 10.1016/j.neuroscience.2005.02.031 [84] Sonati T, Reimann RR, Falsig J, Baral PK, O’Connor T, Hornemann S, Yaganoglu S, Li B, Herrmann US, Wieland B, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Nature 2013; 501:102-6; PMID:23 903654; http://dx.doi.org/ 10.1038/nature12402 [85] Gilch S, Chitoor N, Taguchi Y, Stuart M, Jewell JE, Sch€atzl HM.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
Vet Res 2008; 39:41; PMID:18381058; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
N Engl J Med2014; 371:530-9; PMID:25099577; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"PLoS Pathog2014; 12;10(6):e1004202; http://dx.doi.org/10.1371/ journal.ppat.1004202 [91] Andr /C19eoletti O, Litaise C, Simmons H, Corbi /C18ere F, Lugan S, Costes P, Schelcher F, Vilette D, Grassi J,Lacroux C. Highly efﬁcient prion transmission by blood transfusion.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Ann Neurol 1999; 46:224-33; PMID:10443888; http://dx.doi.org/ 10.1002/1531-8249(199908)46:2%3c224::AID-ANA12%3e3.0.CO;2-W [93] Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P, Gelpi E, Giaccone G, Hauw JJ,H€oftberger R, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Acta Neuropathol 2012; 124:517-529; PMID:22744790; http://dx.doi.org/10.1007/s00401-012-1002-8 [94] Uro-Coste E, Cassard H, Simon S, Lugan S, Bilheude JM, Perret-Liaudet A, Ironside JW, Haik S, Basset-Leo- bon C, Lacroux C, et al.",OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"A novel human disease with abnormal prion protein sensitive to protease.Ann Neurol 2008; 63:697-708; PMID:18571782; http://dx.doi.org/10.1002/ana.21420 [96] Mitrov /C19a E, Kosorinov /C19a D, Gajdo /C20sM , /C20Sebekov /C19aK , Tome /C20ckov /C19a I.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
Eur J Epi- demiol 2014; 29:595-7; http://dx.doi.org/10.1007/ s10654-014-9937-9 [97] EFSA Panel on Biological Hazards (BIOHAZ).,Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
"Emerg Infect Dis 2012; 18:158-9; PMID:22261120; http://dx.doi.org/10.3201/eid1801.111225 [99] Sala C, Morignat E, Oussa €ıd N, Gay E, Abrial D, Ducrot C, Calavas D. Individual factors associated with L- and H-type Bovine Spongiform encephalopathy inFrance.",Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
BMC Vet Res 2012; 8:74; PMID:22647660; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/50/7b/kprn-10-03-1175801.PMC4981192.pdf
Sci Rep 2015; 9(5):11971; http://dx.doi.org/10.1038/srep11971 /C211Jos/C19e A. del R /C19ıo and Rosalina Gav /C19ın.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
1 obtained from https://commons.wikime dia.org/wiki/User:Wgsimon).,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Source: https://commons.wikimedia.org/ wiki/User:Wgsimon through Creative Commons Attribution-ShareAlike License (https://creative- commons.org/licenses/by-sa/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurosci Res 2002;67:211-24; PMID:11782965; http://dx.doi.org/ 10.1002/jnr.10118 [4] Wong BS, Liu T, Li R, Pan T, Petersen RB, Smith MA, Gambetti P, Perry G, Manson JC, Brown DR, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurochem 2001; 76:565-72;PMID:11208919; http://dx.doi.org/10.1046/j.1471- 4159.2001.00028.x [5] Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Nature1997; 390:684-7; PMID:9414160; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurochem 2003; 86:538-44; PMID:12859667; http://dx.doi.org/10.1046/j.1471-4159.2003.01882.x [7] Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J, Chen Y, Wang X, Liu J, Guo X, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"FASEB J 2007; 21:2247-56; PMID:17409275; http://dx.doi.org/10.1096/fj.06-7799com [8] Miranda A, Ramos-Ibeas P, Pericuesta E, Ramirez MA, Gutierrez-Adan A.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Reproduction 2013; 146:R91-9; PMID:23740082; http://dx.doi.org/ 10.1530/REP-13-0100 [9] Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Keller- mann O.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Science 2000; 289:1925-8; PMID:10988071;http://dx.doi.org/10.1126/science.289.5486.1925 [10] Hugel B, Martinez MC, Kunzelmann C, Blattler T, Aguzzi A, Freyssinet JM.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Cell Mol Life Sci 2004; 61:2998-3007; PMID:15583862;http://dx.doi.org/10.1007/s00018-004-4318-2 [11] Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner SB, Aguet M,PrP CFUNCTIONS IN NEURAL TISSUE 33",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Nature 1992; 356:577-82; PMID:1373228; http://dx.doi.org/10.1038/356577a0 [12] Brandner S, Raeber A, Sailer A, Blattler T, Fischer M, Weissmann C, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Proc Natl Acad Sci U S A1996; 93:13148-51; PMID:8917559; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Nature1996; 380:639-42; PMID:8602267; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Behav Brain Res 2012; 227:319-23; PMID:21439331; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Biol Chem 2015; 290:20488- 98; PMID:26152722; http://dx.doi.org/10.1074/ jbc.M115.666156 [16] Criado JR, Sanchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, Race R, Manson JC, Chesebro B, Oldstone MB.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Neurobiol Dis 2005; 19:255-65; PMID:15837581; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Nat Neurosci 2010; 13:310-8; PMID:20098419; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Nat Neurosci 2009; 12:60-9; PMID:19098904; http://dx.doi.org/ 10.1038/nn.2238 [20] Kishimoto Y, Hirono M, Atarashi R, Sakaguchi S, Yoshioka T, Katamine S, Kirino Y. Age-dependentimpairment of eyeblink conditioning in prion pro- tein-deﬁcient mice.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Brain Res 2007; 1158:71-80; PMID:17570349; http://dx.doi.org/10.1016/j.brainres.2007.05.010 [22] Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, Martins VR, Brentani RR.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Epilepsia 1999; 40:1679-82; PMID:10612329; http://dx.doi.org/ 10.1111/j.1528-1157.1999.tb01583.x [23] Rangel A, Burgaya F, Gavin R, Soriano E, Aguzzi A, Del Rio JA.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurosci Res 2007; 85:2741-55; PMID:17304577; http://dx.doi.org/10.1002/ jnr.21215 [24] Khosravani H, Zhang Y, Tsutsui S, Hameed S, Alt- ier C, Hamid J, Chen L, Villemaire M, Ali Z, Jirik FR, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Gen Physiol 2008; 131:i5; PMID:18504311; http://dx.doi.org/ 10.1085/JGP1316OIA5 [25] Gasperini L, Meneghetti E, Pastore B, Benetti F, Legname G. Prion protein and copper coopera- tively protect neurons by modulating NMDAreceptor through S-nitrosylation.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"PLoS One 2012; 7:e33872; PMID:22529900; http://dx.doi.org/10.1371/jour-nal.pone.0033872 [27] Nicolas O, Gavin R, del Rio JA.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Brain Res Rev2009; 61:170-84; PMID:19523487; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"25; PMID:11743735; http://dx.doi.org/10.1006/ jmbi.2000.5183 [30] Santuccione A, Sytnyk V, Leshchyns’ka I, Schach- ner M. Prion protein recruits its neuronal receptorNCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Cell Biol 2005; 169:341-54; PMID:15851519; http://dx.doi.org/10.1083/jcb.200409127 [31] Parkyn CJ, Vermeulen EG, Mootoosamy RC, Sunyach C, Jacobsen C, Oxvig C, Moestrup S, Liu Q, Bu G, Jen A, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Cell Sci 2008; 121:773-83; PMID:18285446; http://dx.doi.org/10.1242/jcs.021816 [32] Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, Krasemann S, Deslys JP, Dormont D, Lasm /C19ezas CI, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"EMBO J 2001; 20:5863-75; PMID:11689427; http://dx.doi.org/10.1093/emboj/ 20.21.5863 [33] Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Nat Med1997; 3:1383-8; PMID:9396609; http://dx.doi.org/ 10.1038/nm1297-1383 [34] Parkin ET, Watt NT, Hussain I, Eckman EA, Eck- man CB, Manson JC, Baybutt HN, Turner AJ, Hooper NM.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Proc Natl Acad Sci U S A 2007;104:11062-7; PMID:17573534; http://dx.doi.org/ 10.1073/pnas.0609621104 [35] Kurschner C, Morgan JI.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Brain Res Mol Brain Res 1995; 30:165-8; PMID:7609638; http://dx.doi.org/10.1016/0169-328X(95)00013-I [36] Brown DR, Schmidt B, Kretzschmar HA.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurosci Res 1998; 52:260-7;PMID:9590434; http://dx.doi.org/10.1002/(SICI) 1097-4547(19980501)52:3%3c260::AID-JNR2% 3e3.0.CO;2-B [37] Nieznanski K, Nieznanska H, Skowronek KJ, Osiecka KM, Stepkowski D. Direct interaction between prion protein and tubulin.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Biochem Bio-phys Res Commun 2005; 334:403-11; PMID:16004966; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neuro-chem 2000; 75:1889-97; PMID:11032878; http://dx.doi.org/10.1046/j.1471-4159.2000.0751889.x[39] Spielhaupter C, Schatzl HM.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Biol Chem 2001; 276:44604-12; PMID:11571277; http://dx.doi.org/10.1074/jbc.M103289200 [40] Llorens F, Del Rio JA.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Prion2012; 6:245-51; PMID:22437735; http://dx.doi.org/10.4161/pri.19639 [41] Nuvolone M, Kana V, Hutter G, Sakata D, Mortin- Toth SM, Russo G, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Exp Med 2013; 210:2539-52; PMID:24145514; http://dx.doi.org/10.1084/jem.20131274 [42] Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A.Prion protein and Abeta-related synaptic toxicityimpairment.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"EMBO Mol Med 2010; 2:306-14; PMID:20665634; http://dx.doi.org/10.1002/ emmm.201000082 [43] Carulla P, Llorens F, Matamoros-Angles A, Agui- lar-Calvo P, Espinosa JC, Gavin R, Ferrer I, Leg- name G, Torres JM, del R /C19ıo JA.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Sci Rep 2015; 5:11971; PMID:26155834; http://dx.doi.org/10.1038/srep11971 [44] Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the backgroundgenotype?,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Trends Neurosci 1996; 19:177-81;PMID:8723200; http://dx.doi.org/10.1016/S0166- 2236(96)20020-7 [45] Smithies O, Maeda N. Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Exp Med 2010; 207:2271-81; PMID:20837697; http://dx.doi.org/ 10.1084/jem.20092401 [47] Herms JW, Kretzchmar HA, Titz S, Keller BU.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Eur J Neurosci 1995; 7:2508-12; PMID:8845956; http://dx.doi.org/10.1111/j.1460- 9568.1995.tb01049.x [48] Lledo PM, Tremblay P, DeArmond SJ, Prusiner SB, Nicoll RA.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"PMID:8637886; http://dx.doi.org/10.1073/ pnas.93.6.2403 [49] Mercer RC, Ma L, Watts JC, Strome R, Wohlge- muth S, Yang J, Cashman NR, Coulthart MB,Schmitt-Ulms G, Jhamandas JH, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Biol Chem 2013;288:37241-55; PMID:24225951; http://dx.doi.org/ 10.1074/jbc.M113.488650 [50] Ratte S, Vreugdenhil M, Boult JK, Patel A, Asante EA, Collinge J, Jefferys JG.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Neuroscience 2011; 179:56-61; PMID:21277354;http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Prion 2013; 7:280-5; PMID:23851597; http://dx.doi.org/ 10.4161/pri.25738 [52] Striebel JF, Race B, Pathmajeyan M, Rangel A, Chesebro B.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Neuroscience 2013; 238:11-8; PMID:23415788; http://dx.doi.org/10.1016/j.neuroscience.2013.02.004 [53] Carulla P, Bribian A, Rangel A, Gavin R, Ferrer I, Caelles C, Del R /C19ıo JA, Llorens F. Neuropro- tective role of PrPC against kainate-induced epi-leptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7- PSD-95 binding.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Mol Biol Cell 2011; 22:3041-54; PMID:21757544; http://dx.doi.org/10.1091/ mbc.E11-04-0321 [54] Rangel A, Madronal N, Gruart A, Gavin R, Llorens F, Sumoy L, Torres JM, Delgado-Garc /C19ıa JM, Del R/C19ıo JA.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"PLoS One 2009; 4:e7592; PMID:19855845; http://dx.doi.org/10.1371/jour- nal.pone.0007592 [55] Benvegnu S, Roncaglia P, Agostini F, Casalone C, Corona C, Gustincich S, Legname G. Developmen- tal inﬂuence of the cellular prion protein on thegene expression proﬁle in mouse hippocampus.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Physiol Genomics 2011; 43:711-25; PMID:21406608; http://dx.doi.org/10.1152/physiolgenomics.00205.2010 [56] Brenner HR, Herczeg A, Oesch B.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Proc Biol Sci 1992;250:151-5; PMID:1282260; http://dx.doi.org/ 10.1098/rspb.1992.0143[57] Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S, Aguzzi A, Weissmann C. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice toscrapie.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"PLoS One 2015; 10:e0117412;PMID:25658480 ; http://dx.doi.org/10.1371/ journal.pone.0117412 [60] Llorens F, Ferrer I, del Rio JA.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Mol Neurobiol 2014; 49:413-23; PMID:23949728; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Nature1994; 370:295-7; PMID:8035877; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Neuroscience 2003; 122:551-61; PMID:14614919; http://dx.doi.org/10.1016/S0306-4522(03)00562-1 [64] Schauwecker PE.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Exp Neurol 2002; 178:219-35; PMID:12504881; http://dx.doi.org/10.1006/exnr.2002.8038 [65] Schauwecker PE.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Prog Brain Res 2002; 135:139- 48; PMID:12143336; http://dx.doi.org/10.1016/ S0079-6123(02)35014-3 [66] McCord MC, Lorenzana A, Bloom CS, Chancer ZO, Schauwecker PE.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Neuro- science 2008; 154:1143-53; PMID:18479826;http://dx.doi.org/10.10 16/j.neuroscience.2008.,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurosci 2012; 32:12093-101; PMID:22933793; http://dx.doi.org/10.1523/ JNEUROSCI.6478-11.2012 [68] Sakudo A, Onodera T. Prion protein (PrP) gene- knockout cell lines: insight into functions of the PrP.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Neurobiol Dis 2013; 55:11-25; PMID:23523635; http://dx.doi.org/10.1016/j.nbd.2013.03.007 [70] Watt NT, Taylor DR, Kerrigan TL, Grifﬁths HH, Rushworth JV, Whitehouse IJ, Hooper NM.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Prion protein facilitates uptake of zinc into neuronal cells.Nat Commun 2012; 3:1134; PMID:23072804; http://dx.doi.org/10.1038/ncomms2135 [71] Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, Hajj GN, Lee KS, Magalh ~aes AC, Caetano FA, Mancini GL, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"FASEB J 2011; 25:265-79; PMID:20876210; http://dx.doi.org/10.1096/fj.10-161653 [72] Zeng F, Watt NT, Walmsley AR, Hooper NM.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurochem 2003; 84:480-90;PMID:12558968; http://dx.doi.org/10.1046/j.1471- 4159.2003.01529.x [73] Sonati T, Reimann RR, Falsig J, Baral PK, O’Co nnor T, Hornemann S, Yaganoglu S, Li B, Herrmann US, Wieland B, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"The toxicity of antiprion antibodies is mediated by the ﬂexible tail of the prion protein.Nature 2013; 501:102-6; PMID:23903654; http://dx.doi.org/10.1038/nature12402 [74] Herrmann US, Sonati T, Falsig J, Reimann RR, Dametto P, O’Connor T, Li B, Lau A, Horne-mann S, Sorce S, et al.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"PLoS Pathog 2015; 11:e1004662; PMID:25710374; http://dx.doi.org/ 10.1371/journal.ppat.1004662 [75] Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, R €ulicke T, Flechsig E, Cozzio A, von Mering C, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Cell 1998; 93:203-14; PMID:9568713; http://dx.doi.org/10.1016/ S0092-8674(00)81572-X[76] Nicolas O, Gavin R, Braun N, Urena JM, Fontana X, Soriano E, Aguzzi A, del R /C19ıo JA.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"FASEB J 2007; 21:3107-17; PMID:17494993; http://dx.doi.org/10.1096/fj.06-7827com [77] Mitteregger G, Vosko M, Krebs B, Xiang W, Kohl- mannsperger V, Nolting S, Hamann GF, Kretzsch- mar HA.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Brain Pathol 2007; 17:174-83; PMID:17388948; http://dx.doi.org/10.1111/j.1750- 3639.2007.00061.x [78] Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, Kellermann O. NADPH oxi- dase and extracellular regulated kinases 1/2 are tar-gets of prion protein signaling in neuronal andnonneuronal cells.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Proc Natl Acad Sci U S A 2003; 100:13326-31; PMID:14597699; http://dx.doi.org/ 10.1073/pnas.2235648100 [79] Gavin R, Braun N, Nicolas O, Parra B, Urena JM, Mingorance A, Soriano E, Torres JM, Aguzzi A, del R /C19ıo JA.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"FEBS Lett 2005; 579:4099-106; PMID:16023105;http://dx.doi.org/10.1016/j.febslet.2005.06.037 [80] Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, DeGiorgio LA,Volpe BT, Wiseman E, Abalos G, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Science 2004; 303:1514-6; PMID:14752167; http://dx.doi.org/10.1126/science.1094273 [81] Klohn PC, Farmer M, Linehan JM, O’Malley C, Fernandez de Marco M, Taylor W, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Science 2012; 335:52; PMID:22223800; http://dx.doi.org/10.1126/science.1215579 [82] Forloni G, Angeretti N, Chiesa R, Monzani E, Sal- mona M, Bugiani O, Tagliavini F. Neurotoxicity of a prion protein fragment.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Nature 1993; 362:543-6; PMID:8464494; http://dx.doi.org/10.1038/362543a0 [83] Sakudo A, Nakamura I, Lee DC, Saeki K, Ikuta K, Onodera T. Neurotoxic prion protein (PrP) frag-ment 106-126 requires the N-terminal half of the hydrophobic region of PrP in the PrP-deﬁcient neu- ronal cell line.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Neurobiol Dis 2008; 30:243-54; PMID:18374587; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Biol Chem 2006;281:28470-9; PMID:16864581; http://dx.doi.org/ 10.1074/jbc.M602774200 [86] Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
EMBO J 2007; 26:548-58;PMID:17245437; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Biochem Biophys Res Commun 2005; 332:75-82; PMID: 15896301;http://dx.doi.org/10.1016/j.bbrc.2005.04.099 [88] Li QQ, Sun YP, Ruan CP, Xu XY, Ge JH, He J, Xu ZD, Wang Q, Gao WC.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Cancer Sci 2011; 102:400-6;PMID:21265952; http://dx.doi.org/10.1111/j.1349- 7006.2010.01811.x [89] Bravard A, Auvre F, Fantini D, Bernardino-Sgherri J, Sissoeff L, Daynac M, Xu Z, Etienne O, Dehen C,Comoy E, et al.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Nucleic Acids Res 2015; 43:904-16;PMID:25539913; http://dx.doi.org/10.1093/nar/ gku1342 [90] Suzuki G, Shimazu N, Tanaka M. A yeast prion, Mod5, promotes acquired drug resistance and cell survival under environmental stress.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Science 2012; 336:355-9; PMID:22517861; http://dx.doi.org/10.1126/science.1219491 [91] Haik S, Peyrin JM, Lins L, Rosseneu MY, Brasseur R, Langeveld JP, Tagliavini F, Deslys JP, Lasm /C19ezas C, Dormont D. Neurotoxicity of the putative transmembrane domain of the prion pro- tein.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Neurobiol Dis 2000; 7:644-56; PMID:11114262; http://dx.doi.org/10.1006/nbdi.2000.0316 [92] Wang X, Bowers SL, Wang F, Pu XA, Nelson RJ, Ma J. Cytoplasmic prion protein induces forebrainneurotoxicity.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Biochim Biophys Acta 2009; 1792:555-63; PMID:19281844; http://dx.doi.org/ 10.1016/j.bbadis.2009.02.014 [93] Vilches S, Vergara C, Nicolas O, Sanclimens G, Merino S, Varon S, Acosta GA, Albericio F, Royo M, Del R /C19ıo JA, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
PLoS One 2013; 8:e70881; PMID:23940658; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Brain Res 2003; 966:231-44; PMID:12618346; http://dx.doi.org/ 10.1016/S0006-8993(02)04173-2 [96] Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Nature 2009; 457:1128-32; PMID:19242475; http://dx.doi.org/10.1038/nature07761 [97] Kostylev MA, Kaufman AC, Nygaard HB, Patel P, Haas LT, Gunther ECg, Vortmeyer A, StrittmatterSM.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
J Biol Chem 2015; 290:17415-38; PMID:26018073; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Hum Mol Genet 2012; 21:1138-44; PMID:22100763; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurosci 2010; 30:6367-74; PMID:20445063; http://dx.doi.org/10.1523/ JNEUROSCI.0395-10.2010 [101] Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Neurosci 2011; 31:7259-63; PMID:21593310; http://dx.doi.org/ 10.1523/JNEUROSCI.6500-10.2011 [102] Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, La Vitola P, Messa M, Colombo L, Forloni G, et al.",Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"J Biol Chem 2013; 288:7857-66; PMID:23362282; http://dx.doi.org/10.1074/jbc.M112.423954 [103] Ordonez-Gutierrez L, Torres JM, Gavin R, Anton M, Arroba-Espinosa AI, Espinosa JC, Vergara C,Del R /C19ıo JA, Wandosell F. Cellular prion protein modulates b-amyloid deposition in aged APP/PS1 transgenic mice.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Neurobiol Aging 2013; 34:2793- 804; PMID:23831375; http://dx.doi.org/10.1016/j.neurobiolaging.2013.05.019 [104] Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A,Wisniewski T, Koleske AJ, et al.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein.Neuron 2013; 79:887-902; PMID:24012003;http://dx.doi.org/10.1016/j.neuron.2013.06.036 [105] Risse E, Nicoll AJ, Taylor WA, Wright D, Badoni M, Yang X, Farrow MA, Collinge J. Identiﬁcationof a compound that disrupts binding of amyloid- b to the prion protein using a novel ﬂuorescence- based assay.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
J Biol Chem 2015; 290:17020-8;PMID:25995455; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
BiochemBiophys Res Commun 2008; 365:164-9;PMID:17981146; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"Microbiol Immunol 2006; 50:203-9; PMID:16547418; http://dx.doi.org/10.1111/j.1348-0421.2006.tb03787.x [108] Cui T, Daniels M, Wong BS, Li R, Sy MS, Sassoon J, Brown DR. Mapping the functional domain of the prion protein.",OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
Eur J Biochem 2003; 270:3368-76; PMID:12899694; http://dx.doi.org/10.1046/ j.1432-1033.2003.03717.x APPENDIX Examples of Pubmed citations on PrPC functions Paragraphs illustrating 3 examples of manu- scripts describing some functions of the PrPC.These manuscripts were selected as examples with the Pubmed search of the subject “cellular prion protein” and the particular process as key- word.,Non-OADS,/arxiv_data1/oa_pdf/0c/a7/kprn-10-01-1126038.PMC4981196.pdf
"PloS One 2015; 10(7): e0131993; PMID:26134409; http://dx.doi.org/10.1371/journal.pone.0131993 /C211Davis M. Seelig, Patricia A. Goodman, and Pamela J. Skinner.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Science 2001; 294:1726-8; PMID:11721058; http://dx.doi.org/10.1126/science.1066838 [2] Hetz C, Maundrell K, Soto C. Is loss of function of the prion protein the cause of prion disorders?Trends Mol Med 2003; 9:237-43; PMID:12829011; http://dx.doi.org/10.1016/S1471-4914(03)00069-8 [3] Caughey B, Chesebro B. Transmissible spongiform encephalopathies and prion protein interconver-sions.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Adv Virus Res 2001; 56:277-311; PMID:11450303; http://dx.doi.org/10.1016/S0065- 3527(01)56031-5 [4] Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C, Torchia M, Yang SL, Serban D, Carlson GA, et al.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Cell 1990; 63:673-86; PMID:1977523; http://dx.doi.org/10.1016/0092- 8674(90)90134-Z [5] Mallik S, Yang W, Norstrom EM, Mastrianni JA.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
J Biol Chem 285:8967-75;PMID:20086009; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"FASEB J 26:2868-76; PMID:22490928;http://dx.doi.org/10.1096/fj.11-200923 [7] Giachin G, Biljan I, Ilc G, Plavec J, Legname G. Probing early misfolding events in prion proteinmutants by NMR spectroscopy.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Molecules 18:9451- 76; PMID:23966072; http://dx.doi.org/10.3390/ molecules18089451 [8] Singh J, Udgaonkar JB.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Angew Chem Int Ed Engl 54:7529-33; PMID:25959220;http://dx.doi.org/10.1002/anie.201501011 [9] Liemann S, Glockshuber R. Inﬂuence of amino acid substitutions related to inherited human prion diseaseson the thermodynamic stability of the cellular prion protein.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"J Biol Chem 2004; 279:18008-14; PMID:14761942; http://dx.doi.org/10.1074/jbc.M313581200 [11] Singh J, Udgaonkar JB.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
Science 2001; 294:178-82; PMID:11546838; http://dx.doi.org/10.1126/science.1063093TREATMENT OF PRION DISEASES 23,Non-OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Nature2003; 422:80-3; PMID:1 2621436; http://dx.doi.org/ 10.1038/nature01457 [14] Horiuchi M, Priola SA, Chabry J, Caughey B. Interac- tions between heterologous forms of prion protein:binding, inhibition of conversion, and species barriers.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
Proc Natl Acad Sci U S A 2000; 97:5836-41; PMID: 10811921; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Science 1973; 182:67-8; PMID:4199733; http://dx.doi.org/10.1126/ science.182.4107.67 [19] Barlow RM, Rennie JC.",Non-OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Proc Natl Acad Sci U S A109:5080-5; PMID:22416127; http://dx.doi.org/ 10.1073/pnas.1120076109 [21] Vidal E, Fernandez-Borges N, Pintado B, Ordonez M, Marquez M, Fondevila D, Torres JM, PumarolaM, Castilla J.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"J Neurosci 33:7778-86;PMID:23637170; http://dx.doi.org/10.1523/JNEUR- OSCI.0244-13.2013 [22] Huang XQ, Hardison RC, Miller W. A space-efﬁ- cient algorithm for local similarities.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
Exp Neurol 2009; 220:217-8;PMID:19682986; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"J Biol Chem 1998; 273:13203-7; PMID:9582363; http://dx.doi.org/10.1074/jbc.273.21.13203 [25] Chabry J, Priola SA, Wehrly K, Nishio J, Hope J, Chesebro B. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptidecontaining a conserved PrP sequence.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
EMBO J2002; 21:202-10; PMID:11823413; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"Proc Natl Acad Sci U S A 2008;105:10238-43; PMID:18632556; http://dx.doi.org/ 10.1073/pnas.0802759105 [28] Toupet K, Compan V, Crozet C, Mourton-Gilles C, Mestre-Frances N, Ibos F, Corbeau P, Verdier JM, Perrier V. Effective gene therapy in a mouse model of prion diseases.",OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
PLoS One 2008; 3:e2773; http://dx.doi.org/10.1371/journal.pone.000277324 Seelig et al.,OADS,/arxiv_data1/oa_pdf/fc/02/kprn-10-01-1123372.PMC4981202.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Nature 2003;425:35-6; PMID:12955129; http://dx.doi.org/10.1038/425035a [3] Miller MW, Williams ES, Hobbs NT, Wolfe LL.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Envi- ronmental sources of prion transmission in mule deer.Emerg Infect Dis 2004; 10:1003-6; PMID:15207049; http://dx.doi.org/10.3201/eid1006.040010 [4] Williams ES.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Vet Pathol 2005; 42:530-49; PMID:16145200; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Wildl Dis 2005; 41:275-90; PMID:16107661; http://dx.doi.org/10.7589/0090- 3558-41.2.275 [7] Rigou P, Rezaei H, Grosclaude J, Staunton S, Qui- quampoix H. Fate of prions in soil: adsorption and extraction by electroelution of recombinant ovine prionprotein from montmorillonite and natural soils.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Envi-ron Sci Technol 2006; 40:1497-503; PMID:16568762; http://dx.doi.org/10.1021/es0516965 [8] Johnson CJ, Phillips KE, Schramm PT, McKenzie D, Aiken JM, Pedersen JA.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"PLoS Pathog 2006; 2:e32; PMID:16617377; http://dx.doi.org/10.1371/journal.ppat.0020032 [9] Brown P, Gajdusek DC.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Lancet 1991; 337:269-70;PMID:1671114; http://dx.doi.org/10.1016/0140-6736(91)90873-N [10] Thomzig A, Kratzel C, Lenz G, Kruger D, Beekes M. Widespread PrP(Sc) accumulation in muscles ofhamsters orally infected with scrapie.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
EMBO Rep 2003; 4:1-4; http://dx.doi.org/10.1038/sj.embor.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Neurotoxicology 2006; 27:777- 87; PMID:16860868; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Mol Cell Neurosci 2009; 41:135-47; PMID:19233277; http://dx.doi.org/10.1016/j.mcn.2009.02.002 [14] Leach SP, Salman MD, Hamar D. Trace elements and prion diseases: a review of the interactions of copper, manganese and zinc with the prion protein.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Anim Health Res Rev 2006; 7:97-105; PMID:17389057;http://dx.doi.org/10.1017/S1466252307001181 [15] Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, WisniewskiT.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Biol Chem 2003; 278:46199-202; PMID:14519758; http://dx.doi.org/10.1074/jbc.C300303200 [16] Brown DR, Haﬁz F, Glasssmith LL, Wong BS, Jones IM, Clive C, Haswell SJ.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"EMBO J 2000;19:1180-6; PMID:10716918; http://dx.doi.org/ 10.1093/emboj/19.6.1180 [17] Pushie MJ, Rauk A, Jirik FR, Vogel HJ.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biometals 2009; 22:159-75; PMID:19140013; http://dx.doi.org/10.1007/s10534-008-9196-x [18] Stockel J, Safar J, Wallace AC, Chohen FE, Prusiner SB.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Prion protein selectively binds copper (II) ions.Biochemistry 1998; 37:7185-93; PMID:9585530;http://dx.doi.org/10.1021/bi972827k [19] Viles JH, Cohen FE, Prusiner SB, Goodin DB, Wright PE, Dyson HJ.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
BMC Syst Biol 2012; 6:132;PMID:23068602; http://dx.doi.org/10.1186/1752- 0509-6-132 [22] Cowan JA ed.,OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"New York: VCH Publishers Inc, 1995 [23] Turnbull S, Tabner BJ, Brown DR, Allsop D. Cop- per-dependent generation of hydrogen peroxidefrom the toxic prion protein fragment PrP106-126.Neurosci Lett 2003; 336:159-62; PMID:12505617; http://dx.doi.org/10.1016/S0304-3940(02)01254-5DIETARY MAGNESIUM AND COPPER AFFECT SURVIVAL TIME AND NEUROINFLAMMATION 247",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Virol 2006; 80:9104-14; PMID:16940522; http://dx.doi.org/10.1128/JVI.00098-06 [26] Kong Q, Huang S, Zou W, Vanegas D, Wang M, Wu D, Yuan J, Zheng M, Bai H, Deng H, et al.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Neurochem 2012; 120:177-89; PMID:22007749; http://dx.doi.org/10.1111/j.1471- 4159.2011.07540.x [28] Choi CJ, Anantharam V, Martin DP, Nicholson EM, Richt JA, Kanthasamy A, Kanthasamy AG.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Toxi- col Sci 2010; 115:535-46; PMID:20176619; http://dx.doi.org/10.1093/toxsci/kfq049 [29] Bolea R, Hortells P, Martin-Burriel I, Vargas A, Ryffel B, Monzon M, Badiola JJ.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Neuro- pathol Appl Neurobiol 2010; 36:300-11; PMID:20070537; http://dx.doi.org/10.1111/j.1365-2990.2010.01065.x [30] Thackray AM, Knight R, Haswell SJ, Bujdoso R, Brown DR. Metal imbalance and compromised anti-oxidant function are early changes in prion disease.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Biochem J 2002; 362:253-8; PMID:11829763; http://dx.doi.org/10.1042/bj3620253 [31] Cowan JA.,OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biometals 2002; 15:225-35; PMID:12206389; http://dx.doi.org/ 10.1023/A:1016022730880 [32] Pushie MJ, Rauk A, Jirik FR, Vogel HJ.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biometals 2009; 22:159-75;PMID:19140013; http://dx.doi.org/10.1007/s10534- 008-9196-x [33] Stockel J, Safar J, Wallace AC, Cohen FE, Prusiner SB.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biochemistry 1998; 37:7185-93; PMID:9585530; http://dx.doi.org/10.1021/bi972827k [34] Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Delineating common molecular mechanisms in Alzheimer’s and prion diseases.Trends in biochemical sciences 2006; 31:465-72; PMID:16820299; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Dalton Trans 2009; (21):4069-76; PMID:19452053; http://dx.doi.org/ 10.1039/b822135a [36] Davies P, Brown DR. Manganese enhances prion protein survival in model soils and increases prion infectivity to cells.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"PLoS One 2009; 4:e7518; PMID:19844576; http://dx.doi.org/10.1371/journal.pone.0007518 [37] Johnson CJ, Pedersen JA, Chappell RJ, McKenzie D, Aiken JM.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
PLoS Pathog 2007; 3:e93; PMID:17616973; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Virol 2011; 85:5476-82; PMID:21430062; http://dx.doi.org/10.1128/JVI.00282-11 [39] Kuznetsova A, McKenzie D, Banser P, Siddique T, Aiken JM.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Prion 2014; 8:92-99; PMID:24618673; http://dx.doi.org/10.4161/pri.28467 [40] Hortells P, Monleon E, Acin C, Vargas A, Vasseur V, Salomon A, Ryffel B, Cesbron JY, Badiola JJ, Monzon M. The effect of metal imbalances on scra- pie neurodegeneration.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Alzheimer Dis Assoc Disord 2003; 17:147-50; PMID:14512827; http://dx.doi.org/10.1097/00002093-200307000-00005 [42] Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Biol Chem 2004; 279:20378-86; PMID:14985339; http://dx.doi.org/10.1074/jbc.M400805200 [43] Kitazawa M, Cheng D, Laferla FM.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Neurochem 2009; 108:1550-60; PMID:19183260; http://dx.doi.org/10.1111/j.1471- 4159.2009.05901.x [44] Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, et al.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
J Biol Chem 1999; 274:37111-6; PMID:10601271;http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Arch Neurol2003; 60:1685-91; PMID:14676042; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Neurochem 2001; 78:1400-8; PMID:11579148; http://dx.doi.org/10.1046/j.1471-4159.2001.00522.x [47] Kim JI, Choi SI, Kim NH, Jin JK, Choi EK, Carp RI, Kim YS.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Neurochem 2004; 88:657-67; PMID:14720215; http://dx.doi.org/10.1046/j.1471-4159.2003.02195.x [49] Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity.Cell 1994; 77:817-27; PMID:8004671; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biochim Biophys Acta 2007; 1768:1976-90; PMID:17433250; http://dx.doi.org/ 10.1016/j.bbamem.2007.02.002 [51] Tabner BJ, Turnbull S, Fullwood NJ, German M, Allsop D. The producti on of hydrogen peroxide during early-stage prote in aggregation: a common pathological mechanism in different neurodegen- erative diseases?",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biochem Soc Trans 2005; 33:548-50; PMID:16042541; http://dx.doi.org/10.1042/BST0330548 [52] Butterﬁeld DA, Bader Lange ML, Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression ofAlzheimer’s disease.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Biochim Biophys Acta 2010; 1801:924-9; PMID:20176130; http://dx.doi.org/ 10.1016/j.bbalip.2010.02.005 [53] White SN, O’Rourke KI, Gidlewski T, VerCauteren KC, Mousel MR, Phillips GE, Spraker TR.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Trace Elem Med Biol 2010; 24:169-73; PMID:20569929; http://dx.doi.org/10.1016/j.jtemb.2010.02.002 [55] Pan HC, Sheu ML, Su HL, Chen YJ, Chen CJ, Yang DY, Chiu WT, Cheng FC.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Diabetes Care 2010; 33:2604-10;PMID:20807870; http://dx.doi.org/10.2337/dc10-0994 [57] C illiler AE, Ozturk S, Ozba kir S. Serum magnesium level and clinical deteriora tion in Alzheimer’s disease.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Gerontology 2007; 53:419-22; PMID:17992016;http://dx.doi.org/10.1159/000110873 [58] Srivastava D, Subramanian RB, Madamwar D, Flora SJ.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Arh Hig Rada Toksikol 2010; 61:153- 9; PMID:20587388; http://dx.doi.org/10.2478/10004-1254-61-2010-1993 [59] Yu J, Sun M, Chen Z, Lu J, Liu Y, Zhou L, Xu X, Fan D, Chui D. Magnesium modulates amy-loid-beta protein precursor trafﬁcking and proc- essing.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Med Hypotheses 1990; 31:211-25; PMID:2092675; http://dx.doi.org/10.1016/0306-9877(90)90095-V [61] Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Ramirez Kitchen CM, Funderburg N,Mesiano S, Bernstein HB.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Immunol 2012;188:6338-46; PMID:22611240; http://dx.doi.org/10.4049/jimmunol.1101765 [62] Lee M, Jantaratnotai N, McGeer E, McLarnon JG, McGeer PL.",Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Brain Res 2011; 1369:21-35; PMID:21040713; http://dx.doi.org/10.1016/j.brainres.2010.10.084 [63] Huang CY, Liou YF, Chung SY, Lin WY, Jong GP, Kuo CH, Tsai FJ, Cheng YC, Cheng FC, Lin JY.Role of ERK signaling in the neuroprotective efﬁ- cacy of magnesium sulfate treatment during focal cerebral ischemia in the gerbil cortex.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Chin J Phys-iol 2010; 53:299-309; PMID:21793341; http://dx.doi.org/10.4077/CJP.2010.AMK063DIETARY MAGNESIUM AND COPPER AFFECT SURVIVAL TIME AND NEUROINFLAMMATION 249,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"Trends Mol Med 2011; 17(1):14-24; http://dx.doi.org/10.1016/j.molmed.2010.09.001 [68] Chiu FC, Goldman JE.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"J Neuroimmunol1985; 8:283-92; PMID:2989328; http://dx.doi.org/ 10.1016/S0165-5728(85)80067-9 [69] Middeldorp J, Hol EM.",OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
Progress in neurobiology 2011; 93:421-43; PMID:21219963; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/kprn-10-03-1181249.PMC4981212.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/12/8e/ndt-12-1977.PMC4981216.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1977–1981Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1977PersPecTivesopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S11065 6 exercise is medicine for patients with major  depressive disorders: but only if the “pill” is taken!",Non-OADS,/arxiv_data1/oa_pdf/12/8e/ndt-12-1977.PMC4981216.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/12/8e/ndt-12-1977.PMC4981216.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/12/8e/ndt-12-1977.PMC4981216.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ndt-12-1983.PMC4981217.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1983–1991Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1983OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11123 0 T wo-year prognosis after residential treatment  for patients with alcohol dependence: three chief  guidelines for sobriety in Japan T etsuji cho1,2 hideki Negoro3 Yasuhiro saka1 Masayuki Morikawa1,2 T oshifumi Kishimoto2 1Mie Prefectural Mental care  center, Tsu-shi, Mie, 2Department of  Psychiatry, Nara Medical University  school of Medicine, Kashihara, Nara,   3Faculty of education, Nara University  of education, Nara, JapanBackground:  In Japan, the three chief traditional guidelines for sobriety (3CGS) are regular  medical checkups, participation in self-help groups, and pharmacotherapy with antidipsotropics.",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ndt-12-1983.PMC4981217.pdf
"In addition, correspondence: Tetsuji cho Mie Prefectural Mental care center,  1-12-1, shiroyama, Tsu-shi,   Mie 514-0818, Japan Tel +81 59 235 2125   Fax +81 59 235 2135 email tetsujicho@ybb.ne.j p Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Cho et al Running head recto: Two-year prognosis of alcohol dependence in Japan DOI: http://dx.doi.org/10.2147/NDT.S111230",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ndt-12-1983.PMC4981217.pdf
"Available from: http://www1.mhlw.go.jp/topics/ kenko21_11/b5f.htm l. Accessed June 10, 2016.",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ndt-12-1983.PMC4981217.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ndt-12-1983.PMC4981217.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/26/ndt-12-1983.PMC4981217.pdf
"The overall trend and quarterly changes in costs when analysis was restricted to only those patientswho survived over the 8 quarters is similar to that in our original sample (see Fig., Supplemental Digital Content 1, http://links.lww.com/MLR/B196).",Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
"In addition, though base-line costs are indeed slightly lower when only surviving patients are included, we see very similar rates of RTM (see Table, Supplemental Digital Content 2, http://links.lww.com/MLR/B197).",Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/st354/stat354.shtml.,OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.newyorker.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.commonwealth fund.org/ ˜/media/files/publications/issue-brief/2014/aug/1764_hong_cari ng_for_high_need_high_cost_patients_ccm_ib.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.chcs.org/media/ SU-Fact-Sheet_41715_Final.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at:http://www.rwjf.org/content/dam/files/rwjf-web-files/Research/2014/Caring%20for%20Health%20Care%27s%20Costliest%20Patients.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.chcs.org/media/HighUtilizerReport_102413_Final3.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
2012.Available at: http://www.cbo.gov/sites/default/files/112th-congress- 2011-2012/workingpaper/WP2012-01_Nelson_Medicare_DMCC_Dem onstrations_1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.the-link-king.com/ index.html.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
"Available at: http://www.state.nj.us/health/charitycare/.Accessed September 14, 2015.",Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: https://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp.,OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
2012.Available at: http://factfinder.census.gov/faces/tableservices/jsf/pages/ productview.xhtml?pid = ACS_11_5YR_S1701&prodType = table.,OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.bls.gov/cpi/cpifact4.htm.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: https://www.ccwdata.org/web/guest/condition-categories.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.hcup-us.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.hcup-us.ahrq.gov/reports/SOI.jsp.,OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
Available at: http://www.stata.com/features/generalized-estimating-equations/.,Non-OADS,/arxiv_data1/oa_pdf/21/8e/mlr-54-860.PMC4981218.pdf
"Codes used to identify treatment are listedin Table (Supplemental Digital Content 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"Although we calculated sensi- tivity, speciﬁcity, PPV, and NPV, we focused our analyseson sensitivity and PPV with the other measures reported in the Supplemental Tables (Supplemental Digital Content 2–4, http://links.lww.com/MLR/A666, http://links.lww.com/MLR/A667, http://links.lww.com/MLR/A668, which shows additional statistics).",OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"The speciﬁcity (range, 93%–100%) and NPV (range, 80%–99%excluding bladder) were high across all characteristics (Table, Supplemental Digital Content 2, http://links.lww.",OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"Thespeciﬁcity overall was 97% and ranged between 94% and100% by characteristic and the NPV was 89% overall and ranged from 82% to 96% (Table, Supplemental Digital Content 3, http://links.lww.com/MLR/A667, which showsadditional statistics for RT).",OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"Similar to CT and RT, the speciﬁcity was high except for distant stage; however, the NPV was only 78% overall (Table,Supplemental Digital Content 4, http://links.lww.com/MLR/A668, which shows additional statistics for HT).",OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"However, for the cancer sitesincluded in this analysis the sensitivity was <90% for all stages and treatment types (See Table, Supplemental Digital Content 5, http://links.lww.com/MLR/A672 which showssensitivity and PPV by cancer site and stage).",Non-OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"As within many site/stage strata SEER reliably identiﬁed individuals who truly received treatment, SEERtreatment data may have a limited role in research projects to identify a cohort of treated individuals within these strata (See Table, Supplemental Digital Content 5, http://links.lww.com/MLR/A672 which shows sensitivity and PPV by cancer site and stage).",Non-OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
"Available at: http://healthservices.cancer.gov/seermedicare/overview/publications.html.Accessed March 8, 2012.",Non-OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
Available at http://seer.cancer.gov/csr/1975_2007/.,Non-OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
Available at http://appliedresearch.cancer.gov/surveys/poc/.,Non-OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
Available at: http://www.iom.edu/B/media/Files/Activity%20Files/Research/HIPAAandResearch/ HIPAAIOMmeeting607rHowe.ashx.,OADS,/arxiv_data1/oa_pdf/1a/a3/mlr-54-e55.PMC4981219.pdf
Korean J Thorac Cardiovasc Surg 2016;49:225-231 □ REVIEW □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.225,Non-OADS,/arxiv_data1/oa_pdf/65/2e/kjtcvs-49-225.PMC4981223.pdf
"However, it is neces-Korean J Thorac Cardiovasc Surg 2016;49:232-241 □ BASIC RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.232",Non-OADS,/arxiv_data1/oa_pdf/cb/f4/kjtcvs-49-232.PMC4981224.pdf
The aims of this study were to  e v a l u a t e  e a r l y  a n d  l o n g - t e r m  r e s u l t s  o f  H TP L  a n d  t o   analyze changes in patient characteristics and clinical Korean J Thorac Cardiovasc Surg 2016;49:242-249 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.242,Non-OADS,/arxiv_data1/oa_pdf/ea/3d/kjtcvs-49-242.PMC4981225.pdf
"In the interest of reviewing outcomes of re- d o - A R R  i n  t h e  c u r r e n t  e r a ,  w e  s o u g h t  t o  e v a l u a t e  t h e  Korean J Thorac Cardiovasc Surg 2016;49:250-257 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.250",Non-OADS,/arxiv_data1/oa_pdf/61/74/kjtcvs-49-250.PMC4981226.pdf
The main concern has been durability and the qual-Korean J Thorac Cardiovasc Surg 2016;49:258-263 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.258,Non-OADS,/arxiv_data1/oa_pdf/16/62/kjtcvs-49-258.PMC4981227.pdf
T o  d e t e r m i n e  t h e  s u p e r i o r i t y  o f  a n  a r c h  Korean J Thorac Cardiovasc Surg 2016;49:264-272 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.264,Non-OADS,/arxiv_data1/oa_pdf/0d/71/kjtcvs-49-264.PMC4981228.pdf
"Namely, ex-t r a c o r p o r e a l  C P R  ( E - C P R )  h a s  s h o w n  i m p r o v e d  s u r - vival as well as superior neurologic outcomes in re- cent observational studies, which were prompted by Korean J Thorac Cardiovasc Surg 2016;49:273-279 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.273",Non-OADS,/arxiv_data1/oa_pdf/64/b9/kjtcvs-49-273.PMC4981229.pdf
ARF is also a major indication for intensive care  unit admissions in patients with hematologic malig-Korean J Thorac Cardiovasc Surg 2016;49:280-286 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.280,Non-OADS,/arxiv_data1/oa_pdf/13/6a/kjtcvs-49-280.PMC4981230.pdf
Available from: https://www.elso.org/Portals/0/IGD/Archive/FileManager/ 989d4d4d14cusersshyerdocumentselsoguidelinesforadul-trespiratoryfailure1.3.pdf.,OADS,/arxiv_data1/oa_pdf/13/6a/kjtcvs-49-280.PMC4981230.pdf
The aim of  t h i s  s t u d y  w a s  t o  d o c u m e n t  t h e  c l i n i c a l  f e a t u r e s  a n d   course of SPM and identify the optimal diagnostic methods and treatment by analyzing a large number  of patients with SPM.Korean J Thorac Cardiovasc Surg 2016;49:287-291 □ CLINICAL RESEARCH □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.287,Non-OADS,/arxiv_data1/oa_pdf/9c/64/kjtcvs-49-287.PMC4981231.pdf
The patient was too small (body weight of 30 kg) to approach transvenously; thus all proce- dures were done via median sternotomy under gen-Korean J Thorac Cardiovasc Surg 2016;49:292-294 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.292,Non-OADS,/arxiv_data1/oa_pdf/75/de/kjtcvs-49-292.PMC4981232.pdf
At the Korean J Thorac Cardiovasc Surg 2016;49:295-297 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.295,Non-OADS,/arxiv_data1/oa_pdf/0f/6a/kjtcvs-49-295.PMC4981233.pdf
The new Valiant Korean J Thorac Cardiovasc Surg 2016;49:298-301 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.298,Non-OADS,/arxiv_data1/oa_pdf/ac/63/kjtcvs-49-298.PMC4981234.pdf
"We could define the site of the air leakage site on the cyst, as observed Korean J Thorac Cardiovasc Surg 2016;49:302-305 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.302",Non-OADS,/arxiv_data1/oa_pdf/28/0d/kjtcvs-49-302.PMC4981235.pdf
"However, Korean J Thorac Cardiovasc Surg 2016;49:306-308 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.306",Non-OADS,/arxiv_data1/oa_pdf/b1/03/kjtcvs-49-306.PMC4981236.pdf
"The upper half of the wound was not closed, and a Korean J Thorac Cardiovasc Surg 2016;49:309-312 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.309",Non-OADS,/arxiv_data1/oa_pdf/b1/3b/kjtcvs-49-309.PMC4981237.pdf
O n e  o f  t h e  t w o  m a s s e s  c o n s i s t e d  o f  a  t h i c k - w a l l e d  Korean J Thorac Cardiovasc Surg 2016;49:313-316 □ CASE REPORT □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.313,Non-OADS,/arxiv_data1/oa_pdf/a6/15/kjtcvs-49-313.PMC4981238.pdf
"Since then, beginning with the second patient who  underwent an operation in March, 1961, open heart Korean J Thorac Cardiovasc Surg 2016;49:317-320 □ HISTORICAL NOTE □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.317",Non-OADS,/arxiv_data1/oa_pdf/a0/bc/kjtcvs-49-317.PMC4981239.pdf
Another fact was also mentioned in the paper:  the test was held together with the examinations of Korean J Thorac Cardiovasc Surg 2016;49:321-324 □ HISTORICAL NOTE □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.321,Non-OADS,/arxiv_data1/oa_pdf/ed/82/kjtcvs-49-321.PMC4981240.pdf
The content of the presentation and discussion at  the meeting was formally published in the first issue  of the “Journal of the Korean Medical Association( 조Korean J Thorac Cardiovasc Surg 2016;49:325-328 □ HISTORICAL NOTE □ http://dx.doi.or g/10.5090/k jtcs.2016.49.4.325,Non-OADS,/arxiv_data1/oa_pdf/28/5b/kjtcvs-49-325.PMC4981241.pdf
"Nami B., et al ., BioImpacts, 2016, 6(2), 105-110 doi: 10.15171/bi.2016.15 http://bi.tbzmed.ac.ir/ Overexpression of molecular chaperons GRP78 and GRP94 in  CD44hi/CD24lo breast cancer stem cells Babak Nami1*, Armin Ghasemi-Dizgah2, Akbar Vaseghi3 1 Department of Medical Genetics and The Women and Children’s Health Research Institute (WCHRI), University of Alberta,  Edmonton, Alberta, Canada 2 Department of Microbiology, Iran University of Medical Sciences, Tehran, Iran 3 Y oung Researchers and Elite Club, Ardabil Branch, Islamic Azad University, Ardabil, Iran *Corresponding author: Babak Nami, Email: namimoll@ualberta.ca  © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/85/ac/bi-6-105.PMC4981248.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/85/ac/bi-6-105.PMC4981248.pdf
"Mahmoudi M., et al ., BioImpacts, 2016, 6(2), 111-115 doi: 10.15171/bi.2016.16 http://bi.tbzmed.ac.ir/ Infection-resistant MRI-visible scaffolds for tissue engineering  applications Morteza Mahmoudi1,2,3, Mingming Zhao4, Yuka Matsuura2, Sophie Laurent5,6, Phillip C. Y ang1,2, Daniel Bernstein1,4,  Pilar Ruiz-Lozano1,4*, Vahid Serpooshan1,4* 1Stanford Cardiovascular Institute, Stanford, CA, 94305 USA 2Division of Cardiovascular Medicine, Stanford University, 300 Pasteur Dr., Stanford, CA 94305 3Nanotechnology Research Center and Department of Nanotechnology, Faculty of Pharmacy, Tehran University of Medical  Sciences, Tehran, 14155-6451, Iran 4Department of Pediatrics, Stanford University, 300 Pasteur Dr., Stanford, CA 94305 5Department of General, Organic, and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons,  Avenue Maistriau, 19, B-7000 Mons, Belgium 6CMMI - Center for Microscopy and Molecular Imaging, Avenue A. Bolland, 8  B-6041 Gosselies, Belgium Biodegradable scaffold systems are a promising tool  for regenerative therapies.1,2 In addition, scaffold  constructs are engineered as biomimetic, three-di - mensional (3D) models to recapitulate and study the cel - lular and molecular biology underlying various diseases  in vitro.3,4 However, both in vitro  and in vivo application of  tissue engineering scaffolds have been challenged by the  difficulty to achieve germ-free biomaterials for safe ther - apeutic use.",Non-OADS,/arxiv_data1/oa_pdf/5c/ae/bi-6-111.PMC4981249.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/5c/ae/bi-6-111.PMC4981249.pdf
"Rafi MA., BioImpacts, 2016, 6(2), 69-70 doi: 10.15171/bi.2016.09 http://bi.tbzmed.ac.ir/ Gene therapy for CNS diseases – Krabbe disease Mohammad A. Rafi* Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvanian 19107, USA The 19th Annual Meeting of the American Society  of Gene and Cell Therapy (ASGCT) took place  from May 4th through May 7th, 2016 at the Marriott  Wardman Park Hotel in Washington, DC, USA.",Non-OADS,/arxiv_data1/oa_pdf/b1/7d/bi-6-69.PMC4981250.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/b1/7d/bi-6-69.PMC4981250.pdf
"Safdari R., et al.,  BioImpacts, 2016, 6(2), 71-78 doi: 10.15171/bi.2016.10 http://bi.tbzmed.ac.ir/ Computerized techniques pave the way for drug-drug interaction  prediction and interpretation Reza Safdari1†, Reza Ferdousi1,2†, Kamal Aziziheris3, Sharareh R. Niakan-Kalhori1, Y adollah Omidi2* 1 Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences,  Tehran, Iran 2 Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran 3 Department of Mathematical Sciences, University of Tabriz, Tabriz, Iran Introduction Errors are plausible in every medical related procedures.",Non-OADS,/arxiv_data1/oa_pdf/37/ce/bi-6-71.PMC4981251.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/37/ce/bi-6-71.PMC4981251.pdf
Drug-drug interaction information was  collected from the Canadian drug bank freely available at: http://www.drugbank.ca/ .,OADS,/arxiv_data1/oa_pdf/37/ce/bi-6-71.PMC4981251.pdf
"Hosseinpour M., et al ., BioImpacts, 2016, 6(2), 79-84 doi: 10.15171/bi.2016.11 http://bi.tbzmed.ac.ir/ The cardiac effects of carbon nanotubes in rat Mina Hosseinpour1, Vahid Azimirad1, Maryam Alimohammadi1*, Parviz Shahabi2, Mina Sadighi2, Ghazaleh  Ghamkhari Nejad2 1Biomechatronics Lab, Department of Mechatronics, School of Engineering Emerging Technologies, University of Tabriz, Tabriz,  Iran 2Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Introduction Carbon nanotubes (CNTs) with their special properties  are regarded as unique materials in various health fields  such as biomedicine and pharmacology.1 Recently, the po - tential application of CNTs in drug and gene delivery has  been clearly demonstrated (e. g. drugs are encapsulated in  CNTs, and then they are injected into cell and are released  there).2 Furthermore, CNTs are promising candidates for  forming the basis of new biological and medical devices  such as pace makers and biosensors.3 For example, the  CNT-based electrochemical biosensors have been used  for detecting chemical redox interactions.4,5 Additional - ly, CNTs are used as scaffolds to promote cell adhesion,  growth, differentiation, and proliferation.",Non-OADS,/arxiv_data1/oa_pdf/04/86/bi-6-79.PMC4981252.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/04/86/bi-6-79.PMC4981252.pdf
"12 http://bi.tbzmed.ac.ir/ Up-regulation of miR-21 and 146a expression and increased DNA  damage frequency in a mouse model of polycystic ovary syndrome  (PCOS) Mohammad Salimi-Asl1, Hossein Mozdarani1*, Mehdi Kadivar2 1Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran  2Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran Introduction   Around 5 to 10 present of women in reproductive age are  affected by polycystic ovary syndrome (PCOS) which is  a complex endocrine disorder.1,2 It is a multigenic disor - der with a high degree of heritability.3 Phenotypically, it  is a heterogeneous disorder.",Non-OADS,/arxiv_data1/oa_pdf/d4/2a/bi-6-85.PMC4981253.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d4/2a/bi-6-85.PMC4981253.pdf
"Pirayesh Islamian J., et al ., BioImpacts, 2016, 6(2), 93-98 doi: 10.15171/bi.2016.13 http://bi.tbzmed.ac.ir/ Enhancing radiosensitivity of TE1, TE8, and TE 11 esophageal  squamous carcinoma cell lines by Hdm2-siRNA targeted gene  therapy in vitro Jalil Pirayesh Islamian1*, Mohsen Mohammadi2, Behzad Baradaran3, Alireza Farajollahi1, Seyed Mahmoud Reza  Aghamiri4, Mohammad Asghari Jafarabadi5, Hadi Karami6, Amir Monfaredan7, Dariush Shanehbandi3 1 Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran 2 Department of Medical Radiation Science, School of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 4 Department of Radiation Medicine, Faculty of Nuclear Engineering, Shahid Beheshti University of Medical Sciences, Tehran, Iran 5 Department of Statistics and Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran  6 Department of Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran 7 Department of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran *Corresponding author: Jalil Pirayesh Islamian, Email: pirayeshj@gmail.com  © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/f0/7a/bi-6-93.PMC4981254.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/f0/7a/bi-6-93.PMC4981254.pdf
"Amirkhani MA., et al ., BioImpacts, 2016, 6(2), 99-104 doi: 10.15171/bi.2016.14 http://bi.tbzmed.ac.ir/ A rapid sonication based method for preparation of stromal  vascular fraction and mesenchymal stem cells from fat tissue Mohammad Amir Amirkhani1, Rashin Mohseni2, Masoud Soleimani3, Alireza Shoae-Hassani2, Mohammad Ali  Nilforoushzadeh1* 1Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran 2Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences,  Tehran, Iran 3Hematology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Introduction To date, the cell therapy notion using isolated stem cells  from various parts of the body with different potencies  has received a lot of attention.",Non-OADS,/arxiv_data1/oa_pdf/ee/f4/bi-6-99.PMC4981255.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/ee/f4/bi-6-99.PMC4981255.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Cell Tissue Res 2013; 352(1):95-122; PMID:22350846; http://dx.doi.org/10.1007/s00441-012-1329-4 [2] Amanatullah DF, Yamane S, Reddi AH.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"BMC Genomics 2008; 9:328; PMID:18620571; http://dx.doi.org/10.1186/ 1471-2164-9-328 [4] Baranova A, Ivanov D, Petrash N, Pestova A, Sko- blov M, Kelmanson I, Shagin D, Nazarenko S, Ger- aymovych E, Litvin O, et al.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
(4):706-16; PMID:15028292; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Biochimica Et Biophysica Acta-Biomem- branes 2012; 1818(8):1807-22; http://dx.doi.org/ 10.1016/j.bbamem.2011.09.019 [6] Barrett-Jolley R, Lewis R, Fallman R, Mobasheri A.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Science 1993; 262 (5142):2039-42; PMID:8266101; http://dx.doi.org/ 10.1126/science.8266101 [8] Binggeli R,Weinstein RC.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Theor Biol 1986; 123(4):377-401; PMID:2443763; http://dx.doi.org/ 10.1016/S0022-5193(86)80209-0 [9] Bond SR, Lau A, Penuela S, Sampaio AV, Underhill TM, Laird DW, Naus CC.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Bone Miner Res 2011;26(12):2911-22; PMID:21915903; http://dx.doi.org/ 10.1002/jbmr.509 [10] Bosnakovski D, Mizuno M, Kim G, Ishiguro T, Okumura M, Iwanaga T, Kadosawa T, Fujinaga T.Chondrogenic differentiation of bovine bone marrow mesenchymal stem cells in pellet cultural system.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Exp Hematol 2004; 32(5):502-9; PMID:15145219;http://dx.doi.org/10.1016/j.exphem.2004.02.009 [11] Brackenbury WJ, Isom LL.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Expert Opin Ther Targets 2008; 12(9):1191- 203; PMID:18694383; http://dx.doi.org/10.1517/14 728222.12.9.1191 [12] Bush PG, Hall AC.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"The volume and morphology of chondrocytes within non-degenerate and degenerate human articular cartilage, Osteoarthritis Cartilage 2003; 11(4):242-51; PMID:12681950; http://dx.doi.org/10.1016/S1063-4584(02)00369-2 [13] Canales RD, Luo Y, Willey JC, Austermiller B, Bar- bacioru CC, Boysen C, Hunkapiller K, Jensen RV,Knight CR, Lee KY, et al.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Nat Biotechnol 2006; 24(9):1115-22;PMID:16964225; http://dx.doi.org/10.1038/nbt1236 [14] Cetinkaya G, Kahraman AS, Gumusderelioglu M, Arat S, Onur MA.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Cytotechnology 2011; 63(6):633-43; PMID:21837435; http://dx.doi.org/10.1 007/s10616-011-9380-7[15] Clark AL, Votta BJ, Kumar S, Liedtke W, Guilak F. Chondroprotective role of the osmotically sen- sitive ion channel transient receptor potential vanilloid 4: age- and sex- dependent progression of osteoarthritis in Trpv4- deﬁcient mice.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Arthritis Rheum 2010a; 62(10):2973-83; http://dx.doi.org/ 10.1002/art.27624 [16] Clark RB, Hatano N, Kondo C, Belke DD, Brown BS, Kumar S, Votta BJ, Giles WR.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Ch annels (Austin) 2010b; 4 (3):179-91; http://dx.doi.or g/10.4161/chan.4.3.11629 [17] Clark RB, Kondo C, Belke DD, Giles WR.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Physiol 2011; 589(Pt 21):5071-89; PMID:21911614; http://dx.doi.org/10.1113/jphysiol.2011.210757 [18] Cleiren E, Benichou O, Van Hul E, Gram J, Boller- slev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W. Albers-Schonberg disease (autosomal dominantosteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Hum Mol Genet 2001; 10(25):2861-7; PMID:11741829; http://dx.doi.org/10.1093/hmg/10.25.2861 [19] Elenes S, Martinez AD, Delmar M, Beyer EC, Moreno AP.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Bio- phys J 2001; 81(3):1406-18; PMID:11509355; http://dx.doi.org/10.1016/S0006-3495(01)75796-7 [20] Gavenis K, Schumacher C, Schneider U, Eisfeld J, Mollenhauer J, Schmidt-Ro h l ﬁ n gB .E x p r e s s i o no fi o n channels of the TRP family in articular chondrocytes from osteoarthritic patient s: changes between native and in vitro propagated chondrocytes.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Biochimica Et Biophysica Acta-Bio- membranes 2013; 1828(1):1-3; http://dx.doi.org/ 10.1016/j.bbamem.2012.10.012 [23] Hodgkin AL, Horowicz P. The effect of sudden changes in ionic concentrations on the membrane potential of single muscle ﬁbres.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Physiol-London1960; 153(2):370-85; http://dx.doi.org/10.1113/ jphysiol.1960.sp006540 [24] Hodgkin AL, Huxley AF.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
J Physiol-London 1945;104(2):176-95; http://dx.doi.org/10.1113/jphysiol.19 45.sp004114104 Asmar et al.,Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
Febs Lett 2008; 582(2):165-70; PMID:18068130; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Phar- macolog Sci 2009; 109(2):293-304; PMID:19212094;http://dx.doi.org/10 .1254/jphs.08278FP [27] Iwamoto T, Nakamura T, Doyle A, Ishikawa M, de Vega S, Fukumoto S, Yamada Y. Pannexin 3 regu-lates intracellular ATP/cAMP levels and promotes chondrocyte differentiation.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Biol Chem 2010; 285 (24):18948-58; PMID:20404334; http://dx.doi.org/10.1074/jbc.M110.127027 [28] Kerrigan MJP, Hook CSV, Qusous A, Hall AC.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Articular chondrocytes express connexin 43 hemichannels and P2 receptors - a putative mech- anoreceptor complex involving the primary cilium?.J Anat 2009; 214(2):275-83; PMID:19207989; http://dx.doi.org/10.1111/j.1469-7580.2008.01021.x [30] Kurita T, Yamamura H, Suzuki Y, Giles WR, Imai- zumi Y.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
Wiley Interdiscip Rev Syst Biol Med 2013; 5(6):657-76; PMID:23897652;http://dx.doi.org/10.1002/wsbm.1236 [32] Levin M. Molecular bioelectricity: how endogenous voltage potentials control cell behavior and instructpattern regulation in vivo.,OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Mol Biol Cell 2014; 25(24):3835-50; PMID:25425556; http://dx.doi.org/ 10.1091/mbc.E13-12-0708 [33] Levin M, Stevenson CG.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Cell Physiol 2011a; 226(11):2979-86; http://dx.doi.org/10.1002/jcp.22646 [35] Lewis R, Feetham CH, Barrett-Jolley R. Cell vol- ume regulation in chondrocytes.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Cell PhysiolBiochem 2011b; 28(6):1111-22; http://dx.doi.org/ 10.1159/000335847 [36] Lewis R, Feetham CH, Gentles L, Penny J, Tregil- gas L, Tohami W, Mobasheri A, Barrett-Jolley R.Benzamil sensitive ion channels contribute to vol- ume regulation in canine chondrocytes.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Br J Phar- macol 2013a; 168(7):1584-96; http://dx.doi.org/10.1111/j.1476-5381.2012.02185.x [37] Lewis R, May H, Mobasheri A, Barrett-Jolley R. Chondrocyte channel transcriptomics: do microar- ray data ﬁt with expression and functional data?.Channels (Austin) 2013b; 7(6):459-67; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Stem Cells Int 2013; 2013:238635; PMID:23766766; http://dx.doi.org/10.1155/2013/ 238635 [39] Lin SS, Tzeng BH, Lee KR, Smith RJ, Campbell KP, Chen CC.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Am J Sports Med 2013; 41(11):2658-67; PMID:24043472;http://dx.doi.org/10.1177/0363546513502945 [41] Martina M, Mozrzymas JW, Vittur F. Membrane stretch activates a potassium channel in pig articularchondrocytes.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Biochim Biophys Acta 1997; 1329(2):205-10; PMID:9371412; http://dx.doi.org/ 10.1016/S0005-2736(97)00154-5 [42] Mayan MD, Carpintero-Fernandez P, Gago-Fuentes R, Fernandez-Puente P, Filgueira-Fernandez P, Goyanes N, Valiunas V, Brink P, Goldberg G, Blanco FJ.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Osteoarthritis Cartilage 2013b; 21: S18-9; http://dx.doi.org/10.1016/j.joca.2013.02.060 [44] Mayan MD, Carpintero-Fernandez P, Gago- Fuentes R, Martinez-de-Ilarduya O, Wang HZ,Valiunas V, Brink P, Blanco FJ.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Am J Pathol 2013c; 182(4):1337-46; http://dx.doi.org/10.1016/ j.ajpath.2012.12.018 [45] Mobasheri A, Gent TC, Womack MD, Carter SD, Clegg PD, Barrett-Jolley R .",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Cell Physiol 2010; 223(2):511-8; PMID:20162564;http://dx.doi.org/10.1002/jcp.22075 [47] Molina SA, Takemoto DJ.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"CommunIntegr Biol 2012; 5(2):114-7; PMID:22808311;http://dx.doi.org/10.4161/cib.18715 [48] Mouw JK, Imler SM, Levenston ME.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Bio- mech Mod Mechanobiol 2007; 6(1–2):33-41; PMID:16767453; http://dx.doi.org/10.1007/s10237-006-0034-1 [49] Mow VC, Guo XE.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
Annu Rev Biomed Eng 2002; 4:175-209; PMID:12117756; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Mol Pharmacol 2013; 83(4):759-69; PMID:23253448; http://dx.doi.org/10.1 124/mol.112.083758 [51] O’Conor CJ, Grifﬁn TM, Liedtke W, Guilak F. Increased susceptibility of Trpv4-deﬁcient mice to obesity and obesity-induced osteoarthritis with very high-fat diet.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Ann Rheum Dis 2013; 72(2):300-4;PMID:23178209; http://dx.doi.org/10.1136/annr- heumdis-2012-202272 [52] O’Conor CJ, Leddy HA, Beneﬁeld HC, Liedtke WB, Guilak F. TRPV4-mediated mechanotransduc-tion regulates the metabolic response of chondro- cytes to dynamic loading.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Biochim Biophys Acta 2013; 1828(1):15-22; PMID:22305965; http://dx.doi.org/10.1016/j.bbamem.2012.01.017 [55] Qusous A, Geewan CS, Greenwell P, Kerrigan MJ.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Membr Biol 2011; 243(1–3):25-34; PMID:21847667; http://dx.doi.org/10.100 7/s00232-011-9389-z [56] Rosenthal AK, Hempel D, Kurup IV, Masuda I, Ryan LM.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Osteoarthritis Cartilage 2010; 18(11):149 6-501; PMID:20709180; http://dx.doi.org/10.101 6/j.joca.2010.08.004 [57] Salameh A, Dhein S. Effects of mechanical forces and stretch on intercellular gap junction coupling.Biochimica Et Biophysica Acta-Biomembranes 2013; 1828(1):147-56; http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Comp Biochem Physiol A Mol Integr Physiol 2003;135(4):575-83; PMID:12890547; http://dx.doi.org/10.1016/S1095-6433(03)00138-7 [59] Sandilos JK, Bayliss DA.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"JPhysiol 2012; 590(Pt 24):6257-66; PMID:23070703; http://dx.doi.org/10.1113/jphysiol.2012.240911 [60] Shakibael M, Mobasheri A. beta 1-integrins co- localize with Na, K-ATPase, epithelial sodium channels (ENaC) and voltage activated calcium channels (VACC) in mechanoreceptor complexes ofmouse limb-bud chondrocytes.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Biolog Chem 2002; 277(12):10482-8; PMID:11790776; http://dx.doi.org/10.1074/jbc.M109902200 [62] Sugimoto T, Yoshino M, Nagao M, Ishii S, Yabu H. Voltage-gated ionic channels in cultured rabbit artic- ular chondrocytes.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Comparat Biochem Physiol C-Pharmacol Toxicol Endocrinol 1996; 115(3):223-32; http://dx.doi.org/10.1016/S0742-8413(96)00091-6 [63] Tian M, Duan Y, Duan X. Chloride channels regu- late chondrogenesis in chicken mandibular mesen-chymal cells.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Arch Oral Biol 2010; 55(12):938-45; PMID:20832772; http://dx.doi.org/10.1016/j.archoral bio.2010.08.005 [64] Varga Z, Juhasz T, Matta C, Fodor J, Katona E, Bartok A, Olah T, Sebe A, Csernoch L, Panyi G, Zakany R. Switch of voltage-gated K Cchannel expression in the plasma membrane of chondrogenic cells affects cytosolic Ca2 C-oscillations and carti- lage formation.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
Plos One 2011; 6(11); http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Membr Biol 2000; 177(2): 95-108; PMID:11003684; http://dx.doi.org/10.1007/s002320001103 [67] Wilson JR, Duncan NA, Giles WR, Clark RB.",Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"J Physiol-London 2004; 557(1):93-104; http://dx.doi.org/10.111 3/jphysiol.2003.058883 [68] Wright MO, Stockwell RA, Nuki G. Response of plasma-membrane to applied hydrostatic-pressure in chondrocytes and ﬁbroblasts.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
"Connect Tissue Res 1992; 28(1–2):49-70; PMID:1628490; http://dx.doi.org/10.3109/03008209209014227[69] Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, an d hypertrophy: ion-channel dependent transduction of mat rix deformation signals.",OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
Exp Cell Res 2000; 256(2):383-91; PMID:10772811;http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
J Cell Physiol 2014b; 229(2):202-12; http://dx.doi.org/10.1002/jcp.24435MEMBRANE CHANNEL GENE EXPRESSION IN HUMAN CHONDROCYTES 107,Non-OADS,/arxiv_data1/oa_pdf/ef/1f/kogg-12-02-1181238.PMC4981366.pdf
Keywords Aging; Amyloid beta; Blood brain barrier; Circadian misalignment; Neurodegeneration; Orexin;  Oxidative stress; Sleep disruption; Slow-wave sleep; Tau This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/20/71/nihms783034.PMC4981560.pdf
"2016 July;22(3):153-155. http://dx.doi.org/10.4258/hir.2016.22.3.153pISSN 2093-3681  •  eISSN 2093-369X  Editorial This is an Open Access article distributed under the terms of the Creative Com-mons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduc-tion in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
"154 www.e-hir.orgHyejung Chang and Mona Choi http://dx.doi.org/10.4258/hir.2016.22.3.153lifestyle, environmental, and health economics data) [6].",Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: https://en.wikipedia.org/wiki/Pok%C3%A9mon_Go.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: http://dmlcentral.net/secret-sauce-pokemon-go.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: https://www.weforum.org/agenda/2016/01/the-fourth-industrial-revolution-what-it-means-and-how-to-respond/.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: http://bigdata-madesimple.com/gartner-predicts-five-big-data-trends-that-will-dominate-2016/.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: https://www-03.ibm.com/press/us/en/pressrelease/49132.wss.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: https://www.genomicsengland.co.uk/.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: https://datascience.nih.gov.,OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: https://www.nih.gov/precision-medicine-initiative-cohort-program.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: http://english.gov.cn/news/policy_brief-ings/2016/06/17/content_281475374009852.htm.,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
Available from: http://www-01.ibm.com/,Non-OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
http://dx.doi.org/10.1016/j.jalz.2016.05.005.,OADS,/arxiv_data1/oa_pdf/14/d4/hir-22-153.PMC4981574.pdf
"2016 July;22(3):156-163.  http://dx.doi.org/10.4258/hir.2016.22.3.156pISSN 2093-3681  •  eISSN 2093-369X  Review Article Submitted: June 29, 2016Accepted: July 18, 2016 Corresponding Author  Dimiter V. Dimitrov, MD, PhDDiavita Ltd., Varna, Bulgaria.",Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
"dimitrov@gmail.com  This is an Open Access article distributed under the terms of the Creative Com-mons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduc-tion in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
"158 www.e-hir.orgDimiter V. Dimitrov http://dx.doi.org/10.4258/hir.2016.22.3.156and services to create totally new kinds of disease treatment  possibilities (e.g., Treatment 2.0).",Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
160 www.e-hir.orgDimiter V. Dimitrov http://dx.doi.org/10.4258/hir.2016.22.3.156value care ; the same is true of private health insurers.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
"162 www.e-hir.orgDimiter V. Dimitrov http://dx.doi.org/10.4258/hir.2016.22.3.156care industry is the remote health monitoring system, where  patients can be monitored and advised from anywhere.",Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Avail-able from: http://www.mckinsey.com/industries/high-tech/our-insights/the-internet-of-things-sizing-up-the-opportunity.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
http://dx.doi.org/10.1002/mds.26676.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: http://ec.europa.eu/health/human-use/clinical-trials/regula-tion/index_en.htm.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: https://www.innit.foundation.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: https://myto-morrows.com.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: http://mydario.com/.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: https://mysleepbot.com/.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: http://www.rankedhealth.com/about/.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: http://www.canaryhealth.com/.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: http://www.cdc.gov/dia-betes/prevention/lifestyle-program/experience/index.html.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
Available from: http://www.hereismydata.com/.,Non-OADS,/arxiv_data1/oa_pdf/e5/87/hir-22-156.PMC4981575.pdf
"2016 July;22(3):164-171.  http://dx.doi.org/10.4258/hir.2016.22.3.164pISSN 2093-3681  •  eISSN 2093-369X  Review Article Submitted: June 22, 2016Accepted: July 18, 2016 Corresponding Author  Paul Kim, PhDThe Office of Innovation and Technology, Graduate School of Edu-cation, Stanford University, 520 Galvez Mall, Stanford, CA 94305-3001, USA.",Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
"Tel: +1-650-723-7729, E-mail: phkim@stanford.edu This is an Open Access article distributed under the terms of the Creative Com-mons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduc-tion in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
166 www.e-hir.orgPaul Kim and Ji-Young An http://dx.doi.org/10.4258/hir.2016.22.3.164III.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
"A SMILE Plug computer (Figure 1) contains the SMILE  server software, KIWIX (mobile downloadable version of Wikipedia, http://www.kiwix.org), Khan Academy Lite (i.e., https://learningequality.org), various open education re-sources including open education textbooks, and different simulation and experiment programs (i.e., current contents listed at http://smile.edify.org/).",Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
"Recently, the SMILE server has become accessible in the  cloud at http://smile.stanford.edu.",Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
168 www.e-hir.orgPaul Kim and Ji-Young An http://dx.doi.org/10.4258/hir.2016.22.3.164descending orders.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
A central cloud server (http://smile.stanford.edu) collects all inquiries and sessions from around the world [30].,OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
Central cloud server (http://smile.stanford.edu/) collecting all questions from around the world.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
"170 www.e-hir.orgPaul Kim and Ji-Young An http://dx.doi.org/10.4258/hir.2016.22.3.164are more contextualized and meaningful to local communi- ties, and analyze such data in ways that can leverage analysis models backed by machine learning and augmented intelli-gence.",Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
Available from: http://www.unesco.org/archives/multimedia/?s=films_details&pg=33&id=2958.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
Available from: http://www.slideshare.net/SMILE_Consortium/smile-talk?qid=29cbb6f1-72f4-40de-bbc1-a639a4795c2c&v=&b=&from_search=3.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
Available from: http://www.wise-qatar.org/paul-kim-flipped-classrooms-stanford.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
Available from: http://www.slideshare.net/SeedsofEmpowerment/smile-stanford-mobile-inquirybased-learning-environ-ment-medical-education?qid=5a6b9290-094f-4b90-8b9e-c244069b3fd4&v=&b=&from_search=2.,Non-OADS,/arxiv_data1/oa_pdf/1a/4b/hir-22-164.PMC4981576.pdf
"2016 July;22(3):172-177.  http://dx.doi.org/10.4258/hir.2016.22.3.172pISSN 2093-3681  •  eISSN 2093-369X  Original Article Submitted: April 8, 2016Revised: June 14, 2016Accepted: June 20, 2016 Corresponding Author  Kichul Shin, MD, PhDCenter for Medical Informatics, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea.",Non-OADS,/arxiv_data1/oa_pdf/03/dd/hir-22-172.PMC4981577.pdf
"Tel: +82-2-870-3204, E-mail: kideb1@snu.ac.kr This is an Open Access article distributed under the terms of the Creative Com-mons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduc-tion in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/03/dd/hir-22-172.PMC4981577.pdf
174 www.e-hir.orgMira Baek et al http://dx.doi.org/10.4258/hir.2016.22.3.1722.,Non-OADS,/arxiv_data1/oa_pdf/03/dd/hir-22-172.PMC4981577.pdf
176 www.e-hir.orgMira Baek et al http://dx.doi.org/10.4258/hir.2016.22.3.172ning and zooming (Figure 3D and 3F).,OADS,/arxiv_data1/oa_pdf/03/dd/hir-22-172.PMC4981577.pdf
"2016 July;22(3):178-185.  http://dx.doi.org/10.4258/hir.2016.22.3.178pISSN 2093-3681  •  eISSN 2093-369X  Original Article Submitted: June 22, 2016Revised: July 18, 2016Accepted: July 18, 2016 Corresponding Author  Young-Taek Park, PhDHealth Insurance Review & Assessment Service, 60, Hyeoksin-ro, Won - ju 26465, Korea.",Non-OADS,/arxiv_data1/oa_pdf/82/b2/hir-22-178.PMC4981578.pdf
"Tel: +82-33-739-1005, E-mail: pyt0601@hira.or.kr This is an Open Access article distributed under the terms of the Creative Com-mons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduc-tion in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/b2/hir-22-178.PMC4981578.pdf
180 www.e-hir.orgYoung-Taek Park et al http://dx.doi.org/10.4258/hir.2016.22.3.178a data warehouse (DW) for the production of daily or weekly  monitoring screens.,OADS,/arxiv_data1/oa_pdf/82/b2/hir-22-178.PMC4981578.pdf
182 www.e-hir.orgYoung-Taek Park et al http://dx.doi.org/10.4258/hir.2016.22.3.178Figure 4.,OADS,/arxiv_data1/oa_pdf/82/b2/hir-22-178.PMC4981578.pdf
